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GENERAL INTRODUCTION
What is prostate cancer?
The prostate is a gland that is located below the urinary bladder and in front of 
the rectum. The normal prostate contains two main types of tissue: glandular tissue and 
fibromuscular	stroma.	The	glands	are	lined	by	two	cell	 layers:	a	flat	basal	cell	 layer	and	
an overlying epithelial cell layer. The latter is responsible for producing a secretion that is 
added	to	the	semen.	The	fibrous	part	of	the	stroma	provides	strength	to	the	tissue,	while	
the	muscular	part	permits	the	prostate	to	contract	and	expel	fluids.	The	prostate	can	be	
divided into several different anatomic regions, most important of which are the peripheral 
zone (outer part) and transition zone (inner part). 
Hyperplasia,	defined	by	an	increase	in	the	number	of	cells	in	a	tissue	or	organ,	mostly	
arises in the transition zone. Microscopically it is characterized by a well-circumscribed 
nodular proliferation of benign stromal and glandular elements. The hyperplastic glands are 
lined by two layers, i.e. basal cell layer and epithelial cell layer. Because benign prostatic 
hyperplasia involves the inner part of the prostate, the nodules often compress the urethra 
leading	 to	 lower	 urinary	 tract	 obstruction.	 Symptoms	 include	 difficulty	 in	 starting	 to	
urinate and intermittent interruption of the urinary stream while voiding. Benign prostatic 
hyperplasia is extremely common and occurs in almost all men as they age. About half of all 
men older than 75 years have symptoms related to hyperplasia.
Prostate cancer arises in the outer (peripheral) glands. Microscopically, the glands 
are usually smaller than benign glands and are lined by a single layer of epithelium. 
Prostate cancer lacks the basal cell layer seen in benign glands. In contrast to benign 
glands, malignant glands are more crowded and are able to invade the surrounding normal 
prostate tissue. Although most prostate cancers are small and asymptomatic, they may be 
palpable as irregular hard nodules on digital rectal examination. More advanced prostate 
cancers may present with symptoms, such as problems with urinating or blood in the urine 
or semen. In general, prostate cancers are discovered on the basis of an elevated serum 
prostate-specific	antigen	(PSA)	level	in	the	blood.	A	prostate	biopsy	is	required	to	confirm	
the diagnosis of prostate cancer in each patient. Using a transrectal ultrasound (TRUS) the 
urologist inserts a thin, hollow needle through the wall of the rectum into the prostate to 
remove small tissue cylinders from the prostate. Most urologists take about 10-12 biopsies 
from different parts of the prostate. The samples are sent to a pathology laboratory and 
processed	by	technicians.	The	tissue	will	be	embedded	in	a	paraffin	block	and	from	each	
block	one	representative	section	of	3-5	μm	is	cut	using	a	microtome.	This	section	is	mounted	
on a microscopic slide and stained with hematoxylin and eosin. After staining, the sections 
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are covered with a glass coverslip and evaluated by a pathologist under the microscope. 
The pathologist will assign a diagnosis and write a report. In the case of prostate cancer, 
the pathologist also assigns a grade, known as a Gleason score. The extent of a prostate 
cancer plays an important role in choosing treatments options for a patient and in predicting 
clinical outcome (prognosis). It is based on prostate biopsy Gleason score, serum PSA level 
at	the	time	of	diagnosis	and	results	of	any	other	tests	that	were	done	to	find	out	how	far	the	
cancer has spread, e.g. bone scan, computed tomography (CT) scan or magnetic resonance 
imaging (MRI) scan. About 1 in 7 men will be diagnosed with prostate cancer during his 
lifetime, most of which are diagnosed in men aged 65 or older. The average age at the 
time of diagnosis is 66. Although prostate cancer follows an aggressive disease course in a 
significant	number	of	men,	most	men	diagnosed	with	prostate	cancer	do	not	die	from	the	
disease. About 1 man in 39 will die of prostate cancer.1
Therapy
 Surgery  - a radical prostatectomy - is a common treatment for prostate 
cancer. The major potential side effects of surgery are urinary incontinence and erectile 
dysfunction. Another treatment option is radiation therapy, which may be used in several 
ways. Most common side effects of radiotherapy are urinary problems, bowel problems, 
fatigue, ejaculatory problems and skin irritation. It can be used as a primary treatment 
to treat low-grade cancers and be administered along with hormone therapy for cancers 
that have grown outside the prostate and into nearby tissues. Radiation therapy is also 
used if the cancer has not been removed completely or comes back in the area of the 
prostate after surgery. Lastly, it can be used in advanced prostate cancer to help prevent 
or relieve symptoms. Hormone therapy, also known as androgen deprivation therapy (ADT), 
has the goal to reduce androgen (male hormone) levels in the body. Androgens are known 
to stimulate cell growth prostate cancer. By depriving androgen blood levels the tumor may 
shrink or grow more slowly over time. However, other organs besides the prostate also use 
androgens. Hormone therapy can subsequently lead to a wide range of side effects, e.g 
lowered	libido,	erectile	dysfunction,	hot	flashes,	nausea,	diarrhea,	liver	damage	and	loss	
of bone density. Hormone therapy alone does not, however, cure a patient from prostate 
cancer. Hormone therapy is often administered to patients in whom the cancer has spread 
too far to be cured by surgery or radiation. Hormone therapy can also be used in case the 
cancer remains or comes back after surgery or radiation therapy. If the prostate cancer has 
spread to distant organs (metastasized) and hormone therapy is not effective anymore, 
chemotherapy	 is	 a	 final	 treatment	 option,	 but	 will	 not	 cure	 the	 patient	 from	 prostate	
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cancer.	Because	prostate	cancer	often	grows	very	slowly,	a	significant	number	of	men	do	not	
need active treatment for their prostate cancer. Instead, urologists offer active surveillance 
in which men with prostate cancer are not treated for their disease. Active surveillance 
usually includes a doctor’s visit with a PSA test and DRE every 6 months, depending on the 
protocol. Several active surveillance protocols exist nowadays, of which PRIAS (Prostate 
cancer Research International: Active Surveillance) was initiated at the Erasmus Medical 
Center in Rotterdam.2
Prostate cancer grading by the pathologist: past and present
In	 one	 of	 the	 first	 publications	 on	 prostate	 cancer,	 which	 appeared	 in	 the	 first	
decade of the 20th century, it was already noted that the microscopic appearance of prostate 
cancer varies greatly.3 More than hundred years ago several histological growth patterns, 
such as acinar, scirrhous and solid, were recognized. In 1966, dr. Donald Gleason developed 
a	histological	classification	of	prostate	cancer,	which	was	solely	based	on	its	architectural	
pattern rather than cytological features (Figure 1a).4 He distinguished 5 basic architectural 
patterns,	numbered	grade	1-5.	Higher	grades	were	considered	to	reflect	more	aggressive	
behavior. 
Pattern 1. Very well differentiated small and closely packed glands forming a 
circumscribed	tumor	mass.	The	glands	are	of	a	uniform	size	and	do	not	infiltrate	adjacent	
benign prostatic glands or stroma. The cells are characterized by having pale cytoplasm, 
small and uniform nuclei and very few mitoses.
Pattern 2. Similar to pattern 1 but with less well circumscribed glands showing 
greater variation in both size and shape. It was also noted that within glands cells may be 
piled into more than one layer and that a mild degree of cribriform pattern may be present.
Pattern 3. This pattern shows a wide variation in morphology ranging from glands 
similar to those seen in pattern 2 but with diffuse stromal penetration of tiny glands or 
single	cells,	to	cribriform	glands	showing	greater	variation	than	those	classified	in	pattern	
2. Cords or masses of cells showing some degree of glandular differentiation may also be 
present.
Pattern 4. Closely packed, large, pale polygonal cells that resemble clear cell renal 
cell carcinoma. These cells usually show some features of glandular differentiation and 
there	is	typically	diffuse	stromal	infiltration.
Pattern 5. Undifferentiated carcinoma with little or no gland formation.
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Figure 1. Gleason grading 1992 – present
Because the majority of the prostate cancers showed more than one type of growth 
pattern, he suggested assigning two patterns to each case in the order of predominance. 
This	grading	system	of	dr.	Gleason	was	validated	in	1974	and,	after	some	modification	of	
the	definitions,	has	since	then	received	a	worldwide	acceptance.5 The Gleason score equals 
the sum of the two most common Gleason grades in radical prostatectomy, and, since 2005, 
the sum of the most common and highest Gleason grades in needle-biopsies.6 To date, 
the Gleason grading system is one of the most powerful predictors of outcome in prostate 
cancer.	The	Gleason	grading	 system	has	undergone	a	major	modification	 in	2005	and	an	
additional minor one in 2014 during International Society of Urological Pathologists (ISUP) 
consensus conferences (Figure 1).6,7
Gleason patterns 1 and 2 are for instance no longer in use in biopsies and the current 
Gleason score 6 (3+3) of 10 is the lowest possible score. Several growth patterns, which 
were originally considered Gleason grade 3, are now reassigned to a grade 4. In 2005 it was, 
for instance, agreed upon that large cribriform glands should be diagnosed as a Gleason 
grade 4, while small cribriform glands could still be assigned a Gleason grade 3. Because 
of the poor inter-observer reproducibility on diagnosing cribriform grade 3 glands, it was 
decided during the following ISUP consensus conference in 2014 that all cribriform glands 
should be considered as a Gleason grade 4 pattern. Grading the glomeruloid pattern has 
been controversial for many years. It has a typical morphology of a cribriform-like structure 
protruding into a gland attached to only one edge of the gland resulting in the structure 
ISUP 2005 GleasonOriginal Gleason ISUP 2014 Gleason
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resembling	a	glomerulus	of	the	kidney.	Although	based	on	scant	scientific	evidence,	it	was	
agreed upon in 2014 that glomeruloid structures are a Gleason grade 4 pattern. Originally, 
Gleason	did	not	describe	and	specifically	grade	ill-formed	glands.	During	the	ISUP	consensus	
conference in 2005, the ill-formed pattern was added to the Gleason grade 4 patterns as 
well. Consequently, from then on Gleason grade 3 only comprised well-delineated malignant 
glands. The contemporary Gleason grade 4 patterns are fused, ill-formed, cribriform and 
glomeruloid. Recently, the 5-tier prognostic grade grouping was introduced by the ISUP and 
recommended by the World Health Organization (WHO).7	The	grading	system	includes	five	
distinct	Grade	Groups	based	on	the	modified	Gleason	score	groups.	Grade	Group	1	=	Gleason	
score	 ≤6,	Grade	Group	 2	=	Gleason	 score	 3	+	4	=	7,	Grade	Group	 3	=	Gleason	 score	 4	+	3	=	7,	
Grade Group 4 = Gleason score 8, Grade Group 5 = Gleason scores 9 and 10. Grade Grouping 
is not a novel grading system per se,	but	comprehensively	distinguishes	clinically	significant	
patient cohorts.
	The	 Gleason	 grade	modification	 led	 to	 significant	 grade	 inflation.8,9 One group, 
for	instance,	reported	a	significant	decrease	in	Gleason	score	6	(3+3)	tumors	from	48%	to	
22%	of	cases,	while	score	7	(3+4	and	4+3)	tumors	increased	from	26%	to	68%.10 We believe 
that this relative increase is strongly associated with the inclusion of ill-formed glands as 
a Gleason grade 4 pattern since 2005. This pattern is, however, poorly reproducible among 
pathologists.11-16 Reproducibility in recognizing Gleason pattern 4 prostate cancer on needle 
biopsy is most critical for clinical decision-making. In general, patients with Gleason score 
6 on needle biopsy do not need immediate treatment and are often candidates for active 
surveillance. Patients with Gleason score 7 mostly undergo active treatment, i.e. surgery or 
radiotherapy.	Today,	both	modified	Gleason	score	6	and	7	patients	have	a	better	prognosis	
than the historic ones, also known as the Will Rogers phenomenon.9
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Cribriform prostate cancer
In	2011,	Iczkowski	et	al.	were	the	first	to	report	that	prostate	cancer	with	cribriform	
growth has a worse biochemical-recurrence-free survival than those with “poorly formed 
glands”.17 Others and we have subsequently validated the adverse prognostic value of prostate 
cancers with a cribriform pattern using different patient groups and outcome measures, 
including	biochemical	recurrence,	metastasis	and	disease-specific	death.18-22 Altogether these 
studies strongly suggest that cribriform growth in prostate cancer does not belong in the same 
risk group as, for instance, ill-formed glands. These studies had, however, been based on 
radical prostatectomy specimens. To affect clinical decision-making, it is essential to validate 
the prognostic value of cribriform growth in prostate cancer in pre-treatment needle biopsies. 
 
Intraductal carcinoma of the prostate
In	recent	years	the	clinical	significance	of	 intraductal	carcinoma	of	the	prostate	
– a morphological mimicker of invasive cribriform carcinoma – has been acknowledged. 
The current concept is that it represents divergent differentiation of a common precursor 
that either spreads invasively or via pre-existing ducts.23 Although not included in the 
Gleason grading system, intraductal carcinoma has been associated with Gleason grade 4 
and 5 patterns, advanced tumor stage, biochemical recurrence and distant metastasis.24-29 
Invasive cribriform carcinoma and intraductal carcinoma are strictly speaking two different 
pathologic entities, but they morphologically mimic each other closely and it is possible 
they relate and exist on a pathological and biological continuum.30,31 In fact, we believe 
that for many decades intraductal carcinoma has been diagnosed as a Gleason grade 4 or 
5 pattern, as immunohistochemistry for basal cells was not available in the early days. 
Moreover, in line with the current 2014 ISUP recommendations, immunohistochemistry to 
distinguish invasive cancer carcinoma from intraductal carcinoma is not necessary. It should 
only be considered in cases where the results of the studies would change the case’s overall 
grade, for example in cases lacking other Gleason grade 4 patterns.7 Since the latter is 
extremely rare, it may indeed be more practical to regard them as one high-grade entity.
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This thesis
This general aim of the thesis is to study the clinical relevance, interobserver 
reproducibility,	and	genetics	of	cribriform	growth	in	prostate	cancer.	More	specifically,	the	
aims and outline of this thesis are
• To	study	the	metastatic	potential	of	modified	Gleason	score	3+3	prostate	cancer	in	
radical prostatectomies. (Chapter 2) 
• To examine the prognostic value of individual Gleason grade 4 patterns in prostate 
cancer in radical prostatectomy and diagnostic biopsy specimens. (Chapter 3 and 4) 
• To examine whether biopsy Gleason score 3+4 patients without cribriform growth 
could be candidates for active surveillance by comparing them with Gleason score 3+3 
patients. (Chapter 5) 
• To study the relation between Gleason grade 4 tumor percentage and cribriform 
prostate cancer in Gleason score 3+4 biopsies. (Chapter 6) 
• To study the reproducibility of various Gleason grade 4 patterns, particularly that of 
cribriform growth, by undertaking an inter-observer reproducibility study among an 
international group of genitourinary pathologists. (Chapter 7) 
• To study which genetic events are associated with cribriform growth in prostate 
cancer by using Next Generation Sequencing technology. (Chapter 8)
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CHAPTER 2 
Disease-specific death and metastasis do not 
occur in patients with Gleason score ≤6 at 
radical prostatectomy
Kweldam CF, Wildhagen MF, Bangma CH, van Leenders GJ
BJU Int. 2015 Aug;116(2):230-5 
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ABSTRACT
Background:	To	assess	the	metastasis-free	survival	(MFS)	and	disease-specific	survival	(DSS)	
in	men	with	Gleason	score	≤6	prostate	cancer	at	radical	prostatectomy	(RP).
Patients and methods: We included 1101 consecutive RP patients operated between March 
1985 to July 2013 at a single institution. The outcome variables were MFS and DSS. The post-
operative survival was estimated by the Kaplan–Meier method.
Results: The Gleason score distribution of the study population (1101 patients) was Gleason 
score	 ≤6	 (449,	 41%),	Gleason	 score	 3+4=7	 (436,	 40%),	Gleason	 score	 4+3=7	 (99,	 9%)	 and	
Gleason	score	8-10	(117,	11%).	The	median	post-operative	follow-up	was	100	months	(IQR	
48-150).	During	 follow-up	197	men	 (18%)	died	of	whom	42	 (3.8%)	 from	prostate	 cancer-
related	causes.	A	total	of	19/1101	patients	(1.7%)	had	documented	lymph	node	metastasis	
at	time	of	operation:	none	with	Gleason	score	≤6,	seven	with	Gleason	score	3+4=7	(1.6%),	six	
with	Gleason	score	4+3=7	(6.1%)	and	six	with	Gleason	score	8-10	(5.1%).	Distant	metastasis	
occurred	 in	56/1101	patients	 (5.1%):	none	with	Gleason	score	≤6,	23	with	Gleason	score	
3+4=7	 (5.3%),	17	with	Gleason	 score	4+3=7	 (17%)	and	16	with	Gleason	 score	8-10	 (14%).	
Disease-specific	 death,	 stratified	 per	Gleason	 score	 group	was:	 none	 in	 ≤6,	 16	 (3.7%)	 in	
3+4=7,	16	(16%)	in	4+3=7	and	10	(8.5%)	in	8-10	group.	
Conclusion:	No	metastasis	or	disease-specific	death	were	seen	in	men	with	Gleason	score	
≤6	prostate	cancer	at	RP,	demonstrating	the	negligible	potential	to	metastasize	in	this	large	
subgroup patients with prostate cancer.
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INTRODUCTION
The Gleason grading system is a strong predictor for disease progression in prostate 
cancer and one of the most important parameters for therapeutic clinical decision-making. 
For instance, many patients with Gleason score 6 on needle biopsy do not require immediate 
therapeutic intervention and are often eligible for active surveillance.1 In contrast, patients 
with	Gleason	score	≥7	prostate	cancer	generally	undergo	active	treatment	for	their	disease.	
In most studies, clinical outcome of prostate cancer is measured by biochemical recurrence 
after	 radical	 prostatectomy	 (RP),	 which	 does	 not	 reflect	 tumor	 biology	 per se. In the 
present study, we assessed the biochemical recurrence-free survival (BCRFS), metastasis-
free	survival	(MFS)	and	disease-specific	survival	(DSS)	in	a	large	cohort	of	men	with	Gleason	
score	≤6	at	RP	at	a	single	institution.	
25
PATIENTS AND METHODS
Patient population
Between March 1985 and July 2013, 1101 consecutive hormone naïve patients 
underwent RP for prostate cancer at the Erasmus Medical Center, Rotterdam, The 
Netherlands. RP specimens were routinely examined at the Department of Pathology of 
our institute. At pathological evaluation, Gleason score, extra-prostatic extension, seminal 
vesicle involvement, bladder neck invasion and surgical margin status were recorded for each 
patient.	From	1985	to	2005,	the	classic	Gleason	grading	system	was	applied,	while	modified	
Gleason grading was used from 2005.2-4 At our institution, Gleason grade 4 was considered 
as	a	tertiary	pattern	and	not	included	in	the	final	Gleason	score,	if	it	encompassed	<5%	of	
the	prostate	 cancer	 volume	both	before	 and	 after	 the	 introduction	 of	modified	Gleason	
grading.	In	894	(81%)	patients	a	pelvic	lymph	node	dissection	was	performed	at	time	of	RP.	
In case intra-operative frozen sections demonstrated lymph node metastasis, RP was not 
performed; respective patients were not included in our study cohort. All pathologic slides 
were available for review.
Follow-up
After surgery, patients were monitored routinely at our outpatient clinic. Local 
recurrence was determined by a palpable mass or tissue biopsy in the presence of an 
elevated	Prostate	Specific	Antigen	(PSA)	level.	Biochemical	recurrence	was	defined	as	a	PSA	
level	of	≥0.2	ng/mL,	assessed	at	two	consecutive	time	points	at	least	3	months	after	radical	
prostatectomy. Metastasis	was	defined	as	presence	of	prostate	cancer	in	a	lymph	node	or	
at	a	distant	site	with	radiologic	or	pathologic	confirmation.	Outcome	variables	were	BCRFS,	
defined	 as	 time	 after	 radical	 prostatectomy	 to	 biochemical	 recurrence;	MFS,	 defined	 as	
time after radical prostatectomy to metastasis (lymph node, distant metastasis or both); 
DSS,	defined	as	time	after	radical	prostatectomy	to	death	attributed	to	prostate	cancer;	
overall	survival	defined	as	time	after	radical	prostatectomy	to	all-cause	death.	Death	and	
disease-specific	death	were	verified	by	medical	 record	review	and	death	certificates.	All	
relevant clinical, pathologic and follow-up data were recorded and regularly updated in a 
prospective study database (MW). Pathologic tumor (pT) stage was categorized according 
to the 2009 TNM system.5
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Statistics
Continuous clinico-pathologic parameters (age at time of operation, follow-up 
and	PSA	 level	at	 time	of	diagnosis)	of	4	Gleason	 score	 subgroups	 (≤6,	3+4=7,	4+3=7	and	
8-10) were compared using the Independent-Samples Kruskal-Wallis Test. The Pearson’s 
Chi-square (X2) test was used for categorical parameters (pelvic lymph node dissection, 
pT-stage, and surgical margins). Survival probabilities were estimated by the Kaplan-Meier 
method. All statistics were performed using SPSS 21 (SPSS Inc., Chicago, USA). A two-sided 
P<0.05	was	considered	significant.
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RESULTS
Baseline patient characteristics
The clinic-pathological characteristics and follow-up information of the 1101 
selected	patients	are	depicted	in	Table	1.	The	median	(interquartile	range,	IQR)	age	at	time	
of	operation	was	64	(60–68)	years.	The	median	(IQR)	PSA	level	was	5.8	(3.9–9.1)	ng/mL.	The	
median	(IQR)	follow-up	was	100	(48–150)	months.	During	follow-up,	197	men	(18%)	died	of	
whom	42	(3.8%)	died	from	prostate	cancer-related	causes.	In	all,	19	(1.7%)	and	56	(5.1%)	
patients had lymph node and distant metastasis, respectively.
Table 1. Clinico-pathologic and follow-up information of prostate cancer patients treated by 
radical prostatectomy (n=1101). 
Clinico-pathologic parameter Mean	(median;	IQR)	or	n	(%)
Age (years) 63 (64; 60-68)
PSA level (ng/mL) 8.4 (5.8; 3.9-9.1)
Follow-up after radical prostatectomy (months) 100 (100; 48-150)
Gleason score ≤6 449 (41)
7 535 (49)
3+4 436 (40)
4+3 99 (9.0)
8-10 117 (11)
Pelvic lymph node dissection 894 (81)
pT-stage (TNM 2009) T2 664 (60)
T3a 351 (32)
T3b 86 (7.8)
Positive surgical margins 333 (30)
Biochemical recurrence 258 (23)
Local recurrence 52 (4.7)
Lymph node metastasis 19 (1.7)
Distant metastasis 56 (5.1)
Lymph node and/or distant metastasis 70 (6.4)
Overall death 197 (18)
Disease-specific death 42 (3.8)
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Gleason score in relation to clinical outcome
Initial	statistical	analysis	of	the	Gleason	score	≤6	group,	revealed	that	six	patients	
had	developed	metastasis	 and	five	patients	 died	 from	prostate	 cancer	during	 follow-up.	
These patients were operated between 1988 and 2001, and graded according to the classic 
Gleason score system. All slides from respective cases were retrieved from our archives 
and reviewed by a urogenital pathologist (G.v.L). At review, all prostate cancer specimens 
revealed	Gleason	grade	4	growth	patterns	in	>5%	of	the	tumor	volume,	and	were	re-assigned	
a	modified	Gleason	 score	 7	 (Fig.	 1,	 Table	 2).	 The	 predominant	 Gleason	 grade	 4	 growth	
pattern at revision was the formation of cribriform glands.
Figure 1. Prostate adenocarcinoma originally graded as Gleason score 3+3=6, with under-recognized 
Gleason	grade	4	patterns	with	A)	ill-defined,	B)	combined	glomeruloid	(arrow)/	cribriform	(arrowheads)	
and C) fused growth patterns.
200x 200x 200x
A B C
Table 2. Histopathological review of cases with classic Gleason score ≤6 at original diagnosis with 
metastasis, disease-specific death or both.
Patient 
#
Lymph 
node 
metastasis
Distant 
metastasis
Disease-
specific 
death
Reviewed 
Gleason 
score
Undergraded pattern(s)
1 Yes Yes 4+3=7 Cribriform
2 Yes 3+4=7 Cribriform, fused, intraductal carcinoma
3 Yes 3+4=7 Cribriform, fused
4 Yes 3+4=7 Cribriform, fused
5 Yes Yes 3+4=7 Fused, glomeruloid
6 Yes 3+4=7 Cribriform, fused, ill-defined, intraductal carcinoma
7 Yes 3+4=7 Fused, ill-defined, tertiary Gleason grade 5 
8 Yes Yes 3+4=7 Cribriform, fused, glomeruloid
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Table 2. Histopathological review of cases with classic Gleason score ≤6 at original diagnosis with 
metastasis, disease-specific death or both.
Patient 
#
Lymph 
node 
metastasis
Distant 
metastasis
Disease-
specific 
death
Reviewed 
Gleason 
score
Undergraded pattern(s)
1 Yes Yes 4+3=7 Cribriform
2 Yes 3+4=7 Cribriform, fused, intraductal carcinoma
3 Yes 3+4=7 Cribriform, fused
4 Yes 3+4=7 Cribriform, fused
5 Yes Yes 3+4=7 Fused, glomeruloid
6 Yes 3+4=7 Cribriform, fused, ill-defined, intraductal carcinoma
7 Yes 3+4=7 Fused, ill-defined, tertiary Gleason grade 5 
8 Yes Yes 3+4=7 Cribriform, fused, glomeruloid
After	 review,	 the	final	distribution	of	 the	Gleason	 score	 in	 the	 study	population	
was	as	follows:	Gleason	score	≤6	(449,	41%),	Gleason	score	3	+	4	=	7	(436,	40%),	Gleason	
score	4+3=7	(99,	9%)	and	Gleason	score	8–10	(117,	11%).	The	distribution	within	the	Gleason	
score	8–10	group	was	3+5=8	(37,	31%),	4+4=8	(20,	17%),	4+5=9	(30,	26%),	5+3=8	(15,	13%),	
5+4=9	(14,	12%)	and	5+5=10	(one,	1%).	The	clinico-pathological	and	follow-up	information	
of	patients	with	prostate	cancer	treated	by	RP,	stratified	by	Gleason	score	(≤6,	3+4=7,	4+3=	
7	and	8–10)	are	summarized	in	Table	3.	Metastasis	and	disease-specific	death	occurred	only	
in	patients	with	prostate	cancer	with	Gleason	score	≥3+4=7.	In	Fig.	2,	the	BCRFS,	MFS,	DSS	
and overall survival are depicted for all Gleason-score subgroups. None of the 449 patients 
with	Gleason	score	≤6	prostate	cancer	with	a	median	(IQR)	follow-up	of	120	(77–160)	months	
developed metastasis or died from prostate cancer-related causes.
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Figure 2. Kaplan-Meier estimates of A) biochemical recurrence-free survival, B) metastasis-free 
survival,	C)	disease-specific	survival	and	D)	overall	survival.
Clinico-pathologic characteristics of Gleason score ≤6
In	 all,	 82%	 (369/449)	 of	 patients	 with	 Gleason	 score	 ≤6	 prostate	 cancer	 at	 RP	
had	organ-confined	disease	(pT2);	78	men	(17%)	had	extra-prostatic	extension	(pT3a)	and	
two	 (0.4%)	 had	 seminal	 vesicle	 involvement	 (pT3b).	 To	 validate	 whether	 Gleason	 score	
≤6	prostate	cancer	had	the	potential	to	spread	into	extra-prostatic	tissues,	we	randomly	
reviewed	30	RPs	with	Gleason	score	≤6	and	≥pT3.	In	all	30	cases	the	pT	stage	and	Gleason	
score	were	concordant	with	initial	pathological	findings.	
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Surgical	margins	were	positive	in	90	RP	specimens	(20%).	In	396/449	patients	(88%),	
a pelvic lymph node dissection was performed, in which no lymph node metastasis was 
observed.	Biochemical	recurrence	was	observed	in	49	patients	(11%).	In	all,	22	of	these	49	
patients	(45%)	had	positive	surgical	margins	and	25	men	had	≥pT3	(51%).	Local	recurrence	was	
seen	in	10	patients	(2%),	two	of	whom	(20%)	had	positive	surgical	margins	and	six	≥pT3	(60%). 
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DISCUSSION
Gleason grading is one of the most important parameters for clinical decision-making 
and prediction of disease outcome. In pathological practice, a Gleason grade is purely based 
on the assignment of architectural prostate cancer growth patterns. The Gleason score is 
determined by adding the two most common Gleason grades in RP specimens; in needle 
biopsies, the most common and highest Gleason grades are added. Essentially, Gleason 
grade pattern 1–3 encompass well-delineated malignant glands; the presence of cribriform, 
fused,	ill-defined	and	glomeruloid	glands	are	not	acceptable	for	Gleason	grade	3	prostate	
cancer.2,6,7
The	metastatic	potential	of	Gleason	score	≤6	prostate	cancer	is	a	topic	of	interest,	
as previous studies have demonstrated negligible rates of biochemical recurrence after 
radical prostatectomy and salvation radiotherapy.8-10 In addition, Hernandez et al. have 
shown	that	patients	with	organ-confined	Gleason	score	≤6	prostate	cancer	do	not	develop	
post-operative metastases nor die from prostate cancer.10 Recent analysis of >14 000 RPs 
performed at Johns Hopkins Medical Institutions demonstrated that lymph node metastasis 
does	not	occur	in	men	with	modified	Gleason	score	≤6	prostate	cancer	during	follow-up.11 
Our	 present	 study	 is	 consistent	with	 these	 findings,	 and	 additionally	 shows	 that	 distant	
metastasis	and	disease-specific	death	do	not	occur	in	non-organ	confined	Gleason	score	≤6	
prostate cancer as well.
Eggener et al.	previously	reported	on	disease-specific	death	 in	a	 large	cohort	of	
12,000 RPs.12	 In	 their	 study,	 the	15-year	disease-specific	mortality	 rates	 in	patients	with	
classic	and	modified	Gleason	score	≤6	were	0.2-1.2%.	In	the	other	Gleason	score	groups	the	
15-year	disease-specific	mortality	rates	were	4.2-6.5%	in	Gleason	score	3+4=7,	6.6-11%	in	
Gleason	score	4+3=7	and	26-37%	in	Gleason	score	8-10.	The	latter	rates	are	consistent	with	
our	present	findings,	except	for	the	Gleason	score	8–10	group.	In	our	present	cohort,	10	of	
117	patients	with	Gleason	score	8–10	(8%)	died	from	prostate	cancer	with	a	median	follow-
up of 66 months, which is lower than the death rate in the Gleason score 4+3=7 group. The 
low	number	of	metastases	and	disease-specific	deaths	in	the	Gleason	score	8–10	group	could	
be	explained	by	a	selection	bias,	as	RP	is	generally	not	the	first	choice	of	therapy	in	men	
with high Gleason score at needle-biopsy in our institute. Furthermore, it might be due to 
the fact that our institute had a policy up to 2002 not to perform RP when intraoperative 
frozen sections showed lymph node metastasis. Also, the relative amount of high-grade 
prostate cancer, i.e. Gleason grade 4 or 5 is less in Gleason score 3+5=8 than in Gleason 
score 4+3=7 tumors, which might also explain the worse outcome of Gleason score 4+3=7 
patients.13 In our present study, nearly one-third of the Gleason score 8–10 patients had 
34
Gleason score 3+5=8. Finally, the relatively short follow-up in the Gleason score 8–10 group 
[median	(IQR)	50	(12–98)	months]	could	have	 led	to	an	underestimation	of	metastasis	or	
death attributed to prostate cancer in this subgroup of patients.
That	Gleason	score	≤6	prostate	cancer	has	very	low,	if	any,	potential	to	metastasize	
raises	the	question	whether	Gleason	score	≤6	prostate	cancer	should	be	considered	as	a	
malignant tumor at all. Berman et al. discussed several problems of diagnosing Gleason 6 
as cancer vs. benign disease.14 First, most prostate cancers occur in older men, progress 
slowly and are not life threatening. Therefore it is unlikely that a man with the lowest 
score	on	RP,	Gleason	score	6,	will	die	from	prostate	cancer.	Although	up	to	90%	of	patients	
with prostate cancer undergo RP, only half of them have potentially life-threatening cancer 
(Gleason	score	≥7).15
One of the most important arguments against diagnosing Gleason score 6 as a 
benign tumor is under-sampling of high-grade cancer on prostate needle biopsy. Unlike 
many tumors, prostate cancer is a very heterogeneous disease, and susceptible to sampling 
error. For instance, in a recent and large study containing 7643 RPs with corresponding 
needle biopsies, Epstein et al.	reported	that	36%	of	cases	(1841/	5071)	were	upgraded	from	
a needle-biopsy Gleason score 6 to a higher grade at RP.16 Based on large active surveillance 
studies	in	men	with	Gleason	score	6	on	biopsy,	up	to	33%	of	the	patients	still	need	therapeutic	
intervention primarily due to Gleason score upgrading.15,17-21 Furthermore, in our present 
study	17%	of	Gleason	score	6	prostate	cancer	had	extraprostatic	expansion	(pT3a)	and	0.4%	
seminal vesicle involvement, indicating that these tumors can show aggressive behavior 
locally.
The major limitation of our present study was that not all RP specimens were 
pathologically	reviewed	and	scored	according	to	the	modified	Gleason	score.	Recently,	Dong	
et al. re-graded 806 radical prostatectomies with Gleason score 3+3=6 and Gleason score 
3+4=7	prostate	cancer	according	to	the	modified	Gleason	grading	system.22 They found an 
upgrade	of	 34%	 from	classical	Gleason	 score	 3+3=6	prostate	 cancer	 to	modified	Gleason	
score	7	or	8	at	radical	prostatectomy.	However,	not	a	single	case	of	Gleason	score	≥7	was	
downgraded	to	a	Gleason	score	≤6	at	RP.	
Therefore, we assume that pathological review in our present study would have 
reduced	the	number	of	patients	with	Gleason	score	≤6	at	RP,	but	would	not	have	changed	
our	finding	that	Gleason	score	≤6	prostate	cancer	does	not	metastasize	or	lead	to	disease-
specific	death.	Another	imitation	of	our	present	study	was	the	unavailability	of	data	on	the	
cause	of	death	in	28	patients	(3%),	of	whom	12	had	Gleason	score	≤6	at	RP.	In	addition,	not	
all	patients	with	Gleason	score	≤6	underwent	a	lymph	node	dissection	at	the	time	of	RP,	so	
that their metastatic status remains unknown. Also, it cannot be excluded that patients who 
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did not undergo RP because of intraoperative lymph node metastasis actually had Gleason 
score	≤6	prostate	cancer	at	RP.	The	present	Gleason	score	≤6	group	had	the	longest	follow-
up in this cohort (median 120 months), but longer follow-up may be needed to further 
exclude	long-term	metastatic	potential	of	Gleason	score	≤6	at	RP.
The	significant	emergence	of	metastatic	potential	of	prostate	cancer,	when	Gleason	
grade 4 or 5 patterns are observed, has major implications for understanding the biology of 
prostate cancer. As growth pattern seems to be associated so strongly with disease outcome, 
it is intriguing to understand the cellular mechanisms that underlie various growth patterns. 
Review	of	prostate	cancer	initially	diagnosed	as	Gleason	score	≤6	with	progression,	revealed	
the presence of cribriform growth in most cases. This pattern was also most frequently 
seen	 in	 the	 revised	aggressive	Gleason	 score	≤6	prostate	cancer	 in	 the	 series	of	Ross	et 
al.11 Recently Dong et al. reported that cribriform growth pattern, in particular, was an 
independent predictor for biochemical recurrence as well as metastasis after RP, suggesting 
that Gleason grade 4 architectural patterns could provide important prognostic information 
beyond	the	current	Gleason	classification	system.23
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CONCLUSION
No	metastasis	or	disease-specific	death	were	seen	in	men	with	Gleason	score	≤6	
prostate cancer at RP, demonstrating the negligible potential to metastasize in this large 
subgroup of patients with prostate cancer. 
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CHAPTER 3 
Cribriform growth is highly predictive for 
postoperative metastasis and disease-specific 
death in Gleason score 7 prostate cancer
Kweldam CF, Wildhagen MF, Steyerberg EW, Bangma CH, van der Kwast TH, van 
Leenders GJ
Mod Pathol. 2015 Mar;28(3):457-64
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 ABSTRACT
Background: Patients with Gleason score 7 prostate cancer on radical prostatectomy 
demonstrate a wide range in clinical outcome. Gleason grade 4 prostate cancer encompasses 
a	heterogeneous	group	of	tumor	growth	patterns	including	fused,	ill-defined,	cribriform	and	
glomeruloid glandular structures. Our objective was to determine the prognostic value of 
different Gleason grade 4 growth patterns. 
Patients and methods: We performed a nested case-control study among 535 patients with 
Gleason score 7 prostate cancer at radical prostatectomy, treated between March 1985 
and July 2013 at a university hospital in The Netherlands. We analyzed 52 cases (with 
metastasis,	disease-specific	mortality	or	both)	and	109	controls,	matched	for	age,	PSA	level	
and pT stage. Presence of the following Gleason grade 4 patterns was recorded: fused, 
ill-defined,	cribriform	and	glomeruloid.	Intraductal	carcinoma	of	the	prostate	and	tertiary	
Gleason grade 5 were additionally assessed. Outcomes were metastasis-free survival and 
disease-specific	 survival.	We	 used	 Cox	 proportional	 hazards	 regression	 to	 determine	 the	
predictive value of Gleason grade 4 patterns for survival time. 
Results:	 The	 overall	 prevalence	 of	 Gleason	 grade	 4	 patterns	 was	 as	 follows:	 fused	 75%	
(n=121),	 ill-defined	 64%	 (n=102),	 cribriform	 48%	 (n=83)	 and	 glomeruloid	 25%	 (n=40).	
Cribriform pattern was the only pattern with an unequal distribution between cases and 
controls.	 Forty-two	 out	 of	 52	 cases	 (81%)	 had	 cribriform	 growth	 pattern	 versus	 41/109	
controls	 (38%).	 In	 multivariate	 analysis,	 presence	 of	 cribriform	 growth	 was	 an	 adverse	
independent	predictor	for	distant	metastasis-free	survival	(HR	8.0,	95%	CI	3.0-21;	P<0.001)	
and	disease-specific	survival	(HR	5.4,	95%CI	2.0-15,	P=0.001).	
Conclusion: cribriform growth in Gleason grade 4 is a strong prognostic marker for distant 
metastasis	and	disease-specific	death	in	patients	with	Gleason	score	7	prostate	cancer	at	
radical prostatectomy. 
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INTRODUCTION
The widely used Gleason grading system for prostate cancer discerns 5 different 
grades based on the architectural tumor growth pattern.1 The Gleason score is determined 
by adding the two most common Gleason grades in radical prostatectomies; in needle-
biopsies the most common and highest Gleason grades are added. The Gleason grading 
system is an important predictor of disease progression, and one of the most important 
variables	 for	 clinical	 decision-making.	 In	 2005,	 large	 cribriform	 and	 ill-defined	 glands,	
classically	described	as	Gleason	grade	3,	were	redefined	as	Gleason	grade	4.2 Later small 
cribriform and glomeruloid glands have been reconsidered Gleason grade 4 as well.3,4 This 
grade migration has led to a decline in reporting of Gleason score 6 on radical prostatectomy, 
joined by a relative increase of Gleason score 7 prostate cancer.5 Whereas patients with 
modified	 Gleason	 score	 6	 on	 radical	 prostatectomy	 represent	 a	 group	 with	 excellent	
outcome, patients with Gleason score 7 demonstrate a wide range in clinical outcome.6-8 
Risk	stratification	within	the	Gleason	score	7	patient	population	remains	a	challenge,	and	
additional prognostic factors are needed. The objective of this study was to determine the 
predictive value of distinctive Gleason grade 4 growth patterns for metastasis and disease-
specific	death	in	men	with	Gleason	score	7	prostate	cancer	on	radical	prostatectomy.	
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MATERIALS AND METHODS
Study design
We	identified	535	hormone-naïve	patients	with	Gleason	score	7	prostate	cancer	on	
radical prostatectomy, treated between March 1985 and July 2013 at Erasmus MC, Rotterdam, 
The	Netherlands.	In	our	cohort	56	patients	had	documented	metastasis	or	disease-specific	
death during follow-up (‘cases’). The control group consisted of 112 Gleason score 7 patients 
without	documented	metastasis	or	disease-specific	death.	We	matched	the	control	group	
for	the	following	3	variables:	age	at	time	of	surgery,	serum	Prostate	Specific	Antigen	(PSA)	
level at time of diagnosis (ng/mL) and pT stage.9 We randomly selected controls in the pT2 
and	pT3a	group	with	follow-up	≥120	months.	Limits	for	age	were	≥47	and	≤74	years.	Limits	
for	PSA	level	were	≥0	and	≤100	ng/mL.	In	7	patients,	histopathologic	slides	and	blocks	could	
not be retrieved from the archive (4 cases and 3 controls), leaving 52 cases and 109 controls 
for analysis with all slides and clinico-pathologic information available.
Pathologic evaluation
After operation, all radical prostatectomy specimens were routinely examined at 
the Department of Pathology of our institute. At pathologic evaluation, Gleason score, pT 
stage and surgical margin status were recorded for each patient. From 1985 to 2005, the 
classic	Gleason	grading	system	was	applied;	the	modified	Gleason	grading	was	used	after	
2005.	The	2009	TNM	classification	was	used	to	assess	pT	stage.9 A positive surgical margin 
was	defined	as	extension	of	the	tumor	into	the	inked	surface	of	the	specimen.	
The	investigator	(CK)	and	a	board	certified	pathologist	with	expertise	in	urogenital	
pathology	(GvL),	reviewed	all	slides	and	routinely	determined	the	modified	Gleason	score.2 
Both reviewers were blinded to the patients’ outcome. The presence of Gleason grade 4 
growth	patterns	was	specifically	recorded	in	each	specimen.	In	addition,	we	assessed	the	
presence of tertiary Gleason grade 5 and intraductal carcinoma of the prostate in each 
specimen, since both have been associated with adverse clinical outcome.10-14 The following 
Gleason	grade	4	growth	patterns,	as	defined	by	the	ISUP-modified	Gleason	grading	scheme,	
were scored as follows: 1) fused glands included fused well- and poorly formed glands 
(Fig.	 1A).	 2)	 Ill-defined	glands	 comprised	glands	with	poorly	 formed	or	 absent	 glandular	
lumina (Fig. 1B). Only a cluster of such glands was acceptable, to exclude the possibility 
of tangentially sectioned Gleason pattern 3 glands. 3) Cribriform was characterized by a 
glandular proliferation with multiple punched-out lumina, without intervening stroma (Fig. 
1C).	 4)	Glomeruloid	 glands	were	 defined	 as	 the	 presence	 of	 dilated	 glands	 containing	 a	
cribriform proliferation that is attached to only one edge of the gland, resulting in the 
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structure	 resembling	 a	 glomerulus	 (Fig.	 1D).	 Tertiary	 Gleason	 grade	 5	 was	 defined	 as	
presence of 1) solid sheets, cords, or single cells with no glandular differentiation or 2) 
comedocarcinoma with central necrosis surrounded by papillary, cribriform, or solid masses 
in	less	than	5%	of	the	radical	prostatectomy	specimen.	Intraductal	carcinoma	was	defined	
as a well-circumscribed lesion surrounded by an intact basal cell layer distended by overtly 
malignant-appearing epithelial populations (Fig. 1E).15 Clear distention of prostate glands 
and presence of necrosis were used as cut-offs to distinguish intraductal carcinoma from 
high-grade prostatic epithelial neoplasia. To distinguish small foci of cribriform pattern 
from fused glands we applied two criteria. Contact of the majority of tumor cells with 
adjacent stroma and more linear orientation of lumina instead of rounded lumina were both 
in	favor	for	fused	glands.	In	addition,	we	did	not	use	a	size	threshold	for	cribriform	fields.	
When cribriform and intraductal carcinoma could not be distinguished morphologically, 
immunohistochemistry for basal cells (34BE12) was performed (n=6); presence of basal cells 
was considered supportive of intraductal carcinoma (Fig. 1F). Consensus was reached in all 
cases during a joint session. 
Figure 1.	Gleason	grade	4	patterns	and	intraductal	carcinoma.	A,	fused	glands.	B,	ill-defined	glands.	
C, cribriform glands. D, glomeruloid gland. E, intraductal carcinoma. F, 34BE12 immunohistochemistry, 
demonstrating the presence of basal cells supportive for intraductal carcinoma.
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Follow-up
After surgery, patients were monitored annually at our outpatient clinic. Biochemical 
recurrence	was	defined	as	a	PSA	level	of	≥0.2	ng/mL,	assessed	at	two	consecutive	time	points	
>3	months	apart	after	radical	prostatectomy.	Metastasis	was	defined	as	presence	of	prostate	
cancer	 in	 a	 lymph	node	or	 at	 a	 distant	 site,	with	 radiologic	 or	 pathologic	 confirmation.	
Since all lymph node metastases in this cohort were diagnosed at time of operation (follow-
up 0 months), they were not included as an endpoint but as a covariate in multivariate 
analysis	of	distant	metastasis	and	disease-specific	death.	Distant	metastases	in	this	study	
were all hematogenous. Outcome variables were biochemical recurrence-free survival 
defined	 as	 time	 after	 radical	 prostatectomy	 to	 biochemical	 recurrence;	metastasis-free	
survival	defined	as	time	after	radical	prostatectomy	to	distant	metastasis;	disease-specific	
survival	defined	as	time	after	radical	prostatectomy	to	death	attributed	to	prostate	cancer;	
overall	survival	defined	as	time	after	radical	prostatectomy	to	all-cause	death.	Death	and	
disease-specific	death	were	administered	by	medical	record	review	and	death	certificates.	
All relevant clinical, pathologic and follow-up data were recorded and regularly updated in 
a prospective study database (MW).
Statistics
Continuous clinico-pathologic variables were analyzed using the Mann-Whitney 
U test, and categorical variables using the Pearson’s Chi-square (X2) test. Correlation 
coefficients	were	calculated	by	the	Spearman’s	rank	Correlation	test.	Survival	probabilities	
were estimated by the Kaplan-Meier method. Unadjusted two-group comparisons for 
survival time were made with log-rank testing. We used Cox proportional hazards regression 
to determine the predictive value of Gleason grade 4 patterns for survival time. Age, PSA 
level, Gleason score, pT stage, surgical margin status, lymph node status, Gleason grade 
4 patterns, intraductal carcinoma and tertiary Gleason grade 5 were all included in the 
multivariable analysis as potential confounders. Dummy variables were created to convert 
pT stage into series of binary groups. All statistics were performed using SPSS 22 (SPSS Inc., 
Chicago,	USA).	A	two-sided	P	value	<0.05	was	considered	significant.
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RESULTS
Patient characteristics
The clinico-pathologic characteristics are listed in Table 1. The median follow-up 
in	controls	was	160	months	(IQR	120-190),	which	was	significantly	longer	than	the	follow-up	
of	the	cases	(100	months;	IQR	78-150;	P=0.001).	As	expected	from	the	matching,	cases	and	
controls had a similar distribution for age, PSA level and pT stage (Table 1). Gleason score 
4+3=7	was	more	frequent	 in	cases	than	controls	 (48%	vs.	19%,	X2 P=0.001). Furthermore, 
cribriform pattern and intraductal carcinoma were both more often present in cases than 
controls:	 81%	 vs.	 38%	 (X2 P<0.001)	 and	 58%	 vs.	 33%	 (X2 P=0.003) respectively. Cases and 
controls	showed	a	similar	distribution	for	fused,	ill-defined	and	glomeruloid	Gleason	grade	4	
patterns, tertiary Gleason grade 5, number of Gleason grade 4 patterns, and surgical margin 
status.
Biochemical	recurrence	occurred	in	44/52	(85%)	of	the	cases	and	in	45/109	(41%)	of	
the	controls.	In	cases,	the	median	time	to	biochemical	recurrence	was	19	months	(IQR	11-
37);	in	controls	this	was	61	months	(IQR	28-110)	(log	rank	P<0.001).	A	total	of	45	(87%)	cases	
had	metastatic	disease,	of	which	11	were	lymph	node	metastasis	(21%)	all	discovered	at	
time	of	operation,	and	37	distant	metastasis	(71%).	The	median	time	to	distant	metastasis	
was	67	months	(IQR	46-94).	Thirty	men	(60%)	of	the	cases	died	from	prostate	cancer.	The	
median	time	to	disease-specific	death	was	110	months	(IQR	91-140).	The	overall	mortality	
rate	was	70%	in	cases,	and	14%	in	controls.	
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Cribriform growth pattern is associated with Gleason score 4+3=7 and intraductal carcinoma
The	clinico-pathologic	characteristics	of	the	study	population	stratified	by	either	
the presence or absence of cribriform pattern are listed in Table 2. Presence of cribriform 
pattern	was	3.0	times	more	frequent	in	patients	with	Gleason	score	4+3=7	(42%	vs.	14%	in	
absence of cribriform pattern, X2 P<0.001).	Intraductal	carcinoma	was	seen	in	54/83	patients	
with	cribriform	pattern	(65%),	and	vice	versa	cribriform	pattern	in	54/66	(82%)	patients	with	
intraductal	carcinoma	(Spearman’s	ρ=0.51,	P<0.001),	while	intraductal	carcinoma	without	
cribriform	pattern	occurred	 in	12/78	patients	 (15%).	Additionally,	cribriform	pattern	was	
positively associated with presence of multiple Gleason grade 4 patterns (Spearman’s 
ρ=0.54,	 P<0.001).	Also,	 lymph	 node	metastases	were	more	 prevalent	 in	 specimens	with	
cribriform	pattern	(11%	vs.	2.6%	in	absence	of	cribriform	pattern,	X2 P=0.037). By contrast, 
ill-defined	glands	were	more	prevalent	when	cribriform	pattern	was	absent	(76%	vs.	52%;	
X2 P=0.002).
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Predictors for biochemical recurrence: seminal vesicle invasion, positive surgical margins 
and cribriform pattern
When cribriform pattern was present, the median time to biochemical recurrence 
was	 34	months	 (IQR	 11-88),	 and	 120	months	 (IQR	 40-170)	 when	 cribriform	 pattern	 was	
absent	(log	rank	P<0.001)	(Figure	2A).	Age,	PSA	level,	Gleason	score	4+3=7,	seminal	vesicle	
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invasion	 (pT3b),	 positive	 surgical	 margins,	 and	 intraductal	 carcinoma	 were	 significant	
predictors for biochemical recurrence-free survival in a univariate analysis (data not 
shown). In multivariable analysis the following 3 variables were independent predictors 
for	biochemical	recurrence-free	survival:	seminal	vesicle	invasion	(HR	2.6,	95%	CI	1.2-5.7,	
P=0.014),	positive	surgical	margins	(HR	1.9,	95%	CI	1.2-3.0,	P=0.010)	and	cribriform	pattern	
(HR	2.0,	95%	CI	1.2-3.4,	P=0.006).
Figure 2. Kaplan-Meier estimates on impact of cribriform growth pattern in A, biochemical recurrence-
free	survival.	B,	distant	metastasis-free	survival.	C,	disease-specific	survival.	D,	overall	survival.
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Cribriform pattern is a strong predictor for distant metastasis and disease-specific death
The median time to distant metastasis in patients with cribriform pattern was 88 
months	(IQR	42-160),	and	150	months	in	men	without	cribriform	pattern	(IQR	120-180)	(log	
rank	P<0.001)	(Figure	2B).	Crude	and	adjusted	hazard	ratios	for	distant	metastasis	are	listed	
in Table 3. Univariate predictors for distant metastasis were Gleason score 4+3=7, cribriform 
pattern, intraductal carcinoma and tertiary Gleason grade 5; in multivariable analysis 
cribriform	pattern	was	the	only	independent	predictor	for	distant	metastasis	(HR	8.0,	95%	
CI	3.0-21,	P<0.001),	adjusted	for	age,	PSA	level,	Gleason	score,	pT	stage,	surgical	margin	
status, lymph node status, Gleason grade 4 patterns, intraductal carcinoma and tertiary 
Gleason grade 5. In contrast, fused pattern was associated with a decreased adjusted 
hazard	ratio	for	distant	metastasis	(HR	0.47,	95%	CI	0.22-1.0,	P=0.048).	The	median	time	
to	disease-specific	death	in	men	with	cribriform	pattern	was	120	months	(IQR	76-170),	and	
150	months	 (IQR	 120-180)	 in	men	without	 cribriform	 pattern	 (log	 rank	 P<0.001)	 (Figure	
2C).	Crude	and	adjusted	hazard	 ratios	 for	disease-specific	 survival	 are	 listed	 in	Table	3.	
Univariate	 predictors	 for	 disease-specific	 survival	 were	 Gleason	 score	 4+3=7,	 cribriform	
pattern	and	 intraductal	 carcinoma	 (Table	3).	 Independent	predictors	 for	disease-specific	
survival	were	both	Gleason	score	4+3=7	(HR	3.1,	95%	CI	1.4-7.1,	P=0.007)	and	cribriform	
pattern	 (HR	 5.4,	 95%CI	 2.0-15,	 P=0.001).	 Furthermore,	 the	 overall	 survival	 in	 patients	
with cribriform pattern was shorter than in patients without cribriform pattern (log rank 
P=0.001) (Figure 2D).
Cribriform pattern in Gleason score 3+4=7 and Gleason score 4+3=7 subpopulations
Primary Gleason grade 4 (Gleason score 4+3=7) was unequally distributed between 
cases and controls (Table 1). Although Cox regression analysis compensated for this unequal 
distribution, we additionally studied the predictive value of cribriform pattern separately in 
Gleason score 3+4=7 (n=115) and Gleason score 4+3=7 (n=46) subpopulations. In Gleason score 
3+4=7, cribriform pattern was an independent predictor for both distant metastasis-free 
survival	(20	events)	(HR	6.0,	95%	CI	2.0-18,	P=0.001)	(log	rank	P<0.001)	and	disease-specific	
survival	 (13	events)	 (HR	4.9,	95%	CI	1.3-18,	P=0.017)	 (log	rank	P=0.013)	 in	multivariable	
analysis. Due to the limited number of events (n=12) and number of covariates no models 
could	be	fitted	for	distant	metastasis-free	survival	in	Gleason	score	4+3=7	prostate	cancer	
patients.	Cribriform	pattern	was,	however,	an	 independent	predictor	 for	disease-specific	
survival	(12	events)	in	Gleason	score	4+3=7	(HR	17,	95%	CI	2.2-130,	P=0.006).
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DISCUSSION
The clinical outcome of Gleason score 7 prostate cancer after radical prostatectomy 
is highly variable. Pathologically, Gleason grade 4 prostate cancer encompasses a 
heterogeneous	 group	 of	 growth	 patterns,	 defined	 as	 fused,	 ill-defined,	 cribriform	 and	
glomeruloid. Our objective was to determine the prognostic value of individual Gleason 
grade 4 patterns in Gleason score 7 prostate cancer patients. 
In this study, we found that presence of cribriform pattern in radical prostatectomy 
specimens	was	a	major	predictive	factor	for	distant	metastasis	and	disease-specific	death	
of prostate cancer. In fact, cribriform pattern was the strongest predictor for both adverse 
clinical events in multivariate analysis, adjusted not only for established clinico-pathologic 
variables (age, PSA, Gleason score, pT stage and surgical margins), but also for contemporary 
additional pathologic variables such as intraductal carcinoma and tertiary Gleason grade 5 
pattern.	Therefore,	identification	of	cribriform	growth	in	daily	pathology	practice	is	a	new,	
fast and cheap adjunct to predict adverse clinical outcome.
The	clinical	significance	of	Gleason	grade	4	patterns	has	only	since	recently	become	
an area of interest. Dong et al. found that metastasis occurred 5 times more frequently in 
patients	with	cribriform	pattern	at	 radical	prostatectomy	 (13%	vs.	2.6%	when	cribriform	
pattern absent) in a consecutive series of 241 patients.16 These results are well in line with 
the	findings	of	the	current	study.	However,	Dong	et al. did not adjust for other important 
variables, such as lymph node status, intraductal carcinoma and tertiary Gleason grade 5.
A	strong	point	of	this	study	is	the	use	of	metastasis-free	and	disease-specific	survival	
as	 endpoints	 since	 they	 objectively	 reflect	 aggressive	 tumor	 biology,	 while	 biochemical	
and local recurrence also depend on surgical margin status, and do not necessarily 
indicate metastatic tumor potential. In addition, we included contemporary pathologic 
characteristics such as intraductal carcinoma and tertiary Gleason grade 5, as covariates 
in our analysis. It is striking that presence of cribriform growth either as invasive prostate 
cancer or as intraductal expansion is associated with disease outcome. In both cribriform 
pattern and intraductal carcinoma, a majority of tumor cells has lost physical contact with 
surrounding stromal matrix or basement membrane, respectively, and only connect to 
adjacent epithelial tumor cells. The presence of intraductal carcinoma has been associated 
with high-grade cancer and adverse outcome.10,12,13 In our study, presence of cribriform 
pattern	 was	 significantly	 associated	 with	 intraductal	 carcinoma.	 Two	 hypotheses	 of	
intraductal carcinoma evolution have been proposed.17 First, established Gleason grade 4 or 
5	prostate	cancer	could	infiltrate	and	expand	pre-existing	glands;	this	theory	is	supported	by	
the fact that intraductal carcinoma is rarely found in absence of high-grade prostate cancer. 
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Alternatively, high-grade prostatic intraepithelial neoplasia, which is generally accepted 
as prostate cancer precursor, might evolve into intraductal carcinoma and consecutively 
invasive high-grade prostate cancer. The molecular and biological connections of separate 
intraductal and invasive growth patterns are intriguing and clinically important, but still 
poorly understood.
A limitation of the current study is the nested case-control design, in which the 
cases had Gleason score 4+3=7 prostate cancer more often than the controls. Although Cox 
regression analysis compensated for the unequal Gleason score distribution, we performed 
additional	analysis	in	3+4	and	4+3	prostate	cancer	subgroups,	which	confirmed	the	prognostic	
value of cribriform pattern. Another caveat of our study was the strict delimitation of 
Gleason	grade	4	patterns	in	4	groups.	This	subdivision	reflects	the	categories	defined	by	the	
ISUP/ WHO, but does not take into account subtle architectural variations such as small and 
large	cribriform	fields,	locally	fused	glands	and	complex	fused	structures	with	intervening	
stroma. In this study, we did not determine the relative percentage or volume of Gleason 
grade	4.	While	subgroup	analysis	of	cribriform	growth	in	Gleason	score	3+4=7	(<50%	Gleason	
grade	4)	and	4+3=7	(≥50%	Gleason	grade	4)	revealed	independent	prognostic	value	in	both	
groups,	further	delineating	of	Gleason	grade	4	percentage	might	have	influenced	outcome.	
Interestingly, Ross et al. suggested in their large study of lymph node metastasis that even 
the slightest presence of cribriform growth could give rise to metastasis.7 Furthermore, we 
did not take prostate cancer volume or an associated parameter into account. Although 
prostate cancer volume might be a confounder in our study, our group has previously shown 
that it did not add prognostic value to established pathologic variables.18 We matched for 
pT stage as a surrogate of prostate cancer volume in this study. 
The	outcome	of	our	 study	 is	of	 significant	clinical	 relevance.	Currently,	patients	
with Gleason score 3+4=7 are considered to be at low to intermediate risk in clinical 
practice; they even might be candidates for active surveillance. However, based on our 
results, Gleason score 7 patients with cribriform growth are more likely to be candidates 
for treatment. If validated on diagnostic prostate needle-biopsies, cribriform growth might 
influence	therapeutic	decision-making	in	clinical	practice.
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CONCLUSION
Cribriform growth is a novel and strong independent histopathological predictor for 
distant	metastasis-free	survival	and	disease-specific	survival	in	patients	with	Gleason	score	
7 prostate cancer at radical prostatectomy. 
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ABSTRACT
Background: Invasive cribriform and intraductal carcinoma in radical prostatectomy 
specimens have been associated with an adverse clinical outcome. Our objective was to 
determine the prognostic value of invasive cribriform and intraductal carcinoma in pre-
treatment	biopsies	on	time	to	disease-specific	death.	
Patient and methods: We pathologically revised the diagnostic biopsies of 1031 patients 
from	the	first	screening	round	of	the	European	Randomized	Study	of	Screening	for	Prostate	
Cancer 1993-2000). Ninety percent of all patients (n=923) had received active treatment, 
whereas	10%	(n=108)	had	been	followed	by	watchful	waiting.	The	median	follow-up	was	13	
years. Patients who either had invasive cribriform growth pattern or intraductal carcinoma 
were	categorized	as	CR/IDC+.	The	outcome	was	disease-specific	survival.	Relationships	with	
outcome were analyzed using multivariable Cox regression and log-rank analysis. 
Results:	In	total,	486	patients	had	Gleason	score	6	(47%)	and	545	had	≥7	(53%).	The	15-year	
disease-specific	survival	rates	were	99%	in	Gleason	score	6	(n=486),	94%	in	CR/IDC-	Gleason	
score	≥7	(n=356)	and	67%	in	CR/IDC+	Gleason	score	≥7	(n=189).	CR/IDC-	Gleason	score	3+4=7	
patients did not have statistically different survival probabilities from those with Gleason 
score	6	(P=.30),	while	CR/IDC+	Gleason	score	3+4=7	patients	did	(P<.001).	In	multivariable	
analysis	CR/IDC+	status	was	independently	associated	with	a	poorer	disease-specific	survival	
(HR	2.6,	95%	CI	1.4-4.8,	P=.002). 
Conclusion: We conclude that CR/IDC+ status in prostate cancer biopsies is associated with a 
worse	disease-specific	survival.	Active	surveillance	criteria	may	potentially	be	extended	to	
CR/IDC- Gleason score 3+4=7 prostate cancer, as these patients have similar survival rates 
to those with Gleason score 6. 
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INTRODUCTION
The management of newly diagnosed prostate cancer is challenging because of its 
heterogeneity in histology, genetics and clinical outcome. Today, clinical-decision making 
mostly	depends	upon	serum	Prostate	Specific	Antigen	(PSA)	level,	clinical	tumor	stage,	and	
pathologic biopsy Gleason score – a grading system based on architectural tumor patterns. 
While	patients	with	the	lowest	Gleason	scores	≤6	have	an	excellent	outcome,	those	with	the	
highest Gleason scores (9-10) have the worst.1
The clinical outcome of Gleason score 7 prostate cancer patients is highly variable. 
Improving risk assessment is of particular interest, as Gleason score 7 prostate cancer on 
biopsy is an important clinical threshold for active treatment. Recent studies have suggested 
that	the	broad	contemporary	definition	of	the	Gleason	grade	4	pattern	may	be	one	of	the	
explanations for the variable outcomes of patients with Gleason score 7 prostate cancer.2-5 
Architecturally, four Gleason grade 4 growth patterns are recognized: ill-formed, fused, 
glomeruloid and cribriform.1,6 Recently, cribriform pattern has been associated with adverse 
outcome after radical prostatectomy in Gleason score 7 prostate cancer.2-5
In recent years the clinical relevance of intraductal carcinoma of the prostate – a 
high-risk	lesion	defined	as	malignant	epithelium	filling	large	acini	or	ducts	with	preservation	of	
basal cells – has been acknowledged. Although not included in the Gleason score, intraductal 
carcinoma has been associated with high Gleason scores, advanced tumor stage, biochemical 
relapse and distant metastasis.7-12 Intraductal carcinoma can, however, microscopically 
mimic invasive cribriform carcinoma requiring additional immunohistochemistry for their 
distinction. Studies on the prognostic value of invasive cribriform and intraductal carcinoma 
have mostly been based on radical prostatectomy specimens.2-5,11,13 The aim of this study 
was to determine the prognostic value of invasive cribriform and intraductal carcinoma in 
diagnostic	biopsies	on	time	to	disease-specific	death.
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MATERIALS AND METHODS
Patient selection
We	included	all	1078	men	from	the	first	screening	round	of	the	Dutch	part	of	the	European	
Randomized Study of Screening for Prostate Cancer (ERSPC), who had been diagnosed with 
prostate cancer between November 1993 and March 2000 in Erasmus Medical Center, Rotterdam, 
The Netherlands. The trial protocol has been published previously.14,15 The ERSPC is an ongoing 
multicenter randomized screening trial that was initiated in the early 1990s to evaluate the effect 
of	screening	with	PSA	testing	on	disease-specific	mortality	rates.	Exclusion	criteria	of	the	present	
study	were	unavailability	of	slides	or	paraffin	blocks	for	review	(n=24),	and	presence	of	lymph	
node or distant metastasis at time of diagnosis (n=23), leaving 1031 patients for analysis.
Pathological evaluation
Three investigators (C.K., I.K., G.v.L.), who were blinded to patient information and 
outcome, revised all histopathological slides. For each biopsy core we recorded tumor percentage, 
tumor length (mm), Gleason score, presence of intraductal carcinoma, and presence of Gleason 
grade 4 and 5 growth patterns.1	The	overall	tumor	percentage	per	patient	was	defined	as	the	sum	
of total tumor length (mm) divided by the sum of total biopsy length (mm). The label CR/IDC+ was 
given to patients who either had invasive cribriform carcinoma, intraductal carcinoma or both, CR/
IDC−	to	those	who	had	neither.	CR/IDC	specific	tumor	percentage	per	patient	was	defined	as	the	
sum of total length CR/IDC glands (mm) divided by the sum of total biopsy length (mm). Gleason 
grading was performed according to the 2014 ISUP recommendations.1 To distinguish invasive 
cribriform carcinoma from intraductal carcinoma, and high-grade prostatic epithelial neoplasia 
(HGPIN) from intraductal carcinoma we used morphological criteria as described by Guo et al.7 In 
case morphological distinction between invasive cribriform carcinoma and intraductal carcinoma 
was	not	certain	(105/193,	54%),	we	applied	high-molecular-weight-keratin	immunohistochemistry	
to detect the presence of basal cells. 
Clinical follow-up 
After diagnosis and initial treatment, patients were semi-annually monitored by chart 
review to assess potential progression and secondary treatments. The cause of death was 
evaluated by an independent cause-of-death committee, where death due to causes related to 
screening were also counted as prostate cancer deaths.16 Although data on the occurrence of 
distant metastases were available, we did not include this endpoint in our study, as these events 
largely	overlapped	with	the	number	of	disease-specific	deaths.
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Statistical analysis 
Continuous parameters were analyzed by the Mann-Whitney U test or Kruskal-Wallis 
test,	categorical	parameters	by	the	Pearson’s	Chi-square	(χ2) test. Non-normally distributed 
continuous variables underwent log base 2 transformation such that effects related to a 
doubling in unit. We estimated survival probabilities using the Kaplan-Meier method. 
Unadjusted comparisons for survival time were made using log-rank tests with censoring of 
men lost to follow-up or dying of other causes. Crude and adjusted hazard ratios (HRs) for 
survival time were calculated using Cox proportional hazards regression. The concordance 
index (c-index) was used to quantify the ability of single variables and combinations of 
variables in multivariable models to discriminate between patients with and without the 
event of interest.17 The c-index takes values between 0.5 and 1, where 0.5 indicates that 
the	model	 is	not	better	 than	chance	classification	and	1	means	perfect	discrimination.18 
Regression models were compared using the Likelihood-ratio test. All statistical analyses 
were	performed	in	R	version	3.1.2	(R,	Vienna,	Austria).	Two-sided	P	values	of	<0.05	were	
considered	statistically	significant.
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RESULTS
Patient characteristics 
The	median	age	of	the	entire	cohort	(N=1031)	was	66	years	(IQR	62-71)	and	the	
median	follow-up	13	years	(IQR	9.4-16,	Table	1).	In	total,	90%	of	all	patients	(n=923)	had	
received	active	treatment,	whereas	10%	(n=108)	had	been	followed	by	watchful	waiting.	A	
total of 496 patients died during follow-up, 72 of whom from prostate cancer. The majority 
(53%)	of	patients	had	Gleason	score	3+4=7	or	higher.	Gleason	score	was	positively	associated	
with age, PSA level, tumor percentage and percentage of positive cores. The most frequently 
observed	Gleason	grade	4	pattern	in	Gleason	score	3+4=7	or	higher	was	ill-formed	(80%),	
followed	by	 fused	 (53%),	 cribriform	 (20%)	 and	 glomeruloid	 (15%).	 Presence	of	 cribriform	
growth was the most discriminative Gleason grade 4 pattern between Gleason score 3+4=7 
and	 4+3=7	 (7.7%	 versus	 37%,	 χ2	 P<.001).	 We	 found	 a	 similar	 association	 for	 intraductal	
carcinoma	 (13%	 versus	 42%,	 χ2	 P<.001).	 Intraductal	 carcinoma	 co-existed	 with	 invasive	
cribriform	carcinoma	in	57	out	of	111	patients	(51%).	 Invasive	cribriform	and	 intraductal	
carcinoma were predominantly seen in Gleason score 4+3=7 and higher prostate cancer. 
In total, 193 patients had CR/IDC+ status; the distribution among Gleason score is shown 
in Table 1. Most low-risk patients had undergone radical prostatectomy whereas high-risk 
patients had received radiotherapy. 
Prognostic value of CR/IDC status
Presence	 of	 intraductal	 carcinoma	 (crude	 HR	 7.6,	 95%	 CI	 4.8-12,	 P<.001,	
c-index=0.697)	 and	 invasive	 cribriform	 carcinoma	 (crude	HR	 6.3,	 95%	CI	 3.9-10,	 P<.001,	
c-index=0.639)	were	 both	 significantly	 associated	with	worse	 disease-specific	 survival	 in	
univariate analyses. The combined CR/IDC+ status was also strongly associated with worse 
disease-specific	survival	(crude	HR	11,	95%	CI	6.6-18,	P<.001,	c-index=0.758)	and	was	similar	
if intraductal carcinoma and invasive cribriform carcinoma were analyzed as separate 
predictors in a model (c-index = 0.761). When separating each Gleason score group for CR/
IDC	status	the	disease-specific	survival	rates	were	significantly	lower	in	CR/IDC+	patients	
with Gleason score 3+4=7, 8, and 9-10. (Figure 1). Although we saw some evidence of lower 
survival rates in CR/IDC+ Gleason score 4+3=7, differences between groups did not meet 
conventional	levels	of	statistical	significance	(log	rank	P=.054).	The	Gleason	score	6	group	
contained only 4 CR/IDC+ patients (all intraductal carcinoma). CR/IDC- Gleason score 3+4=7 
patients	did	not	have	significantly	different	survival	probabilities	from	those	with	Gleason	
score	6	(log	rank	P=.30),	while	CR/IDC+	Gleason	score	3+4=7	patients	had	significantly	worse	
survival	rates	than	those	with	Gleason	score	6	(log	rank	P<.001)	and	CR/IDC-	Gleason	score	
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3+4=7 (log rank P=.001). The survival probabilities of CR/IDC- patients with 4+3=7 or higher 
were	significantly	lower	than	of	those	with	Gleason	score	6	(log	rank	P<.001,	P=.03	and	P<.001	
respectively). CR/IDC- Gleason score 4+3=7 patients also had worse survival probabilities 
than those with CR/IDC- 3+4=7 (P=.03). Although patients with CR/IDC- Gleason score 9-10 
had poorer survival probabilities than those with CR/IDC- Gleason score 3+4=7 prostate 
cancer	 (log	 rank	 P=.001),	 there	was	 no	 statistical	 difference	 in	 disease-specific-survival	
probabilities comparing CR/IDC- Gleason score 9-10 with CR/IDC- Gleason score 4+3=7 and 
CR/IDC- Gleason score 8 patients (log rank P=.41 and P=.40, respectively). In general, the 
15-year	disease-specific-survival	probabilities	were	94%	(95%	CI	91-97%)	in	CR/IDC-	Gleason	
score	3+4=7	or	higher	(n=356)	and	67%	(95%	CI	59-76%)	in	CR/IDC+	Gleason	score	3+4=7	or	
higher	(n=189).	Presence	of	CR/IDC	growth	affected	disease-specific	survival	regardless	of	
its extent (Figure 1F). 
 
Figure 1.	Kaplan-Meier	disease-specific	survival	(DSS)	according	to	Gleason	score	and	CR/IDC	status.	A)	
Gleason score 6. B) Gleason score 3+4=7. C) Gleason score 4+3=7. D) Gleason score 8. E) Gleason score 
9-10. F) DSS probabilities according to percentage of CR/IDC glands.
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In a multivariable model, we analyzed the added prognostic value of CR/IDC 
status in combination with currently used clinically relevant variables, i.e. age, PSA level, 
treatment modalities, Gleason score, tumor percentage, and percentage of positive cores. 
In the model without CR/IDC status the following variables were independently associated 
with	a	worse	disease-specific	survival:	PSA	level,	tumor	percentage,	percentage	of	positive	
cores, and Gleason score 4+3=7 or higher (Table 2). After adding CR/IDC status into the 
model, Gleason score 4+3=7 and 8 were not independently associated with worse disease-
specific	survival	anymore.	We	found	that	the	c-index	significantly	increased	from	0.868	to	
0.877 after CR/IDC status was added to the model (Likelihood-ratio test P=.001). There was 
no	 statistically	 significant	 interaction	between	CR/IDC	 status	and	 treatment	 (Likelihood-
ratio test, P=.14) or CR/IDC status and Gleason score (Likelihood-ratio test P=.71).
Table 2. Adjusted HRs on time to disease-specific death in a clinical setting: the added value of 
CR/IDC status (N=1031). 
Model without CR/IDC status Model with CR/IDC status
Adjusted HR 95%	CI P value Adjusted HR 95%	CI P value
Age (years) 0.99 0.94-1.0 .60 0.99 0.94-1.0 .63
PSA level (log2) 1.2* 1.0-1.5 .02 1.2* 1.0-1.5 .04
Percentage of positive cores 
(log2)
1.8* 1.2-2.6 .006 1.6* 1.0-2.4 .03
Tumor percentage (log2) 1.5* 1.1-2.1 .02 1.4* 1.0-2.0 .05
Gleason score
  6 Reference Reference 
  3+4=7 1.2 0.48-3.1 .69 0.99 0.38-2.6 .99
  4+3=7 3.1 1.2-8.0 .02 1.9 0.67-5.4 .23
  8 3.7 1.4-10 .01 2.3 0.78-6.9 .13
  9-10 5.1 2.0-13 <.001 3.3 1.2-9.3 .02
CR/IDC+ status 2.6 1.4-4.8 .002
Radical prostatectomy 0.23 0.058-0.92 .04 0.26 0.064-1.0 .05
Radiotherapy 1.3 0.40-4.5 .63 1.4 0.42-4.7 .58
* Per doubling unit
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DISCUSSION
The current study showed that CR/IDC status in diagnostic biopsies is associated with 
a	worse	disease-specific	survival.	Adding	CR/IDC	status	to	a	predictive	model	resulted	in	a	
significantly	better	discriminative	ability.	The	most	interesting	finding	of	our	study	was	the	
overall good outcome of patients whose biopsies lacked CR/IDC growth, particularly in those 
with	CR/IDC−	Gleason	score	3+4=7,	whose	survival	did	not	differ	from	patients	with	Gleason	
score 6 prostate cancer. We additionally found that presence of a limited CR/IDC tumor 
component	(≤5%)	in	biopsies	was	already	associated	with	an	unfavorable	outcome.	This	finding	
is in line with the study of Trudel et al., who showed that any amount of large cribriform 
or intraductal carcinoma was associated with shorter time to biochemical recurrence after 
radical prostatectomy.13
In recent radical prostatectomy studies, intraductal carcinoma and invasive cribriform 
carcinoma	have	both	been	identified	as	independent	prognostic	factors.2-5,11,13 To date, only 
few studies have analyzed the prognostic value of intraductal carcinoma in pre-treatment 
diagnostic biopsies.7-9 They showed that intraductal carcinoma is associated with high-grade 
and	non-organ	confined	prostate	cancer	in	subsequent	radical	prostatectomies.7,8 In addition, 
Van der Kwast et al. demonstrated that intraductal carcinoma was associated with shorter 
time to biochemical recurrence and distant metastasis after radiotherapy in intermediate- to 
high-risk prostate cancer patients.9
Although	CR/IDC	status	in	our	predictive	model	led	to	significantly	better	discriminative	
ability, the absolute c-indices in the models with and without CR/IDC status only differed 
marginally. CR/IDC status might not affect clinical decision-making in patients with Gleason 
score 8-10 since these patients will undergo active treatment either way. CR/IDC status 
could, however, be useful to stratify Gleason score 3+4=7 patients for active surveillance 
or treatment. A drawback of the current Gleason grading system is its considerable inter-
observer variability, in particular when distinguishing Gleason score 3+4=7 from Gleason score 
6 prostate cancer.19,20	Variability	in	assignment	of	grade	is	significantly	related	to	the	presence	
of ill-formed and fused growth patterns; these represented the majority of Gleason score 
3+4=7 prostate cancers in this study. Egevad et al. found that cribriform growth was not 
statistically associated with Gleason score inter-observer variability among 337 pathologists.21 
This	indicates	that	CR/IDC	status	may	be	a	more	robust	parameter	for	patient	stratification	
than grading as either Gleason score 6 or 3+4=7.  
Although invasive cribriform carcinoma and intraductal carcinoma are two different 
pathologic entities, they may be related on a pathological and biological level.22,23 Their 
morphologic	distinction	 is	often	difficult	 requiring	 immunohistochemical	 staining	 for	basal	
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cells. While presence of basal cells is strongly supportive of intraductal carcinoma, lack of 
basal cells is not pathognomonic for invasive cribriform growth; basal cells can be scattered 
and not be sampled in the tissue section, which is also known to occur in HGPIN.24 The 
use of combined CR/IDC status is practical for pathologic diagnosis since it does not affect 
prognostic value of separate entities nor requires additional immunohistochemistry. This is 
also in line with the latest 2014 ISUP recommendations on Gleason grading, in which Epstein 
et al. advised that immunohistochemistry to distinguish invasive cribriform from intraductal 
carcinoma should only be considered in cases where the results of the studies would change 
the case’s overall grade, for example in cases lacking other Gleason grade 4 patterns.1
Several studies have reported on genetic abnormalities related to CR/IDC growth. 
Qian	et al. found gain of chromosome 7, 12 and Y, loss of chromosome 8, and extra copies 
of c-MYC in both cribriform HGPIN and invasive cribriform carcinoma, suggesting that these 
growth patterns are genetically more alike to Gleason grade 5 than Gleason grade 3 or 4 
prostate cancer.25,26 Dawkins et al. reported frequent losses of 8p22 and 16q23.1 in intraductal 
carcinoma.27 Bettendorf et al. found that intraductal carcinoma has more frequent loss of 
TP53, RB1 and PTEN.28 Using break-points regions to infer phylogenetic relationships, Lindberg 
et al. showed that the clone closely related to the metastases was found in intraductal 
carcinoma.29 We hypothesize that both invasive cribriform and intraductal carcinoma are 
architectural substrates of genetic aberrations associated with aggressive disease behavior. 
The fact that small CR/IDC components were already associated with worse outcome could 
be explained by the emergence of aggressive tumor clones irrespective of their volume.
A limitation of the current study is the fact that the original ERSPC biopsy protocol 
included sextant biopsies, while current biopsy schemes are more extensive and increasingly 
MRI	targeted	reducing	the	chance	of	sampling	error.	Future	research	is	needed	to	confirm	
that CR/IDC status’ prognostic value is similar in contemporary biopsy protocols. Another 
limitation is the difference in treatment modalities nowadays as compared to the 1990s. Low-
risk patients in this study had mostly received active treatment, while active surveillance 
would have been an acceptable strategy nowadays. The strengths of the current study are 
its	 large	number	of	patients	with	 long-term	follow-up,	the	use	of	disease-specific	survival	
as an outcome measure, and the meticulous pathological review. In conclusion, CR/IDC+ 
status	 in	prostate	cancer	biopsies	 is	 independently	associated	with	poorer	disease-specific	
survival. Active surveillance criteria may potentially be extended to CR/IDC- Gleason score 
3+4=7 prostate cancer, since these patients have similar survival rates as those with Gleason 
score 6. 
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Prostate cancer outcomes of  men with biopsy 
Gleason score 6 and 7 without cribriform or 
intraductal carcinoma
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ABSTRACT
Background: Gleason score (GS) 3+4=7 prostate cancer patients with presence of cribriform 
or intraductal carcinoma (7+)	 have	 a	worse	 disease-specific	 survival	 than	 those	without.	
The aim of this study was to compare the clinico-pathologic characteristics and patient 
outcomes of men with biopsy GS 3+4=7 without cribriform or intraductal carcinoma (7-) to 
those with GS 3+3=6. 
Patients	 and	 methods:	 We	 included	 all	 patients	 from	 the	 first	 screening	 round	 of	 the	
European Randomized Study of Screening for Prostate Cancer (1993-2000) with a revised 
GS	≤	3+4=7	(n=796)	following	the	2014	ISUP	criteria.	Relations	with	biochemical	recurrence	
after radical prostatectomy or radiotherapy were analyzed using log-rank testing and 
multivariable Cox regression analysis.
Results: In total 486 patients had GS 6 and 310 had GS 7, 54 of whom had GS 7+	(17%).	During	
a	median	follow-up	of	15	years,	biochemical	recurrence	was	seen	in	61	(20%)	GS	6,	54	(21%)	
GS 7- and 22 GS 7+	patients	(41%).	Both	biopsy	GS	7- and 7+	patients	had	significantly	higher	
PSA	levels,	mean	tumor	percentage,	percentage	of	positive	cores	and	≥cT3	than	those	with	
GS	6	(all	P<.001).	GS	7- patients did not have a poorer biochemical-recurrence-free-survival 
(BCRFS) after radical prostatectomy than GS 6 patients (log rank P=.13), whereas those with 
GS 7+ had (log rank P=.05). In multivariable analyses, biopsy GS 7- was not associated with 
poorer	BCRFS	after	radical	prostatectomy	(HR	1.3,	95%	CI	0.67-2.4,	P=.47)	or	radiotherapy	
(HR	0.88,	95%	CI	0.51-1.5,	P=.63).	GS	7+ was independently associated with poorer BCRFS 
after	radical	prostatectomy	(HR	3.0,	95%	CI	1.1-7.8,	P=.03),	but	not	after	radiotherapy	(HR	
1.2,	95%	CI	0.58-2.3,	P=.67).
Conclusion: Men with biopsy GS 7- prostate cancer have similar BCRFS after radical 
prostatectomy or radiotherapy to those with GS 6 and may be candidates for active 
surveillance.
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INTRODUCTION
The	use	of	prostate-specific	antigen	(PSA)	testing	has	led	to	substantially	increased	
detection	 of	 insignificant	 prostate	 cancers	 in	 the	 past	 two	decades.1 Active surveillance 
has gradually emerged as a valuable alternative treatment option for these men. While 
active	surveillance	has	the	benefit	of	avoiding	overtreatment,	it	also	retains	the	option	for	
active treatment in case of disease progression. Although most active surveillance protocols 
are limited to Gleason score (GS) 3+3=6, some institutions have extended their criteria to 
include biopsies containing small amounts of Gleason grade 4.2-5 Contemporary Gleason 
grade 4 prostate cancer represents a heterogeneous group of various growth patterns 
comprising ill-formed, fused, cribriform and glomeruloid glands. While Gleason grade 4 is 
not	sub-classified	in	daily	practice,	recent	studies	have	suggested	that	among	Gleason	grade	
4 growth patterns, cribriform growth is associated with worse clinical outcome, while fused, 
glomeruloid and ill-formed glands are not.6-9
 In recent years the clinical relevance of intraductal carcinoma of the prostate – a 
high-risk	lesion	defined	as	malignant	epithelium	filling	large	acini	or	ducts	with	preservation	
of basal cells – has been acknowledged. Although not included in the Gleason grading 
system, intraductal carcinoma has been associated with high GS, advanced tumor stage, 
biochemical relapse and distant metastasis.10-15 Intraductal carcinoma can microscopically 
mimic invasive cribriform carcinoma and immunohistochemistry is often required for 
their distinction. Recently, our group has shown that biopsy GS 3+4=7 patients without 
cribriform or intraductal carcinoma (7-)	have	comparable	disease-specific	survival	rates	to	
those with GS 3+3=6, while those with cribriform or intraductal carcinoma in their biopsies 
(7+)	had	significantly	worse	outcomes.16 Although various studies have shown the adverse 
prognostic value of invasive cribriform and intraductal growth in GS 7 prostate cancer 
patients, it is not yet clear to what extent the outcome of men with GS 7- differs from 
those with GS 6 prostate cancer. Since GS 3+4=7 prostate cancer patients generally undergo 
active treatment, identifying low-risk GS 3+4=7 tumors could offer a rationale for active 
surveillance in this large subgroup of prostate cancer patients. The aim of this study was to 
compare the clinico-pathologic characteristics and long-term outcomes of men with biopsy 
GS 3+3=6 or GS 3+4=7 without invasive cribriform or intraductal prostate cancer.
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MATERIALS AND METHODS
Patient selection
We	 identified	 all	 1078	men	 from	 the	 first	 screening	 round	 of	 the	 Dutch	 part	 of	
the European Randomized Study of Screening for Prostate Cancer (ERSPC), who had been 
diagnosed with prostate cancer between November 1993 and March 2000 in Erasmus Medical 
Center, Rotterdam, The Netherlands. The trial protocol has been published previously.17,18 
After pathologic review of all available slides (n=1055) according to the 2014 International 
Society of Urological Pathology (ISUP) recommendations, we selected all patients with a 
highest biopsy GS 3+4=7 or lower for the current study (n=803).19 Exclusion criteria were 
presence	of	a	lymph	node	or	distant	metastasis	at	time	of	diagnosis	(n=7).	The	final	selection	
included 796 patients, 486 of whom had GS 3+3=6 and 310 had 3+4=7.
Pathological evaluation
Three investigators (C.K., I.K., G.v.L.), who were blinded to patient information 
and outcome, revised all histopathological slides. For each biopsy core we recorded GS, 
and presence of cribriform pattern or intraductal carcinoma. Since invasive cribriform 
and	 intraductal	 carcinoma	 often	 co-exist,	 and	 separate	 classification	 is	 challenging,	 we	
combined both patterns to one group (CR/IDC). The mean tumor percentage per patient 
was	defined	as	the	sum	of	total	tumor	length	(mm)	divided	by	the	sum	of	total	biopsy	length	
(mm). The label 7+ was given to patients with GS 3+4=7 who either had invasive cribriform 
carcinoma, intraductal carcinoma or both, 7- to those who had neither. Gleason grading 
was done according to the 2014 ISUP recommendations.20	The	2009	TNM	classification	was	
used to assess pT stage.21	A	positive	surgical	margin	at	radical	prostatectomy	was	defined	as	
extension of the tumor into the specimen’s inked surface. 
Clinical evaluation 
Up to February 1997, transrectal ultrasound-guided sextant biopsies were taken 
based on a combination of digital rectal examination, transrectal ultrasonography, and PSA 
testing (with a cutoff value of 4.0 ng per milliliter); in 1997, this combination was replaced by 
PSA testing only. After diagnosis and initial treatment, patients were semi-annually monitored 
by chart review to assess potential progression and secondary treatments. Biochemical 
recurrence	was	defined	as	a	PSA	level	of	≥0.2	ng/mL	assessed	at	two	consecutive	time	points	
> 3 months apart after radical prostatectomy or any PSA increase >2 ng/mL higher than 
the PSA nadir value after radiotherapy.22 Biochemical-recurrence-free survival (BCRFS) was 
defined	as	time	after	radical	prostatectomy	or	radiotherapy	to	biochemical	recurrence
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Statistical analysis 
Continuous parameters were analyzed by the Mann-Whitney U test, categorical 
parameters	 by	 the	 Pearson’s	 Chi-square	 (χ2) test. Non-normally distributed continuous 
variables underwent log base 2 transformation such that effects related to a doubling 
in unit. We estimated survival probabilities using the Kaplan-Meier method. Unadjusted 
comparisons for survival time were made using log-rank tests with censoring of men lost to 
follow-up. Crude and adjusted hazard ratios (HRs) for survival time were calculated using 
Cox proportional hazards regression. Median values of continuous variables were used to 
create adjusted survival curves. All statistical analyses were performed in R version 3.2.2 
(R, Vienna, Austria). Two-sided P values	of	<0.05	were	considered	statistically	significant.
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RESULTS
Patient characteristics 
The	median	(IQR)	age	was	66	(62-70)	years	and	the	median	(IQR)	follow-up	15	(10-
17)	years	(Table	1).	Patients	with	GS	7	had	significantly	higher	mean	PSA	 levels	 (P<.001)	
and	more	often	clinical	extra-capsular	extension	than	GS	6	patients	(P<.001).	Quantitative	
measurements	 of	 tumor	 involvement,	 such	 as	 mean	 tumor	 percentage	 (P<.001)	 and	
percentage	of	positive	cores	(P<.001),	were	also	higher	in	GS	7	patients.	Although	lymph	
node and distant metastases were relatively rare in the entire cohort, men with GS 7 had 
more	distant	metastases	during	follow-up	than	those	with	GS	6	(5.6%	versus	1.9%,	P=.009).	
CR/IDC	growth	was	observed	in	54	out	of	310	(17%)	GS	7	patients.	GS	7+ patients had higher 
mean PSA levels (P=.018), percentage of positive cores (P=.015) and tumor percentage 
(P<.001)	than	those	with	7-. The number of distant metastases in patients with GS 7+ was 4.3 
fold higher than in GS 7-	men	(15%	versus	3.5%,	P=.003).	Although	GS	7- patients had higher 
PSA	levels	(P<.001)	and	more	biopsy	tumor	involvement	(P<.001)	than	GS	6	patients,	the	
number of observed distant metastases was not statistically different between both groups 
(P=.25).	Overall	biochemical	recurrence	was	seen	in	61	(20%)	GS	6,	54	(21%)	GS	7- and 22 
GS 7+	patients	(41%).
Primary treatment
In the 1990s, treatment modalities differed from nowadays with relatively few 
patients having been selected for active surveillance. In the current study, 80 out of 486 
(16%)	GS	6	patients	were	followed	by	active	surveillance,	while	84%	and	93%	of	men	with	
GS	6	and	7,	 respectively,	had	undergone	active	 treatment.	The	median	 (IQR)	age	of	 the	
radiotherapy cohort was 69 years (64-72), whereas the radical prostatectomy cohort was 
younger	having	a	median	 (IQR)	age	of	64	years	 (60-67,	P<.001).	Seventy-four	out	of	342	
(22%)	 radiotherapy	 patients	 had	 clinical	 extra-capsular	 extension	 at	 diagnosis	 compared	
to	27	out	of	345	(7.8%)	radical	prostatectomy	patients	(P<.001).	The	mean	biopsy	tumor	
involvement did not differ statistically between the radiotherapy and radical prostatectomy 
cohort (P=.85 and P=.22 for percentage of positive cores and mean tumor percentage, 
respectively).	GS	7	patients	had	more	often	received	radiotherapy	(50%	versus	39%;	P=.003),	
whereas	watchful	waiting	was	more	 frequently	 chosen	 in	GS	 6	 patients	 (16%	 versus	 7%;	
P<.001).	Because	patient	characteristics	differed	between	the	two	treatment	modalities,	
we decided to focus our further analyses on the separate treatment groups.
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Radical prostatectomy
Patients with GS 7-	prostate	cancer	had	significantly	higher	mean	PSA	levels	(P=.018)	
and	more	tumor	involvement	(P<.001)	in	their	biopsies	than	those	with	GS	6	(Table	2).	In	
the corresponding radical prostatectomy specimen, extra-prostatic extension (pT3/4) was 
more frequently observed in biopsy GS 7-	than	in	GS	6	patients	(29%	versus	12%,	P=.001).	
Similarly, biopsy GS 7- patients had more often positive surgical margins than those with GS 
6	(29%	versus	17%,	P=.01).	We	did	not	find	statistically	significant	differences	in	clinical	and	
pathologic characteristics of GS 7- and GS 7+ patients.  
Patients with biopsy GS 7 had a poorer BCRFS than those with GS 6 (log rank P=.03, 
Figure	 1A).	After	 15	 years	 of	 follow-up,	 87%	 (95%	CI	 82-92%)	 of	 patients	with	 biopsy	GS	
6	had	been	biochemical-recurrence	 free	versus	80%	 (95%	CI	73-87%)	of	 those	with	GS	7.	
After stratifying the GS 7 population for CR/IDC growth, GS 7+	patients	had	a	significantly	
worse BCRFS than those with GS 6 (P=.002) and GS 7- (P=.05, Figure 1). In contrast, BCRFS 
did not differ statistically between patients with GS 6 and 7- (log rank P=.13, Figure 1B). 
BCRFS	also	differed	significantly	when	comparing	GS	6	and	7- together versus 7+ (P=.006). 
In multivariable analysis, including clinically relevant variables, PSA level and presence of 
CR/IDC (7+) were independently associated with a poorer BCRFS, while GS 7- was not (Table 
3, Figure 1C). 
Figure 1. Biochemical-recurrence-free survival after radical prostatectomy of A) Gleason score 
6 and 7 patients, B) Gleason score 6, 7- and 7+ patients. C) Adjusted Biochemical-recurrence-free-
survival probabilities of Gleason score Gleason score 6, 7- and 7+ patients who had undergone radical 
prostatectomy.
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Radiotherapy
Regardless of CR/IDC growth, biopsy GS 7 patients had higher mean PSA levels, 
more tumor involvement and clinical extra-capsular extension than those with GS 6 (Table 
4). Unlike in the radical prostatectomy cohort, patients with GS 7+	had	significantly	higher	
PSA	 levels	 (P=.031),	 biopsy	 tumor	 involvement	 (P<.001),	 and	more	 often	 clinical	 extra-
capsular extension (P=.04) than those with GS 7-. Although biopsy GS 6 patients had more 
often cT1 stage compared to GS 7-	patients	(50%	versus	33%,	P=.004),	there	was	no	statistical	
difference	in	clinical	extra-capsular	extension	(16%	versus	24%,	P=.10).	
Patients	with	biopsy	GS	7	had	a	poorer	BCRFS	than	those	with	GS	6	(P<.001,	Figure	2A).	
After	15	years	of	follow-up,	78%	(95%	CI	72-85%)	of	patients	with	GS	6	had	been	biochemical-
recurrence	free	versus	62%	(95%	CI	53-71)	of	those	with	GS	7.	After	stratifying	GS	7	patients	
for CR/IDC growth, 7+	patients	had	significantly	worse	BCRFS	than	those	with	GS	6	(log	rank	
P<.001)	and	7- (log rank P=.01, Figure 2B). Biochemical-recurrence free survival probabilities 
of 7-	patients	were	significantly	worse	than	those	with	GS	6	in	the	crude	analysis	(log	rank	
P=.04). In multivariable analysis, PSA level, percentage of positive cores and mean tumor 
percentage were the only variables independently associated with biochemical recurrence, 
while GS 7- and GS 7+ were not (Table 5, Figure 2C).
Table 3. Adjusted HRs on time to biochemical recurrence after radical prostatectomy (n=345).
Radical prostatectomy (n=345)
HR 95%	CI P value
Age at diagnosis 1.0 0.96-1.1 .39
PSA level at diagnosis 1.4* 1.0-2.0 .03
Gleason score
  6 Reference
  7- 1.3 0.67-2.4 .47
  7+ 3.0 1.1-7.8 .03
Mean tumor percentage 0.94* 0.74-1.2 .69
Percentage of positive cores 1.3* 0.89-1.9 .17
* Per doubling unit
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Figure 2. Biochemical-recurrence-free survival after radiotherapy of A) Gleason score 6 and 7 patients, 
B) Gleason score Gleason score 6, 7- and 7+ patients. C) Adjusted Biochemical-recurrence-free-survival 
probabilities of Gleason score Gleason score 6, 7- and 7+ patients who had undergone radiotherapy.
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Table 5. Adjusted HRs on time to biochemical recurrence after radiotherapy (n=337).
HR 95%	CI P value
Age at diagnosis 1.0 0.96-1.1 .71
PSA level at diagnosis 2.2* 1.8-2.8 <.001
Gleason score
  6 Reference
  7- .88 0.51-1.5 .63
  7+ 1.2 0.58-2.3 .67
Mean tumor percentage 1.4* 1.1-1.8 .006
Percentage of positive cores 1.4* 1.1-1.9 .02
* Per doubling unit
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DISCUSSION
 Patients with GS 7, regardless of CR/IDC growth, had higher PSA levels, more tumor 
involvement, and more often clinical extra-capsular extension at biopsy than those with 
GS 6. We found that GS 7- patients did not have a statistically different BCRFS and number 
of distant metastases than those with GS 6, while men with GS 7+	performed	significantly	
worse.	In	multivariable	analyses,	there	was	no	statistically	significant	difference	in	BCRFS	
between GS 7- and GS 6 prostate cancer patients in both treatment groups, whereas GS 7+ 
was associated with a poorer BCRFS after radical prostatectomy. Although previous studies 
have indicated that both cribriform and intraductal carcinoma are associated with worse 
outcome	in	GS	7	patients,	our	study	was	specifically	focused	on	the	comparison	of	GS	6	and	
GS 7- prostate cancer.6-11,23 GS 7 prostate cancer patients do not have worse outcome than 
GS 6, if CR/IDC growth, PSA level and biopsy involvement are taken into account.
An increasing number of studies is providing evidence that invasive cribriform 
and intraductal carcinoma at prostate biopsy are associated with adverse outcome.6-11,23 
Khani and Epstein reported that most men with biopsy GS 6 with intraductal carcinoma 
had	aggressive	 tumor	 features	with	 a	 20%	 rate	of	disease	progression	after	 treatment.24 
Keefe et al.	reported	a	29%	(n=30)	prevalence	of	cribriform	growth	in	their	cohort	of	104	
biopsy GS 3+4=7 patients who had all been treated with radical prostatectomy. Of these 
30	patients,	 18	 (60%)	had	pT3	 stage	at	 radical	 prostatectomy.25 In our cohort we report 
both	a	 lower	prevalence	of	CR/IDC	growth	 (13%)	 in	 the	biopsies	and	pT3	 stage	 (29%)	at	
radical prostatectomy. The study design may offer an explanation for these differences, 
as our cohort comprised screen-detected prostate cancers, while Keefe et al. included 
clinically detected prostate cancer patients.10,25 In our study, CR/IDC growth in GS 7 was 
independently associated with a poorer BCRFS after radical prostatectomy, but not after 
radiotherapy. 
Van der Kwast et al. previously suggested that IDC at biopsy is independently 
associated with a poorer BCRFS after radiotherapy.10 This similarly holds true for our study 
if we only adjust for CR/IDC growth and Gleason score in our multivariable model (data not 
shown). Our multivariable model, however, also took other variables into account such as 
PSA and biopsy tumor involvement, after which CR/IDC growth did not have independent 
prognostic value anymore. In addition, our radiotherapy cohort included patients with cT3 
at diagnosis or PSA levels of 20 ng/mL and higher, both of which were exclusion criteria in 
the study of van der Kwast et al.10 
Gleason grade 4 prostate cancer encompasses a heterogeneous group of growth 
patterns including ill-formed, fused, glomeruloid and cribriform. The most frequently 
85
reported	grade	4	pattern	in	our	entire	biopsy	cohort	(N=1031)	was	ill-formed	(73%	in	GS	3+4=7	
and	74%	in	GS	≥4+3=7),	followed	by	fused	(49%	in	GS	3+4=7	and	38%	in	GS	≥4+3=7),	cribriform	
(7.7%	in	GS	3+4=7	and	20%	in	GS	≥4+3=7)	and	glomeruloid	(11%	in	GS	3+4=7	and	13%	in	GS	
≥4+3=7).16 During the 2005 ISUP conference it was decided that any component of a higher 
grade in biopsies should be included in the GS.26 In practice, this means that even a single 
tumor component interpreted as Gleason grade 4, in an otherwise GS 6 tumor, is increasing 
the GS to 7. A disadvantage of current Gleason grading is the considerable inter-observer 
variability, particularly in distinguishing Gleason grade 6 from 3+4=7 prostate cancer.27-30 
In a study among 337 pathologists, Egevad et al. found that the percentage of fused and 
ill-formed glands was inversely correlated with agreement among pathologists, while the 
cribriform	pattern	had	no	significant	correlation	with	inter-observer	variability.30 McKenney 
et al. found that the variability in grading predominantly occurred between tangentially 
sectioned Gleason grade 3 glands and grade 4 ill-formed glands.27 In a recent inter-observer 
study focusing on Gleason grade 4 patterns, our group similarly demonstrated a poor inter-
observer reproducibility of fused and ill-formed glands, while agreement was substantial for 
glomeruloid and cribriform pattern (unpublished data). We therefore propose a place for GS 
7-	patients	in	active	surveillance,	as	their	grade	may	more	likely	reflect	a	change	in	grading	
practice rather than tumor biology.
Long-term data have shown that active surveillance for low-risk cancers is safe, 
reporting	10-	and	15-year	actuarial	cause-specific	survival	rates	of	98	and	94%,	respectively.31 
This evidence does, however, not yet apply to intermediate-risk patients, such as those with 
GS 3+4=7. Ploussard et al. found in 2323 patients with biopsy GS 3+4=7 that nearly half of 
the	patients	had	unfavorable	disease	at	 radical	prostatectomy,	defined	by	pathologic	GS	
≥4+3	(21%),	pT3-4	stage	(37%),	or	both.32 In GS 3+4=7 patients that met the Prostate cancer 
Research	International:	Active	Surveillance	(PRIAS)	criteria	for	active	surveillance	(cT	≤T2,	
PSA	≤10	ng/ml,	PSA	density	<0.2	ng/ml/ml,	≤	2	positive	biopsy	cores)	the	rate	of	unfavorable	
disease	decreased	 to	31%	 (19%	GS	≥4+3	and	22%	pT3-4	 stage).32 Radical prostatectomies 
that had been performed in men meeting the PRIAS criteria showed upstaging to Gleason 
score	≥4+3=7	in	14%-19%	and	pT3	stage	in	10%-19%	together	with	5-year	biochemical-free-
survival	rates	of	91%.33,34 The comparable rate of upgrading and upstaging in biopsy GS 6 
and 7-	patients	meeting	active	surveillance	criteria	is	in	line	with	our	findings,	and	forms	a	
rationale for including low-risk 7- subpopulations in active surveillance protocols. 
A limitation of the current study is that the original ERSPC biopsy protocol included 
sextant biopsies, while current biopsy schemes are more extensive and increasingly MRI 
targeted reducing the chance of sampling error. Another limitation is the difference in 
treatment modalities nowadays as compared to the 1990s. Patients eligible for active 
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surveillance nowadays all had undergone radical prostatectomy in this study. In addition, 
the	radiotherapy	dose	given	during	the	1990s	was	lower	(66-68	Gy)	and	less	efficient	as	the	
current radiotherapy protocols (78 Gy).35 Finally, we were not able to compare our revised 
biopsy GS according to the ISUP 2014 with the GS at radical prostatectomy, because the 
prostatectomy	GS	had	been	assigned	prior	 to	 the	2005	 ISUP	modification	and	 specimens	
were unavailable for review. The strengths of the current study are its large number of 
patients with long-term follow-up, the meticulous pathological review of the biopsies, and 
the focus on GS 3+3=6 and 3+4=7 patients.
In conclusion, men with biopsy GS 7- prostate cancer have similar BCRFS after 
radical prostatectomy or radiotherapy to those with GS 6 and may be candidates for active 
surveillance as long as other inclusion criteria such as on PSA and tumor volume are met.
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CHAPTER 6 
Presence of  invasive cribriform or intraductal 
growth at biopsy outperforms percentage 
grade 4 in predicting outcome of  Gleason score 
3+4=7 prostate cancer
Kweldam CF, Kümmerlin IP, Nieboer D, Steyerberg EW, Bangma CH, Incrocci L, 
van der Kwast TH, Roobol MJ, van Leenders GJ
Mod Pathol. 2017 Aug;30(8):1126-1132
91
ABSTRACT
Background: Relative increase of grade 4 and presence of invasive cribriform and/or 
intraductal carcinoma have individually been associated with adverse outcome of Gleason 
score 7 prostate cancer. The objective of this study was to investigate the relation of 
percentage	Gleason	grade	4	(%GG4)	and	invasive	cribriform	and/or	intraductal	carcinoma	in	
Gleason score 3+4=7 prostate cancer biopsies. 
Patients and methods: We reviewed 1031 prostate cancer biopsies from the European 
Randomized Study of Screening for Prostate Cancer. In total 370 men had Gleason score 
3+4=7.	The	 relation	 of	 invasive	 cribriform	 and/or	 intraductal	 carcinoma	 and	 %GG4	with	
biochemical recurrence-free survival (BCRFS) after radical prostatectomy (n=146) and 
radiation therapy (n=195) was analysed using Cox regression. 
Results:	Invasive	cribriform	and/or	intraductal	carcinoma	occurred	in	7/121	(6%)	patients	
with	1-10%	GG4,	29/131	(22%)	with	10-25%,	and	52/118	(44%)	with	25-50%	GG4	(P<.001).	
In	crude	analysis,	both	invasive	cribriform	and/or	intraductal	carcinoma	(HR	2.72;	95%	CI	
1.33-5.95;	 P=.006)	 and	 10-50%	GG4	 (HR	 2.43;	 95%	 CI	 1.10-5.37;	 P=.03)	were	 associated	
with BCRFS after prostatectomy. In adjusted analysis, invasive cribriform and/or intraductal 
carcinoma	 was	 an	 independent	 predictor	 for	 BCRFS	 (HR	 2.40;	 95%	 CI	 1.03-5.60;	 P=.04)	
after		prostatectomy,	while	percentage	%GG4	(HR	1.00;	95%	CI	0.97-1.03;	P=.80)	was	not.	
While	invasive	cribriform	and/or	intraductal	carcinoma	(HR	2.58;	95%	CI	1.59-4.21;	P<.001)	
performed	better	 than	 10-50%	GG4	 (HR	1.24;	 95%	CI	 0.67-2.29;	 P=.49)	 for	 prediction	 of	
BCRFS	after	radiation	therapy,	both	parameters	were	insignificant	in	analysis	adjusted	for	
PSA	(P=.001),	positive	biopsies	(P<.001)	and	tumor	volume	(P=.05).	
Conclusion:	 Increased	 %GG4	 is	 associated	 with	 invasive	 cribriform	 and/or	 intraductal	
carcinoma in GS 3+4=7 prostate cancer biopsies. Invasive cribriform and/or intraductal 
carcinoma	is	an	independent	parameter	for	BCR	after	prostatectomy,	while	%GG4	is	not.	
Presence of invasive cribriform and/or intraductal carcinoma has to be included in pathology 
reports and should act as exclusion criterion for active surveillance.
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INTRODUCTION
The	Gleason	score	(GS)	is	an	important	pathologic	parameter	for	risk	stratification	
and therapeutic decision-making in prostate cancer patients. While many patients with GS 
6 are eligible for surveillance, active treatment is generally preferred in men with GS 3+4=7 
cancer. GS 3+4=7 prostate cancer shows considerable heterogeneity in pathologic features, 
molecular background and clinical outcome. For optimal individual therapeutic decision-
making,	therefore,	risk	stratification	of	men	with	GS	3+4=7	prostate	cancer	is	crucial.
Since GS at biopsies is determined by adding the predominant and highest Gleason 
grade, GS 3+4=7 encompasses cancer with variable quantities of Gleason grade 4 patterns 
ranging	from	less	than	5%	to	up	to	50%.1,2 The risk of biochemical recurrence (BCR) after 
radical prostatectomy is incremental with the percentage of Gleason pattern 4 at the 
surgical specimen.3-5 On the other hand, it has been shown that cribriform pattern Gleason 
grade	4	is	associated	with	BCR	and	disease-specific	death.5-9 Finally, presence of intraductal 
carcinoma of the prostate (IDC-P), representing a malignant epithelial proliferation within 
pre-existent dilated glandular structures, is a marker for aggressive disease behavior.7,9-11 
Invasive cribriform Gleason grade 4 prostate cancer and intraductal carcinoma show 
overlapping	 morphologic	 features,	 and	might	 be	 difficult	 to	 differentiate	 without	 basal	
cell immunohistochemistry. For practical purposes, therefore, we have labeled invasive 
cribriform and intraductal growth pattern as one group.7 
While	Gleason	grade	4	tumor	percentage	(%GG4)	and	presence	of	invasive	cribriform	
and/or	 intraductal	carcinoma	are	both	of	clinical	 importance	for	risk	stratification	of	GS	
3+4=7 patients, it is unclear how both pathologic parameters are related and whether they 
both provide independent clinical information. The aim of the current study was to analyze 
the relation between both parameters on diagnostic biopsies, and to determine their 
relevance in predicting clinical outcome in GS 3+4=7 prostate cancer patients.
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METHODS
Patient selection
We	 included	 all	 1078	 men	 from	 the	 first	 screening	 round	 of	 the	 Dutch	 part	 of	
the European Randomized Study of Screening for Prostate Cancer (ERSPC), who had been 
diagnosed with prostate cancer between November 1993 and March 2000 in Erasmus Medical 
Center, Rotterdam, The Netherlands. The trial protocol has been published previously.12,13 
After pathologic review of all available slides (n=1054) and exclusion of men with metastatic 
disease at time of diagnosis (n=23), we selected patients with overall biopsy GS 3+4=7 for 
the current study (n=370). 
Pathological evaluation
Three investigators (C.K., I.K., G.v.L.), who were blinded to patient information 
and outcome, revised all pathological slides in common sessions. For each biopsy core 
we recorded GS according to the 2014 ISUP recommendations, total biopsy length, total 
tumor length, estimated Gleason grade 4 tumor percentage, presence of invasive cribriform 
pattern and intraductal carcinoma.2 Since distinction of invasive cribriform and intraductal 
carcinoma	lacks	clinical	 relevance	 in	the	majority	of	cases	and	might	be	difficult,	 if	not	
impossible without the use of immunohistochemistry, we labeled both patterns as one group 
(CR/IDC) as was also suggested by the ISUP 2014 consensus conference (Figure 1).2,7 Mean 
tumor	percentage	per	patient	was	defined	as	the	sum	of	total	tumor	length	(mm)	divided	by	
the	sum	of	total	biopsy	length	(mm).	Percentage	Gleason	grade	4	(%GG4)	was	determined	
by dividing the total length of invasive Gleason grade 4 and intraductal carcinoma by the 
total tumor length in all biopsies. 
Clinical follow-up 
After diagnosis and initial treatment, patients were semi-annually monitored by 
chart	 review	to	assess	potential	progression	and	secondary	treatments.	BCR	was	defined	
as	a	Prostate	Specific	Antigen	(PSA)	levels	of	≥0.2	ng/mL	assessed	at	two	consecutive	time	
points > 3 months apart after radical prostatectomy, or any PSA increase >2 ng/mL higher 
than the PSA nadir value after radiation therapy.14
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Figure 1. Intraductal	carcinoma	of	the	prostate	consisting	of	a	dilated	gland	filled	with	a	malignant	
cribriform epithelial proliferation with a continuous pre-existent basal cell layer (A, B). Invasive 
cribriform Gleason grade 4 prostate cancer consists of a malignant cribriform proliferation without 
basal cell layer (C, D). Hematoxylin & eosin (HE; A, C), high-molecular weight keratin (34BE12; B, D). 
Original	magnifications,	200x.
Statistical analysis 
For	comparison	of	%GG4	with	clinical	and	pathologic	parameters	we	grouped	the	
cases	as	follows:	>0%	and	<10%,	≥10%	and	<25%,	and	≥25%	and	<50%	Gleason	grade	4	pattern.	
Continuous parameters were analyzed by the Kruskal-Wallis test, categorical parameters 
by	the	Pearson’s	Chi-square	(χ2) test. We estimated survival probabilities using the Kaplan-
Meier method. Unadjusted comparisons for survival time were made using log-rank tests 
with censoring of men lost to follow-up. Crude and adjusted hazard ratios (HRs) for survival 
time were calculated using Cox proportional hazards regression. All statistical analyses 
were performed in SPSS version 21 (IBM, Chicago, Illinois). Two-sided P values	of	<.05	were	
considered	statistically	significant.
A 
D C 
B 
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RESULTS
Patient characteristics 
A	total	of	370	patients	with	overall	biopsy	GS	3+4=7	prostate	cancer	were	identified	
(Table	1).	One	hundred	and	twenty	one	patients	(33%)	had	less	than	10%	GG4	component,	
131	men	(35%)	had	10-25%	GG4	and	118	(32%)	had	25-50%	GG4.	Age	(P=.001),	PSA	(P<.001)	
and	biopsy	 tumor	volume	 (P=.001)	were	all	 significantly	higher	 in	 tumors	with	a	greater	
%GG4.	The	mean	percentage	of	positive	biopsy	cores	was	higher	in	men	with	<10%	GG4,	in	
whom only four patients had one positive biopsy core (P=.01). 
The primary therapeutic interventions for the entire cohort were radical 
prostatectomy	(n=146;	39%),	radiation	therapy	(n=195;	53%),	watchful	waiting	(n=25;	7%)	
and	 endocrine	 therapy	 (n=3;	 1%).	 Radiation	 therapy	 was	 performed	more	 often	 (P=.02)	
and	radical	prostatectomy	less	frequently	(P=.04)		in	patients	with	higher	%GG4.	Prostate	
cancer-specific	death	occurred	in	4	(3%),	6	(5%)	and	13	(11%)	men	with	<10%,	10-25%	and	
25-50%	GG4	component,	respectively	(log	rank,	P=.02).	
Invasive cribriform and/or intraductal carcinoma was observed in 88 GS 3+4=7 
patients	(24%).	Invasive	cribriform	and/or	intraductal	carcinoma	was	present	in	7/121	(6%)	
men	with	less	than	10%	GG4,	in	29/131	(22%)	men	with	10-25%	GG4	and	52/118	(44%)	men	
with	25-50%	GG4	pattern	 (P<.001).	Mean	PSA	 level	 in	men	with	 invasive	cribriform	and/
or	 intraductal	carcinoma	was	12.9	ng/mL	(median	5.2;	 IQR	8.7-13.7	ng/mL)	and	8.5	ng/
mL	(median	4.0;	 IQR	5.8-8.7	ng/mL)	 in	men	without	 (P=.001).	Biopsy	tumor	volume	was	
56%	(median	40%;	IQR	55-70%)	and	41%	(median	23%;	IQR	39-56%)	in	men	with	and	without	
invasive	cribriform	and/or	intraductal	carcinoma		(P<.001),	respectively.	Mean	%GG4	was	
28%	(median	14%;	IQR	24-33%)	in	men	with	invasive	cribriform	and/or	intraductal	carcinoma	
and	16%	(median	6%;	IQR	12-24%)	in	those	without	(P<.001).
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Radical prostatectomy
The	mean	follow-up	after	radical	prostatectomy	was	14.6	years	(median	15.5;	IQR	
14.0-17.2	 years),	with	 35/146	 (24%)	men	experiencing	BCR	after	 5.8	 years	 (median	4.4;	
IQR	2.0-9.2	years).	BCR	occurred	more	often	in	men	with	10-25%	(log	rank,	P=.04)	and	25-
50%	GG4	(log	rank,	P=.03)		than	in	those	with	<10%	GG4,	but	was	not	statistically	different	
between the three groups (log rank for trend, P=.08). Presence of invasive cribriform and/or 
intraductal carcinoma was associated with post-operative BCR (log rank, P=.004). In bivariate 
Cox	regression	analysis,	invasive	cribriform	and/or	intraductal	carcinoma	(HR	2.73;	95%	CI	
1.22-6.10; P=.04) was associated with biochemical recurrence-free survival (BCRFS), while 
%GG4	as	continuous	parameter	(HR	1.00;	95%	CI	0.98-1.03;	P=.99)	was	not.	Adjusted	analysis	
for age, PSA, percentage positive biopsies, tumor volume revealed invasive cribriform and/
or intraductal carcinoma (P=.04) as the only  independent parameter for BCRFS after radical 
prostatectomy (Table 2). 
Table 1. Clinical and pathologic characteristics of Gleason score 3+4=7 biopsies. 
Mean (median; IQR) or absolute number (%) are given.
Parameter Percentage Gleason grade 4 P value
0-10% 10-25% 25-50%
Number 121 131 118
Age 65 (66; 61-70) 67 (68; 63-72) 68 (69; 65-72) .001
PSA (ng/mL) 7.8 (5.2; 3.7-7.1) 9.2 (5.9; 4.2-9.0) 11.7 (8.5; 5.4-13.4) <.001
%	positive	biopsies 51 (50; 33-67) 44 (43; 29-57) 48 (43; 29-67) .01
%	tumor	volume 39 (37; 25-52) 44 (45; 27-59) 50 (51; 34-65) .001
CR/IDC 7	(6%) 29	(22%) 52	(44%) <.001
Therapy
  Radical prostatectomy 58	(48%) 50	(38%) 38	(32%) .04
  Radiation therapy 52	(43%) 71	(54%) 72	(61%) .02
  Endocrine therapy 1	(1%) 2	(2%) 0 .41
  Watchful waiting 9	(7%) 8	(6%) 8	(7%) .92
   Unknown 1	(1%) 0 0
Disease-specific death 4	(3%) 6	(5%) 13	(11%) .02
PSA: Prostate Specific Antigen; CR/IDC: invasive cribriform and/or intraductal carcinoma
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Since recent surveillance protocols include GS 3+4=7 patients with low amounts 
of	GG4	pattern,	we	also	analyzed	the	predictive	value	of	dichotomized	%GG4.15,16 In crude 
regression	analysis,	men	with	10-50%	GG4	were	at	elevated	 risk	 for	BCRFS	as	 compared	
to	those	<10%	GG4	(HR	2.43;	95%	CI	1.10-5.37;	P=.03).	 In	bivariate	analysis,	presence	of	
invasive	cribriform	and/or	 intraductal	carcinoma	(HR	2.33;	95%	CI	1.12-4.84;	P=.02)	was	
predictive	for	BCRFS,	while	10-50%	GG4	did	not	meet	conventional	measures	of	statistical	
significance	(HR	2.12;	95%	CI	0.95-4.74;	P=.07).	
Table 2. Crude and adjusted Cox regression analysis for time to biochemical recurrence after 
radical prostatectomy.
Univariate P value Multivariable P value
HR	(95%	CI) HR	(95%	CI)
Age 1.03 (0.95-1.11) .49 1.03 (0.95-1.11) .54
PSA 1.03 (0.98-1.09) .31 1.01 (0.95-1.08) .69
Percentage positive biopsies 3.68 (0.85-15.95) .08 2.27 (0.51-10.09) .28
Tumor volume 2.20 (0.50-9.76) .30 1.71 (0.34-8.50) .51
Percentage GG4 1.01 (0.99-1.04) .29 1.00 (0.97-1.03) .80
CR/IDC 2.72 (1.33-5.95) .006 2.40 (1.03-5.60) .04
PSA: Prostate Specific Antigen; CR/IDC: invasive cribriform and/or intraductal carcinoma
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Radiation therapy
The	mean	follow-up	after	radiation	therapy	was	11.9	years	(median	13.1;	IQR	8.4-
15.9	years).	In	total,	72	out	of	195	(37%)	men	experienced	BCR	after	5.7	years	(median	4.9;	
IQR	3.4-7.6	years).	BCR	occurred	more	frequently	in	patients	with	higher	%GG4	(log	rank	
P=.02)	and	in	men	with	invasive	cribriform	and/or	intraductal	carcinoma	(log	rank,	P<.001).	
In bivariate Cox regression analysis, invasive cribriform and/or intraductal carcinoma 
(HR	2.43;	95%	CI	1.49-4.00;	P<.001),	but	not	%GG4	(HR	1.01;	95%	1.00-1.03;	P=.14)		was	
associated with BCRFS. Adjusted analysis showed that PSA (P=.001), number of positive 
biopsies	 (P<.001)	 and	 tumor	 volume	 (P=.05)	were	 independently	 predictive	 BCRFS	 after	
radiation	therapy,	while	%GG4	(P=.19)	and	invasive	cribriform	and/or	intraductal	carcinoma	
(P=.53)	were	not	 (Table	3).	Dichotomization	of	%GG4	revealed	no	statistically	 significant	
difference	in	BCRFS	between	men	with	<10%	and	10-50%	GG4	(HR	1.67;	95%	CI	0.93-3.00;	
P=.09). Bivariate analysis showed that invasive cribriform and/or intraductal carcinoma (HR 
2.58;	95%	CI	1.59-4.21;	P<.001)	was	predictive	for	BCRFS,	while	10-50%	GG4	was	not	(HR	
1.24;	95%	CI	0.67-2.29;	P=.49).
Table 3. Crude and adjusted Cox regression analysis for time to biochemical recurrence after 
radiation therapy.
Univariate P value Multivariable P value
HR	(95%	CI) HR	(95%	CI)
Age 1.00 (0.95-1.04) .90 1.00 (0.95-1.06) .89
PSA 1.05 (1.04-1.07) <.001 1.03 (1.01-1.04) .001
Number positive biopsies 20.10 (7.70-52.51) <.001 8.55 (2.78-26.32) <.001
Tumor volume 7.55 (2.69-21.23) <.001 3.24 (1.00-10.53) .05
Percentage GG4 1.02 (1.01-1.04) .009 1.01 (0.99-1.04) .19
CR/IDC 2.73 (1.72-4.35) <.001 1.20 (0.68-2.13) .53
PSA: Prostate Specific Antigen; CR/IDC: invasive cribriform and/or intraductal carcinoma
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DISCUSSION
Recent studies have indicated that relative quantity of GG4 pattern and presence 
of invasive cribriform and/or intraductal carcinoma are promising parameters for risk 
stratification	 of	 GS	 3+4=7	 prostate	 cancer	 patients.	 In	 this	 study,	 we	 demonstrated	 that	
increased GG4 pattern was strongly associated with presence of invasive cribriform and/or 
intraductal	 carcinoma.	Patients	with	 <10%	GG4	had	 invasive	 cribriform	and/or	 intraductal	
carcinoma	in	6%,	while	it	was	present	in	44%	of	men	with	25-50%	GG4.	In	bivariate	analysis,	
invasive cribriform and/or intraductal carcinoma was an independent parameter for BCR 
after	radical	prostatectomy	and	radiation	therapy,	while	%GG4	as	nominal	or	dichotomized	
parameter was not. In adjusted analysis, invasive cribriform and/or intraductal carcinoma 
was an independent parameter for BCR after radical prostatectomy, but not after radiation 
therapy.	These	 results	 indicate	 that	 the	worse	outcome	of	men	with	high	%GG4	might	be	
explained by more frequent presence of invasive cribriform and/or intraductal carcinoma in 
this group.
	Our	results	on	the	clinical	relevance	of	%GG4	and	invasive	cribriform	and/or	intraductal	
carcinoma are in line with previous studies. In a large number of radical prostatectomies, 
Sauter et al.	found	that	increased	%GG4	went	together	with	BCR.4	While	%GG4	pattern	in	GS	
3+4=7 biopsies has been associated with adverse features at radical prostatectomy, it was not 
an independent predictive factor for post-operative BCR.17,18 Biopsy invasive cribriform growth 
and/or	intraductal	carcinoma	are	related	to	non-organ	confined	disease	as	well	as	BCR	after	
radical prostatectomy and radiation therapy.11,19-21 Choy et al. found independent prognostic 
value	of	both	%GG4	and	invasive	cribriform	architecture	on	radical	prostatectomy	for	BCR.5 
The discordance with the current study might be explained by the fact that we determined 
%GG4	at	diagnostic	biopsies	instead	of	radical	prostatectomy	specimens,	and	that	Choy	et al. 
did not include intraductal carcinoma in their analysis. 
 The clinical relevance of intraductal carcinoma, invasive cribriform carcinoma 
and percentage Gleason grade 4 is increasingly being acknowledged. The World Health 
Organization (WHO) and International Society of Urological Pathology (ISUP) recommend that 
presence	of	intraductal	carcinoma	is	routinely	mentioned	in	pathology	reports	and	that	%GG4	
is reported in GS 7 prostate cancer patients.2,22 Percentage GG4 is currently applied as a novel 
parameter for inclusion of GS 3+4=7 prostate cancer patients in some active surveillance 
protocols.15,16 Yamamoto et al.	for	instance	found	that	GS	3+4=7	patients	with	less	than	5%	
GG4 on surveillance did not experience metastasis.23 Although presence of invasive cribriform 
growth and/or intraductal carcinoma has not been formally acknowledged yet as an exclusion 
criterion for surveillance protocols, it has been suggested to exclude patients with intraductal 
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carcinoma from surveillance.24 The results of our study implicate that invasive cribriform 
growth and/or intraductal carcinoma might be a more reliable factor for therapeutic 
stratification	than	%GG4	only,	and	should	be	included	in	pathology	reports.	
Considerable inter-observer variability exists in differentiating GS 3+4=7 and GS 6 on 
biopsies.25-28	We	expect	that	this	variability	is	mainly	present	in	cases	with	low	%GG4,	which	
has	been	one	of	the	rationales	for	including	GS	3+4=7	patients	with	low	%GG4	in	surveillance	
protocols.15,16 Grading variability is most prominent in distinguishing ill-formed and fused GS 
7 glands from tangentially sectioned GS 6 glands, while concordance on cribriform growth 
is generally much better.25,27 The reproducibility of cribriform growth further supports the 
potential relevance of invasive cribriform and/or intraductal carcinoma for therapeutic 
decision-making.
 In this study, we applied overall instead of highest GS 3+4=7 as inclusion criterion.7 
Since GS might differ between separate cores of the same biopsy session, the overall GS 
presumes that all biopsies are part of the same tumor. This means that a patient could have 
positive	biopsies	with	GS	6,	3+4=7,	4+3=7	or	4+4=8	as	long	as	the	total	%GG4	is	less	than	50%.	
In contrast, highest GS 3+4=7 excludes patients with GS 4+3=7 and GS 4+4=8 in single biopsy 
cores. We have not selected for highest GS 3+4=7 in this study since this would have excluded 
patients	with	overall	less	than	50%	GG4.	Other	groups	have	shown	improved	performance	of	
overall versus highest GS in biopsies, challenging clinical practice to classify patients according 
to the highest GS.4,17
In	this	study,	regression	analysis	of	%GG4	dichotomized	at	a	cut-off	10%	performed	
better	than	%GG4	as	continuous	parameter.	Post-operative	BCR	between	patients	with	25-50%	
GG4	was	not	statistically	significant	from	men	10-25%	GG4.	Such	a	trend	was	also	found	by	
others, and is probably due to small sample size.18 Despite the lack of independent prognostic 
value	of	%GG4,	GG4	quantity	might	still	be	of	interest	for	further	studies.	Since	this	study	with	
long term follow-up was performed on sextant biopsies in 1990s, it is important to further 
elaborate	on	the	predictive	value	of	biopsy	%GG4	and	invasive	cribriform	and/or	intraductal	
carcinoma in the current era of multiple and MRI-targeted biopsies.
	In	 conclusion,	 we	 demonstrate	 that	 increased	 %GG4	 is	 associated	 with	 a	 higher	
frequency of invasive cribriform and/or intraductal carcinoma in GS 3+4=7 prostate cancer 
biopsies. Invasive cribriform and/or intraductal carcinoma is an independent parameter for 
BCR	 after	 radical	 prostatectomy,	while	 %GG4	 is	 not.	 Therefore,	 stratification	 for	 invasive	
cribriform and/or intraductal carcinoma could be more reliable for inclusion of GS 3+4=7 
prostate	cancer	patients	 in	active	surveillance	than	%GG4	alone.	The	presence	of	 invasive	
cribriform and intraductal carcinoma should therefore routinely be included in pathology 
reports.
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ABSTRACT
Background: To assess the interobserver reproducibility of individual Gleason grade 4 growth 
patterns.
Patients and methods: Twenty-three genitourinary pathologists participated in the evaluation 
of	60	selected	high-magnification	photographs.	The	selection	included	10	cases	of	Gleason	
grade 3, 40 of Gleason grade 4 (10 per growth pattern), and 10 of Gleason grade 5. Participants 
were asked to select a single predominant Gleason grade per case (3, 4, or 5), and to indicate 
the	predominant	Gleason	grade	4	growth	pattern,	if	present.	‘Consensus’	was	defined	as	at	
least	80%	agreement,	and	‘favoured’	as	60–80%	agreement.	
Results:	Consensus	on	Gleason	grading	was	reached	 in	47	of	60	(78%)	cases,	35	of	which	
were	assigned	to	grade	4.	In	the	13	non-consensus	cases,	ill-formed	(6/13,	46%)	and	fused	
(7/13,	54%)	patterns	were	involved	in	the	disagreement.	Among	the	20	cases	where	at	least	
one	pathologist	assigned	the	ill-formed	growth	pattern,	none	(0%,	0/20)	reached	consensus.	
Consensus	 for	 fused,	cribriform	and	glomeruloid	glands	was	 reached	 in	2%,	23%	and	38%	
of	cases,	 respectively.	 In	nine	of	35	 (26%)	consensus	Gleason	grade	4	cases,	participants	
disagreed on the growth pattern. Six of these were characterized by large epithelial 
proliferations	with	delicate	intervening	fibrovascular	cores,	which	were	alternatively	given	
the designation fused or cribriform growth pattern (‘complex fused’).
Conclusion: Consensus on Gleason grade 4 growth pattern was predominantly reached on 
cribriform and glomeruloid patterns, but rarely on ill-formed and fused glands. The complex 
fused	glands	seem	to	constitute	a	borderline	pattern	of	unknown	prognostic	significance	on	
which a consensus could not be reached.
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INTRODUCTION
The Gleason grading system is one of the most important predictors of prostate 
cancer progression. In 2005, the International Society of Urological Pathology (ISUP) 
organized a consensus conference on Gleason grading of prostate cancer.1 The goal of this 
meeting	 was	 to	 achieve	 consensus	 among	 leading	 genitourinary	 pathologists	 in	 specific	
areas of Gleason grading. At this meeting, large cribriform and ill-formed glands, which are 
classically	described	as	Gleason	grade	3,	were	redefined	as	Gleason	grade	4.1 Subsequently, 
during the 2014 ISUP consensus conference on prostate cancer grading, it was decided that 
small cribriform and glomeruloid glands should also be considered to be Gleason grade 4.2 As 
a result, contemporary Gleason grade 4 prostate cancer represents a heterogeneous group of 
various growth patterns consisting of ill-formed, fused, cribriform and glomeruloid glands. 
Although	Gleason	grade	4	is	not	subclassified	in	daily	clinical	practice,	recent	studies	have	
suggested that, among Gleason grade 4 growth patterns, cribriform growth is associated 
with a worse clinical outcome.3-6
One of the major limitations of the Gleason grading system is its considerable 
interobserver variability.7-19 Fused glands or small glands without lumina may, for instance, be 
interpreted as tangentially sectioned Gleason grade 3 or as a focal Gleason grade 4 prostate 
cancer.15	Despite	this	 interobserver	variability,	accurate	identification	of	Gleason	grade	4	
prostate cancer is important for subsequent therapeutic decision-making.7-19 For instance, 
patients with Gleason score 3+3=6 prostate cancer are often eligible for active surveillance, 
whereas patients with 3+4=7 are frequently excluded.20 To support future studies on Gleason 
grade	4	architectural	subclassification,	it	is	important	for	individual	growth	patterns	to	be	
well	defined	and	reproducible.	We	therefore	undertook	an	interobserver	variability	study	
among genitourinary pathologists to assess the interobserver agreement regarding individual 
Gleason grade 4 growth patterns.
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MATERIALS AND METHODS
Case selection
Case selection (n = 60) was undertaken by two investigators (C.K. and G.v.L.), 
and included a representative collection of various Gleason grade 4 growth patterns.1 The 
selection was aimed at including 10 Gleason grade 3, 40 Gleason grade 4 (10 per growth 
pattern) and 10 Gleason grade 5 cases, several of which were deliberately chosen because 
they showed ambiguous Gleason grade 4 patterns. In this study, we did not include ductal, 
intraductal or small-cell prostate cancer. Digital images of haematoxylin and eosin-stained 
slides from selected prostate cancer cases were obtained with a NanoZoomer digital slide 
scanner (Hamamatsu Photonics, Hamamatsu City, Japan). To ensure that all participants 
evaluated the same tumour structures, tumour regions of interest were delineated in each 
case with a yellow line.
Images were incorporated into a digital questionnaire. An international group of 
26 genitourinary pathologists were invited to participate in the study. The investigators 
involved in the case selection (C.K. and G.v.L.) were not included in this group. Participants 
were asked to select a single predominant Gleason grade per case (3, 4, or 5). If a case was 
assigned to Gleason grade 4, participants were asked to indicate a single predominant growth 
pattern (ill-formed, fused, cribriform, or glomeruloid). Participants had the opportunity 
to add comments by free-text. Finally, we collected basic demographic information from 
participants. No consensus training preceded the study. The questionnaire, including all 
cases and instructions, is shown in Appendix S1.
Analysis
Consensus	was	 defined	 as	 at	 least	 80%	 agreement	 on	Gleason	 grade	 or	 Gleason	
grade	4	subclassification.	When	60–80%	of	 the	participants	agreed,	 the	classification	was	
considered to be ‘favoured’. The latter thresholds were chosen arbitrarily. Although 
participants were asked to select only one predominant grade and/or pattern per case, 
a combination of grades or patterns, e.g. ‘grade 3 and 4’ or ‘fused and ill-formed’, was 
assigned in a few cases. We considered these combinations as separate categories in the 
analysis. This also applied to cases that were assigned by free-text to Gleason grade 2, 
which was not a selection option. In addition, some cases had been assigned to ‘Gleason 
grade 3 cribriform’ (n = 4) or ‘Gleason grade 3 glomeruloid’ (n = 1). The latter cases were 
considered to be Gleason grade 3 for the analysis. Their growth patterns, however, were 
included in the Gleason grade 4 pattern analysis.
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RESULTS
Participants
Replies	 were	 received	 from	 23	 genitourinary	 pathologists	 (88%	 response	 rate)	
residing in 13 countries: the USA (n = 8), Canada (n = 3), the UK (n = 2), Australia (n = 1), 
Brazil (n = 1), France (n = 1), Germany (n = 1), Italy (n = 1), Singapore (n = 1), Spain (n = 1), 
Sweden (n = 1), Switzerland (n = 1), and New Zealand (n = 1). Twenty participants were in 
academic	practice	(87%),	two	were	in	private	practice	(8.7%),	and	one	was	in	academic,	
community	and	private	practice	(4%).	The	numbers	of	diagnostic	prostate	biopsies	analysed	
per	year	were	as	follows:	100–250	(n	=	1;	4%),	250–500	(n	=	7;	30%),	500–1000	(n	=	7;	30%),	
and	>1000	(n	=	8;	35%).
Gleason grading
Consensus	on	Gleason	grade	was	reached	in	47	(78%)	cases:	eight	were	assigned	to	
Gleason	grade	3,	35	to	Gleason	grade	4,	and	four	to	Gleason	grade	5.	In	nine	cases	(15%),	a	
Gleason grade was favoured: four cases were favoured as Gleason grade 3, one as Gleason 
grade	4,	and	 four	as	Gleason	grade	5.	 In	 four	cases	 (7%),	 there	was	<60%	agreement	on	
Gleason	 grading	 (Figure	 1).	 If	 <80%	 of	 participants	 agreed	 on	 Gleason	 grade,	 ill-formed	
(6/13,	46%)	and	fused	(7/13,	54%)	were	the	involved	growth	patterns.	The	frequencies	of	
the Gleason grades and grade 4 patterns per case are listed in Table S1.
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Figure 1.	Cases	with	<60%	agreement	on	Gleason	grade.	A,	Case	22:	grade	3,	n	=	11;	grade	4,	n	=	12	
(fused, n = 12). B, Case 24: grade 4, n = 11; grade 5, n = 11; grades 4 and 5, n = 1 (ill-formed, n = 7; 
fused, n = 2; cribriform, n = 1; fused and ill-formed, n = 2). C, Case 51: grade 4, n = 13; grade 5, n = 8; 
grades 4 and 5, n = 2 (fused, n = 1; ill-formed, n = 11; fused and ill-formed, n = 2). D, Case 58: grade 3, 
n = 12; grade 4, n = 11 (fused, n = 7; cribriform, n = 4; cribriform grade 3, n = 1).
Gleason grade 4 patterns
The number of cases in which a Gleason grade 4 pattern was assigned by at least one 
participant	was	as	follows:	fused,	n	=	41	(68%);	cribriform,	n	=	30	(50%);	ill-formed,	n	=	20	
(33%);	and	glomeruloid,	n	=	13	(22%).	Consensus	on	a	Gleason	grade	4	pattern	was	reached	
in	13	(37%)	of	35	consensus	Gleason	grade	4	cases:	cribriform,	n	=	7	(54%);	glomeruloid,	n	=	5	
(38%);	and	fused,	n	=	1	(8%).	None	of	the	cases	reached	consensus	for	ill-formed	glands.
Among the 13 cases in which at least one participant assigned a glomeruloid growth 
pattern,	consensus	on	a	glomeruloid	pattern	was	present	in	five	(38%)	cases	(cases	12,	18,	
25,	29,	and	31).	The	glomeruloid	pattern	was	favoured	in	two	(15%)	cases	(cases	15	and	38);	
in both cases, a considerable number of participants preferred cribriform, or a combination 
of both cribriform and glomeruloid. Consensus on a glomeruloid pattern was found in cases 
showing relatively small glomerulations, whereas the favoured cases all comprised large 
glomeruloid formations in which the cribriform pattern was the preferred alternative 
(Figure 2).
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Figure 2. Agreed (A,B) and favoured (C,D) cases with a glomeruloid pattern. A, Case 18: glomeruloid, 
n = 20; cribriform, n = 1; cribriform and glomeruloid, n = 1. B, Case 29: glomeruloid, n = 19; cribriform, 
n = 3; fused, n = 1. C, Case 15: glomeruloid, n = 16; cribriform, n = 5; cribriform and glomeruloid, n = 2. 
D, Case 38: glomeruloid, n = 14; cribriform, n = 4; cribriform and glomeruloid, n = 5.
Among the 30 cases in which at least one participant assigned a cribriform pattern, 
consensus	on	a	cribriform	pattern	was	reached	in	seven	(23%)	cases	(cases	4,	9,	17,	27,	30,	
43,	and	48),	two	of	which	(cases	4	and	48)	reached	100%	agreement.	All	seven	consensus	
cases had large cribriform glands with multiple punched-out lumina (Figure 3A–D). When 
a	cribriform	pattern	was	favoured	(n	=	2;	7%),	fused	glands	were	also	considered	by	other	
participants in these cases (cases 16 and 59). Case 16 represented a relatively small gland 
containing	 several	 small	 mucin-filled	 spaces	 and	 delicate	 intervening	 stroma	 containing	
capillaries (Figure 3E). Case 59 showed a large glandular proliferation with elongated and 
round	lumina	and	discrete	fibrovascular	cores	(Figure	3F).
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Figure 3. Agreed (A–D) and favoured (E,F) cases with a cribriform pattern. A, Case 4: cribriform, n = 23. 
B, Case 9: cribriform, n = 21; fused, n = 2. C, Case 27: cribriform, n = 20; glomeruloid, n = 2; cribriform 
grade 3, n = 1. D, Case 48: cribriform, n = 23. E, Case 16: cribriform, n = 14; fused, n = 6; glomeruloid, 
n = 1; cribriform and glomeruloid, n = 1; cribriform and fused, n = 1. F, Case 59: cribriform, n = 15; 
fused, n = 7; cribriform and fused, n = 1.
No consensus was reached on the ill-formed pattern in any of the cases, although 
this	pattern	was	favoured	in	five	(25%)	(cases	2,	5,	7,	39,	and	45;	Figure	4).	In	all	of	these	
cases, the fused pattern was also considered by other participants. Consensus on the fused 
pattern	was	reached	in	only	one	(2%)	case	(case	46),	whereas	the	fused	pattern	was	favoured	
in	four	(10%)	(cases	19,	32,	54,	and	57;	Figure	5).	In	the	latter	cases,	a	cribriform	pattern	
was also given by others. Here, the tumour glands had a complex architecture showing 
anastomosing glands with elongated lumina and delicate intervening stroma and capillaries.
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Figure 4. Cases with a favoured ill-formed pattern. A, Case 2: ill-formed, n = 14; fused, n = 7; fused 
and ill-formed, n = 1. B, Case 5: ill-formed, n = 18; fused, n = 2; fused and ill-formed, n = 1. C, Case 
39: ill-formed, n = 16; fused, n = 2; fused and ill-formed, n = 2. D, Case 45: ill-formed, n = 18; fused, 
n = 3; fused and ill-formed, n = 1.
Figure 5. Cases with a favoured fused pattern. A, Case 19: fused, n = 16; cribriform, n = 2; fused and 
ill-formed, n = 1. B, Case 32: fused, n = 17; cribriform, n = 5; ill-formed, n = 1. C, Case 54: fused, n = 17; 
cribriform, n = 2; cribriform and fused, n = 1; cribriform and ill-formed, n = 1. D, Case 57: fused, n = 14; 
cribriform, n = 4; ill-formed, n = 1; fused and ill-formed, n = 1; cribriform and fused, n = 1.
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There	was	<80%	agreement	on	the	pattern	subclassification	in	22	of	35	consensus	
Gleason grade 4 cases. In these cases, pattern disagreement occurred mostly for fused versus 
ill-formed and fused versus cribriform. Cases in which no agreement could be reached on 
a fused or an ill-formed pattern showed glands that were relatively small with an irregular 
border (cases 3 and 36; Figure 6A,B). The other type of disagreement was characterized 
by	 complex	 epithelial	 anastomosing	 glands	with	 delicate	 intervening	 fibrovascular	 cores	
(‘complex fused), which were alternatively given the designation fused or cribriform 
pattern (cases 20, 23, 37, 40, 42, and 53; Figure 6C–H). The distribution of the Gleason 
grade	4	patterns	related	to	disagreement	on	Gleason	grading	or	grade	4	subclassification	
are summarized in Figure 7.
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Figure 6. Cases	 with	 <80%	 agreement	 on	 Gleason	 grade	 4	 subclassification.	A,	 Case	 3:	 ill-formed,	
n = 13; fused, n = 4; fused and ill-formed, n = 3. B, Case 36: ill-formed, n = 13; fused, n = 4; fused and 
ill-formed, n = 3. C, Case 23: fused, n = 12; cribriform, n = 7; cribriform and fused, n = 2; fused and 
ill-formed, n = 1. D, Case 20: fused, n = 13; cribriform, n = 6; cribriform and fused, n = 1; cribriform 
and fused and ill-formed, n = 1. E, Case 37: cribriform, n = 11; fused, n = 6; glomeruloid, n = 1; fused 
and glomeruloid, n = 1; cribriform and glomeruloid, n = 1; fused and ill-formed and glomeruloid, n = 1. 
F, Case 40: cribriform, n = 13; fused, n = 8; fused and ill-formed, n = 1. G, Case 42: cribriform, n = 13; 
fused, n = 7; cribriform and fused, n = 1. H, Case 53: fused, n = 11; cribriform, n = 10; fused and ill-
formed, n = 1; cribriform and ill-formed, n = 1.
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Figure 7.	Schematic	overview	showing	types	of	disagreement	in	cases	with	<80%	consensus	on	Gleason	
grading	(n	=	13/60,	blue	arrows)	and	grade	4	subclassification	(n	=	22/35,	red	arrows).	The	percentages	
represent the proportion of cases involved in a particular type of disagreement. The ellipse represents 
Gleason grade 3 pattern, the trapezium Gleason grade 5 pattern, and the rectangles Gleason grade 4 
pattern.
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DISCUSSION
To	facilitate	future	studies	on	Gleason	grade	4	subclassification,	it	is	important	for	
individual	growth	patterns	 to	be	well	defined	and	reproducible.	We	therefore	 initiated	an	
interobserver study among genitourinary pathologists to assess the interobserver agreement 
regarding individual Gleason grade 4 growth patterns. We found that consensus on a Gleason 
grade 4 growth pattern was predominantly reached on cribriform and glomeruloid glands, but 
hardly on ill-formed and fused glands. Although most participants agreed on classifying large 
epithelial proliferations with multiple punched-out lumina lacking intervening stroma as the 
cribriform	 pattern,	 there	was	 considerable	 interobserver	 variation	 in	 the	 subclassification	
of large complex epithelial proliferations with subtle intervening stroma; these were 
alternatively regarded as cribriform or fused. To our knowledge, this histological category of 
‘complex fused’ has not been described previously. Also, glomerulations with large intraluminal 
cribriform proliferations were alternatively regarded as cribriform or glomeruloid.
Fused and ill-formed glands were the two patterns that were most related to Gleason 
grade	variability	 (3,	4,	or	5).	Our	findings	are	 in	 line	with	two	previous	studies	by	Egevad	
et al., who investigated the interobserver reproducibility of Gleason grade 4 patterns among 
15 and 337 pathologists, respectively.21,22 In one of these studies, the percentage of fused 
and ill-formed glands was inversely correlated with agreement among pathologists, whereas 
the	 cribriform	 pattern	 had	 no	 significant	 correlation	with	 interobserver	 variability.22 Zhou 
et al. recently suggested that adjacent tumour glands play an important role in decision-
making in cases showing ambiguous ill-formed patterns.19 They recommend that >10 poorly 
formed glands not immediately adjacent to other well-formed glands should be considered to 
represent ill-formed Gleason pattern 4. In contrast, poorly formed glands that are intermixed 
with	well-formed	glands,	or	≤5	poorly	formed	glands,	regardless	of	their	location,	should	be	
diagnostic	features	arguing	against	Gleason	pattern	4.	Because	our	study	specifically	focused	
on	growth	pattern	subclassification	and	lacked	sufficient	adjacent	tumour	glands,	we	were	
unable to make such observations.
Although Gleason grading is subject to interobserver variability, accurate 
identification	of	Gleason	grade	4	prostate	 cancer	 is	 important	 for	 subsequent	 therapeutic	
decision-making.7-19 In many institutes, patients with Gleason score 6 prostate cancer are 
candidates for active surveillance, whereas patients with Gleason score 7 generally undergo 
therapeutic intervention.20	 It	 has	 been	 estimated	 that	 up	 to	 13%	 of	 patients	 would	 have	
been recommended different treatments solely on the basis of pathological re-evaluation of 
diagnostic biopsies.13,18 Although the presence of a Gleason 4 pattern is a clinical threshold for 
active treatment, Gleason grade 4 comprises a heterogeneous tumour group, covering at least 
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four morphologically distinct patterns. Recent studies have suggested that individual Gleason 
grade 4 growth patterns are associated with clinical outcome.3-6 Dong et al. found, in a 
consecutive series of 214 patients, that the presence of cribriform growth was associated with 
a shorter time to biochemical recurrence and metastasis after radical prostatectomy, whereas 
fused and ill-formed glands were not.5 In a cohort of 161 Gleason grade 7 prostate cancer 
patients, our group also found that the presence of cribriform growth was associated with 
worse	metastasis-free	survival	and	disease-specific	survival,	whereas	fused,	glomeruloid	and	
ill-formed glands were not.6 In a screen-detected cohort of 1031 men, we recently reported 
similar	 findings	 for	 cribriform	 growth	 in	 diagnostic	 biopsies.23 We therefore recommend 
reporting the presence of cribriform tumour glands in pathology reports, as this pattern 
appears to confer a less favourable outcome.
The present study has several limitations. Cases were selected by two investigators, 
who intentionally included both classic and ambiguous cases. For instance, large epithelial 
proliferations	with	punched-out	lumina	and	subtle	scattered	fibrovascular	cores,	which	are	
difficult	 to	classify	as	either	cribriform	or	 fused,	are	 relatively	uncommon.	 It	 is	 therefore	
difficult	to	draw	conclusions	on	the	general	agreement	on	Gleason	grade	4	growth	patterns	
in daily clinical practice. Second, participants were asked to score delineated tissue areas to 
ensure that categorization discordances were not attributable to the evaluation of different 
tumour areas. However, the participants were therefore not able to interpret tumour growth 
patterns in a larger context.
The present study did not make use of a statistical measure of agreement, such as 
Cohen’s κ or Krippendorff’s α.23,24 Because of the study design, in which a Gleason grade 4 
subclassification	only	had	to	be	indicated	when	Gleason	grade	4	was	present,	we	had	missing	
values	 for	 grade	 4	 subclassification	 when	 participants	 assigned	 a	 case	 to	 Gleason	 grade	
3 or 5. Cohen’s κ was therefore not a suitable statistical measure in this context, as it is 
known	to	be	highly	influenced	by	missing	values.25 Although Cohen’s κ is commonly used in 
the	medical	literature,	its	value	may	not	be	sufficiently	informative,	because	it	relates	the	
proportion of observed agreement to variation in a sample (i.e. relative measure), whereas 
the clinical question of observer variation in individual cases calls for an absolute measure, 
i.e. percentage agreement.26
In conclusion, consensus on Gleason grade 4 growth pattern was predominantly 
reached on glomeruloid and cribriform patterns, and rarely on ill-formed and fused patterns. 
These data indicate that Gleason grade 4 cribriform morphology, which has been associated 
with a worse clinical outcome, is a reasonably reproducible pattern in Gleason grade 4 
prostate cancer. The complex fused glands seem to represent a borderline pattern of unknown 
prognostic	significance	on	which	a	consensus	could	not	be	reached.
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ABSTRACT 
Background: Invasive cribriform and intraductal carcinoma (CR/IDC) is associated with 
adverse outcome of prostate cancer patients. The aim of this study was to determine 
the molecular aberrations associated with CR/IDC in primary prostate cancer, focusing on 
genomic instability and somatic copy number alterations (CNA).
Methods: Whole-slide images of The Cancer Genome Atlas Project (TCGA, n=260) and the 
Canadian Prostate Cancer Genome Network (CPC-GENE, n=199) radical prostatectomy 
datasets were reviewed for Gleason score (GS) and presence of CR/IDC. Genomic instability 
was assessed by calculating the percentage of genome altered (PGA). Somatic copy number 
alterations (CNA) were determined using Fisher-Boschloo tests and logistic regression. 
Primary analysis were performed on TCGA (n =260) as discovery and CPC-GENE (n=199) as 
validation set.
Results:	CR/IDC	growth	was	present	in	80/260	(31%)	TCGA	and	76/199	(38%)	CPC-GENE	cases.	
Patients	with	CR/IDC	and	≥	GS	7	had	significantly	higher	PGA	than	men	without	this	pattern	
in both TCGA (2.2 fold; P= 0.0003) and CPC-GENE (1.7 fold; P= 0.004) cohorts. CR/IDC growth 
was	associated	with	deletions	of	8p,	16q,	10q23,	13q22,	17p13,	21q22,	and	amplification	
of	8q24.	CNAs	comprised	a	total	of	1299	gene	deletions	and	369	amplifications	in	the	TCGA	
dataset, of which 474 and 328 events were independently validated, respectively. Several 
of the affected genes were known to be associated with aggressive prostate cancer such as 
loss of PTEN, CDH1, BCAR1 and gain of MYC. Point mutations in TP53, SPOP and FOXA1 were 
also associated with CR/IDC, but occurred less frequently than CNAs.
Conclusion: CR/IDC growth is associated with increased genomic instability clustering to 
genetic regions involved in aggressive prostate cancer. Therefore, CR/IDC is a pathologic 
substrate for progressive molecular tumour derangement.
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INTRODUCTION
Prostate cancer is heterogeneous with respect to its pathologic features, genetic 
background and clinical outcome. Clinical-decision making mostly depends upon serum 
Prostate	Specific	Antigen	(PSA)	level,	clinical	tumor	stage,	and	pathologic	biopsy	Gleason	
score (GS) – a grading system based on architectural tumor patterns.1 While patients with 
the	lowest	GS	≤6	(WHO/ISUP	group	1)	have	an	excellent	patient	outcome,	those	with	the	
highest GS 9-10 (WHO/ISUP group 5) have the worst.1,2 The clinical outcome of GS 3+4=7 
(WHO/ISUP group 2) prostate cancer patients is variable. Improving risk assessment in this 
subgroup of patients is of clinical relevance as biopsy GS 3+4=7 is an important threshold 
for active treatment. Recent studies have indicated that, among Gleason grade 4 growth 
patterns, cribriform growth is mostly associated with a worse clinical outcome.3-6
In recent years the clinical relevance of intraductal carcinoma of the prostate (IDC) 
–	a	malignant	epithelial	proliferation	filling	and	extending	pre-existent	glands	–	has	been	
acknowledged. Although not included in the Gleason grading system, IDC has been associated 
with high GS, advanced tumor stage, biochemical relapse and distant metastasis.7-12 IDC 
often mimics invasive cribriform carcinoma, and basal cell immunohistochemistry is often 
necessary for their distinction. Recently, our group has shown that patients with cribriform 
and/or	 intraductal	 carcinoma	 (CR/IDC),	 have	 significantly	worse	disease-specific	 survival	
probabilities than those without, regardless of GS.13 In addition, patients with focal CR/IDC 
have similar outcomes as men with extensive CR/IDC, indicating that the mere presence of 
this growth pattern is already an adverse feature.13,14
Although the number of mutational events in prostate cancer is relatively low, 
copy	number	alterations	 (CNAs)	are	 significantly	more	 frequent.15-24 Several studies have 
developed molecular prognostic signatures, showing that indolent tumors have relatively few 
CNAs in contrast to large-scale CNAs in high-grade or metastatic tumours.16,17,25,26 Both the 
intra-	and	inter-tumor	heterogeneity,	however,	pose	significant	challenges	for	personalizing	
treatment in patients with prostate cancer.27-29 GS 7 prostate cancers, for instance, harbor 
a	wide	range	of	CNA	burden	varying	between	<1%	and	50%.26
Since presence of CR/IDC growth pattern is an independent, adverse clinico-
pathologic parameter, we hypothesize that CR/IDC represents a morphological substrate of 
genomic alterations associated with aggressive disease.13 The objective of this study was 
to determine the CNAs and single nucleotide variants (SNVs) associated with CR/IDC using 
bioinformatics analyses of datasets from The Cancer Genome Atlas Project (TCGA) and the 
Canadian Prostate Cancer Genome Network (CPC-GENE).
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MATERIALS AND METHODS
Pathological review
Via online access (http://cancer.digitalslidearchive.net) and mScope Portal (Aurora 
Interactive, Montréal, Canada) three investigators with expertise in urogenital pathology 
(C.K., Th.v.d.K., and G.v.L.) reviewed available whole-slide images of frozen sections of both 
TCGA (n=260) and CPC-GENE (n=199) cohorts. Both cohorts contained radical prostatectomy 
specimens without prior hormonal or radiation therapy. Each slide was reviewed for GS, 
tumor	percentage	and	percentage	CR/IDC.	Percentage	CR/IDC	was	defined	as	estimated	
number of CR/IDC tumor cells divided by the total number of cells present in the tissue 
slice. Since invasive cribriform and IDC-P were morphologically indistinguishable, they were 
not scored individually.13
Somatic copy number alterations
All statistical analyses were performed in the statistical programming language R 
v3.2.1 and all genomic coordinates in this manuscript are based on the latest hg19 genome 
build. Gene-wise log2 ratios for revised TCGA PRAD samples (based on Affymetrix SNP 6.0 
arrays) were retrieved via the TCGA-Assembler R-package.30 To obtain discrete values, 
gains or deletions of genetic regions were called if a sample’s copy number exceeded the 
threshold of ±log2(1.5/2). Similarly, a gene-by-sample matrix was obtained for all revised 
CPC-GENE samples based on Affymetrix OncoScan arrays as described previously.17 Percent 
genome altered (PGA) was calculated for both the whole genome (excluding chrX and chrY) 
and separately for individual chromosome arms as described previously.17 For chromosome 
arms,	separate	PGAs	for	amplifications	and	deletions	were	obtained	by	dividing	the	number	
of	 bases	 affected	by	 a	 deletion/amplification	 by	 the	 number	 of	 bases	 of	 the	 respective	
chromosome arm, taking into account only one DNA strand as PGA does not account for the 
strand of CNAs. For all values, a Wilcoxon-Mann-Whitney test was performed to test for 
significant	differences	between	GS	categories.
To identify CR/IDC-associated events, the TCGA cohort was used as a discovery 
set and the CPC-GENE cohort was used for validation. We initially used all CR/IDC positive 
samples for our analyses, but subsequently limited the CR/IDC group to cases with at 
least	30%	to	account	for	possible	signal	 losses	due	to	dilution	effects	caused	by	non-CR/
IDC tissue without CNAs. This dilution effect can be envisioned by assuming that CNAs of 
interest are CR/IDC-associated and corresponding signals therefore mainly originate from 
the CR/IDC compartment of the tumor. Surrounding non-CR/IDC tissue hence likely does 
not harbor these CNAs and only contributes to background signal leading to a reduced 
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signal-to-noise ratio when trying to detect the CNAs in a mixture of both tissues. Prior to 
analysis, duplicated gene names, known read-throughs, genes on non-random/haplotype 
chromosomes, as well as genes in pseudoautosomal regions and with missing data were 
removed.	After	these	filtering	steps,	22,350	and	22,420	genes	remained	for	analysis	of	the	
TCGA and CPC-GENE cohort, respectively. Next, adjacent genes exhibiting the same CNA 
profiles	were	grouped	into	regions	to	further	reduce	the	number	of	tests.	Boschloo’s	exact	
test	(one-sided,	R-package	‘Exact’)	was	applied	to	regions	with	CNAs	in	at	least	10%	of	all	
samples	to	identify	events	that	occurred	significantly	more	often	in	samples	with	CR/IDC.	
Multiple testing correction was performed via false discovery rate (FDR) and regions with 
a	q-value	below	0.05	were	considered	significant.	To	integrate	both	cohorts,	all	genes	in	
regions	that	were	identified	as	significant	in	the	TCGA	cohort	were	tested	in	the	CPC-GENE	
cohort. Genes with a q-value below 0.1 were considered validated. A logistic regression was 
used	to	assess	which	individual	deletion	or	amplification	events	were	predictive	for	CR/IDC	
status while accounting for PGA and GS as confounding factors. To account for correlations 
between PGA and individual CNAs, PGA was re-calculated for each event by excluding the 
chromosome the particular event was located on. Visualization of results was done with 
BoutrosLab.plotting.general R-package (v5.6.10).
ERG expression, chromothripsis and kataegis
To quantify ERG expression in the TCGA cohort, RSEM ‘scaled estimates’ were 
obtained via TCGA-Assembler and multiplied by 106 to convert them to transcripts per million 
(TPM). Subsequently a log10 transformation was applied and UCSC transcript uc002yxa.2 was 
used to estimate ERG expression. Deletion events located between TMPRSS2 and ERG were 
determined by combining deletions of the genes ETS2, BACE2, BRWD1, PSMG1 and HMGN1. 
For the CPC-GENE cohort, scores for chromothripsis and kataegic regions were computed 
using the ShatterProof and SeqKat algorithms.31,32 The maximum values for each sample 
were used for comparison (Wilcoxon-Mann-Whitney test) to ascertain that despite their rare 
occurrence, any presence of these phenomena in the CPC-GENE samples could be detected 
and tested for association with CR/IDC.
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Somatic mutations
Automated and curated somatic mutation calls for exome sequencing data from 
TCGA PRAD samples were obtained via the TCGA Data Portal (https://tcga-data.nci.nih.
gov/tcga/). Functional events were summarized patient-wise for each gene (i.e. multiple 
mutations in one gene were only counted once per patient, excluding categories ‘Silent’ 
and	‘RNA’).	In	addition,	non-recurrent	events	and	events	that	occurred	in	less	than	5%	of	
all tested samples were excluded from further analysis; all remaining gene mutations were 
tested	 for	 significant	 enrichment	 in	 CR/IDC	positive	 samples	 using	 Boschloo’s	 exact	 test	
(one-sided, R-package ‘Exact’). CPC-GENE whole genome sequencing-derived SNVs were 
filtered	to	only	include	functional	mutations	located	in	exonic	regions	and	then	processed	
as described above.32
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RESULTS
Patient characteristics
Patient characteristics of both TCGA (n=260) and CPC-GENE (n=199) cohorts are 
listed in Table 1. The TCGA cohort included more patients with adverse characteristics than 
the CPC-GENE cohort, having higher PSA levels (Wilcoxon rank sum test, P=2.2·10-16), GS 
(Pearson’s	χ2	test,	P=4.0·10-5)	and	pT	stage	(Pearson’s	χ2	test,	P=3.1·10-9), which can be 
explained	by	the	specific	inclusion	of	clinically	intermediate-risk	disease	in	the	latter	cohort.	
Moreover, tumor cellularity was higher in TCGA than CPC-GENE (Supplementary Figure 1). 
Representative	prostate	cancer	samples	of	GS	6	and	GS	≥	7	are	depicted	in	Figure	1.
Figure 1. Representative images of reference HE slides of GS 6 (A, E) without CR/IDC, and GS 3+4=7 (B, 
F), 4+3=7 (C, G) and 4+4=8 (D, H) with CR/IDC growth.
A
E
B
F
C
G
D
H
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CR/IDC is associated with genomic instability
To assess whether CR/IDC was associated with genomic instability, we calculated 
PGA	for	all	patients	and	used	a	Wilcoxon-test	to	identify	significant	differences.17,26 PGA was 3 
fold (P=1.6·10-4) higher in men with CR/IDC as compared to men without (Figure 2). Exclusion 
of men with GS 6, who generally lack CR/IDC growth, yielded similar results with 2.2 fold 
(P=3·10-4) PGA increase in cases containing CR/IDC. Subgroup analysis revealed that PGA was 
significantly	higher	in	samples	with	CR/IDC	in	GS	4+3=7	(2.2	fold;	P=5.3·10-3), but not in GS 
3+4=7 (2.1 fold; P=0.19), GS 8 (5.1 fold; P=0.57) and GS 9-10 (1.7 fold; P=0.10). Moreover, 
PGA	scores	did	not	differ	significantly	between	GS	3+4=7	without	CR/IDC	pattern	and	GS	6	
(1.2 fold; P=0.51). Validation within the CPC-GENE cohort revealed overall 1.7 fold higher 
PGA	of	CR/IDC	positive	men	with	GS	≥	3+4=7	(P=4·10-3). Subgroup analysis showed 1.3 fold 
(P=0.02) higher PGA in GS 3+4=7 cases with CR/IDC as compared to those without. PGA scores 
were	significantly	lower	in	GS	6	as	compared	to	GS	3+4=7	with	CR/IDC	(2.2	fold;	P=4.7·10-7) 
than	those	without	CR/IDC	(1.6	fold;	P=0.07).	Since	32	out	of	35	CPC-GENE	patients	with	GS	≥	
4+3=7 had CR/IDC, statistical analysis in respective subgroups lacked statistical power.
Table 1. Clinical and pathological patient characteristics of the TCGA and CPC-GENE cohorts. 
Entire cohort CR/IDC positive  CR/IDC negative
TCGA CPC-GENE TCGA CPC-GENE TCGA CPC-GENE
Mean	(IQR)	or	n	(%)
Number 260 (100) 199 (100) 80 (31) 76 (38) 180 (69) 123 (62)
Age (years) 60 (56-66) 61 (57-66) 61 (57-66) 61 (58-66) 60 (55-70) 61 (57-64)
PSA (ng/mL) 10 (5.1-11) 7.6 (4.8-9.3) 12 (6.4-15) 8.1 (4.9-10) 9.5 (4.6-9.7) 7.3 (4.8-9.1)
GS
  3+3 96 (37) 69 (35) 0 0 96 (53) 69 (56)
  3+4 78 (30) 95 (48) 27 (34) 44 (58) 51 (28) 51 (41)
  4+3 39 (15) 25 (12) 22 (27) 22 (29) 17 (10) 3 (3)
  8 19 (7.3) 9 (4) 17 (21) 9 (12) 2 (1) 0
  9-10 28 (11) 1 (1) 14 (18) 1 (1) 14 (8) 0
pT stage
  T2 112 (43) 84 (42) 20 (25) 20 (26) 92 (51) 64 (52)
  T3a 80 (31) 58 (29) 28 (35) 26 (35) 52 (29) 32 (26)
  T3b 55 (21) 15 (8) 31 (39) 10 (13) 24 (13) 5 (4)
  T4 4 (2) 0 1 (1) 0 3 (2) 0
  Tx 9 (3) 42 (21) 0 20 (26) 9 (5) 22 (18)
GS (Gleason score); PSA (Prostate Specific Antigen)
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Figure 2:	Boxplot	of	patient-wise	PGA	stratified	by	CR/IDC	percentage	and	Gleason	score	in	the	TCGA	
(A) and CPC-GENE (B) cohort.
To determine whether genomic instability in CR/IDC was a global phenomenon 
or	affected	specific	genomic	regions,	we	computed	PGA	for	 individual	chromosome	arms	
utilizing	 deletion	 and	 amplification	 events	 independently.	We	 found	 that	 deletions	were	
mostly present on chromosome arms 1p, 4p, 4q, 5q, 7q, 8p, 10p, 10q, 12p, 13q, 16q, 17p, 
18q	and	21q	in	samples	with	CR/IDC	(P<0.05,	Supplementary	Figures	2	and	3;	Supplementary	
Table	1),	while	 amplifications	were	 found	on	 chromosome	4q,	 8p,	 8q,	 9p,	 14q	and	18p.	
Several of these chromosome arms have been linked to advanced prostate cancer.21,33-36 
Increased PGA for chromosome 4p, 8p, 10q, 12p and 16q deletions were also present in the 
CPC-GENE	cohort	(P<0.05,	Supplementary	Figures	4	and	5;	Supplementary	Table	1).
Somatic CNAs associated with aggressive clinical outcome are enriched in CR/IDC 
To identify somatic CNAs associated with CR/IDC we applied Boschloo’s exact test 
independently	for	each	gene	locus	in	GS	≥	3+4=7	samples.	We	found	592	gene	deletions	and	
366	 amplifications	 significantly	 associated	 with	 CR/IDC	 (q<0.05).	 These	 events	 clustered	
in	 specific	 chromosomal	 regions	 known	 to	 be	 associated	 with	 aggressive	 disease	 such	 as	
deletions of 8p (PPP2R2A, NKX3-1)37-39, 16q22 (CDH1)40, 16q23 (BCAR1, CTRB1, CTRB2, WWOX 
and MAF)15,41,42, 16q2443, 10q23 (PTEN)44,45, 17p13 and 18q21 (CCBE1)46	as	well	as	amplification	
of 8q24 (MYC and LY6 family members)15,47,48, Figure 3 and Supplementary Table 2).
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Since	 it	 was	 unclear	 whether	 genomic	 alterations	 occurred	 specifically	 in	 CR/
IDC structures or also in non-cribriform prostate cancer glands adjacent to CR/IDC, we 
excluded	samples	with	<30%	CR/IDC	growth	pattern.	Comparing	GS	≥	3+4=7	men	with	≥30%	
CR/IDC	(n=44)	to	those	without	(n=84)	resulted	in	a	total	of	1299	significant	deletions	and	
369	 amplifications.	Additional	 deletions	 in	 cases	 with	 ≥30%	 CR/IDC	 included	 the	 “Down	
syndrome critical region” located between ERG and TMPRSS2 on 21q2249, 16q22 (CTCF)50, 
13q14 (RB1)51,52, 17p13 (TP53)53, and parts of 6q54,55 (Supplementary Table 3). Although 
genetic deletions of genes located between the TMPRSS2 promoter and ERG occurred 
more	frequently	 in	CR/IDC	cases,	we	were	unable	to	find	a	significant	difference	 in	ERG 
mRNA	expression	(Supplementary	Figure	6).	This	paradoxical	finding	might	be	explained	by	
relatively more frequent genomic translocation than deletion mechanism for TMPRSS2:ERG 
corresponding to lower genomic instability in cases without CR/IDC.56
A	 trend	 towards	 lower	q-values	was	observed	when	excluding	 tumors	with	<30%	
CR/IDC	 pattern	 suggesting	 that	 signal	 strength	 from	 CR/IDC	 specific	 events	 was	 diluted	
in cases with low CR/IDC quantity. Subsequent analyses were all performed using CR/IDC 
samples	with	at	least	30%	cribriform	architecture.	In	total	474	deleted	and	328	amplified	
genes	were	validated	in	the	CPC-GENE	cohort	(q<0.1),	located	on	chromosomes	8p,	10q23,	
13q22, 16q23-24, 17p13, 21q22, as well as 8q24, respectively (Supplementary Table 4 
and Supplementary Figure 7). We noticed that q-values were generally lower in TCGA as 
compared to CPC-GENE, regardless of whether a threshold on CR/IDC was applied or not, 
indicating relatively lower statistical power of the latter cohort.
Since genomic instability and GS might act as confounding factors in assessing 
CNA events, we performed logistic regression analysis correcting for GS and PGA based on 
the	1668	previously	identified	events.	A	total	of	779	gene	deletions	and	317	amplifications	
were	 independently	 associated	 with	 CR/IDC	 (q<0.1,	 Supplementary	 Table	 5).	 Deletions	
were mostly located on 8p21-23, 13q14, 16q21-24 as well as 18q21-23, but also included 
the genomic loci containing PTEN (10q23)57, RYBP/FOXP1 (3p13)16 and CASP8AP2 (6q15)58. 
The PPP2R2A/BNIP3L/PNMA2 locus (8p21)37 featured the lowest q-value for deletions 
(P=0.00018, q=0.02, OR=10.2, 3.24-38), while the MAFA/PTP4A3 locus (8q24)59,60 did for 
amplifications	 (P=0.007,	q=0.08,	OR=7.77,	1.98-41.95).	For	CPC-GENE,	 logistic	 regression	
did	 not	 yield	 significant	 results	 after	 correcting	 for	multiple	 comparisons,	which	 can	be	
attributed	to	 lower	statistical	power	and	significant	differences	 in	pathological	features. 
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Somatic SNVs are not main driver events for CR/IDC growth
To identify genes affected by functional SNVs we used TCGA exome sequencing 
data	 (https://tcga-data.nci.nih.gov/)	of	 samples	with	GS	≥	7,	and	compared	88	 samples	
with	≥	30%	CR/IDC	against	143	without.	Filtering	for	genes	that	harbored	SNVs	in	at	least	
5%	of	all	samples,	FOXA1	(15%	versus	5%;	P=0.007),	TP53 and SPOP	(both	19%	versus	10%;	
P=0.035)	showed	significantly	higher	mutation	rates	in	cases	with	CR/IDC	compared	to	those	
without (Boschloo’s exact test). Although SNV data were available for CPC-GENE samples, 
the number of cases, i.e. 8 with and 30 without CR/IDC was too low for statistical analysis. 
We	did	 not	 find	 significant	 differences	 in	 overall	 frequency	 or	 total	 number	 of	 affected	
genes with functional SNVs (data not shown), indicating that SNVs are unlikely to be driver 
events for CR/IDC growth.
Finally, we investigated whether recently discovered DNA repair-related phenomena 
were linked to CR/IDC.61,62 We utilized available computational scores for kataegis, a 
pattern of localized hypermutation, and chromothripsis, a catastrophic event during which 
single chromosome arms or entire chromosomes are rearranged and/or lost. No statistically 
significant	differences	could	be	identified	between	cases	with	and	without	CR/IDC	albeit	
sample numbers were low (data not shown).
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DISCUSSION
Recent studies have validated the clinical importance of both invasive cribriform 
and intraductal carcinoma of the prostate.6,13,14 In the current study, we hypothesized 
that CR/IDC represents a morphologic substrate of genomic alterations associated with 
aggressive disease. We found that CR/IDC was associated with increased genomic instability 
showing chromosomal deletions of 3p13, 6q15, 8p21-23, 10q23, 13q14, 16q21-24, 18q21-
23,	and	amplification	of	8q24.	The	genetic	losses	and	amplifications	included	several	genes	
related to aggressive prostate cancer, such as loss of PTEN, RB1, TP53	and	amplification	of	
MYC.	These	findings	altogether	support	our	hypothesis	that	CR/IDC	is	a	specific	morphologic	
substrate of genomic alterations associated with aggressive disease.
Our study is in line with previous studies on genetic abnormalities related to CR/IDC 
growth. Dawkins et al. and Bettendorf et al. observed more frequently loss of heterozygosity 
(LOH) in IDC than in the invasive prostate cancer component.63,64	Qian	et al. showed gain of 
chromosomes	7,	12,	and	Y,	loss	of	chromosome	8,	and	amplification	of	c-MYC in cribriform 
cancer compared to other Gleason grade 3 and 4 patterns.65 In a meta-analysis on recurrent 
CNAs, Williams et al.34 compared 568 primary prostate cancer tumor samples from 8 
previous studies16,19,20,66-70 with 115 metastatic prostate cancer samples from 5 previous 
studies.16,22,68,71,72 Strikingly, the prevalence of recurrent CNAs in metastatic prostate cancers 
corresponded with several of the CNAs that were enriched in CR/IDC growth, such as PTEN 
and NKX3-1. Recently, Chua et al. studied differences in RNA expression in prostate cancer 
with and without CR/IDC. They found that the long non-coding RNA SChLAP1, which has 
been	associated	with	tumor	progression,	was	significantly	higher	in	CR/IDC,	and	that	CR/
IDC growth was associated with hypoxia.73-75	Together	these	findings	further	support	a	strong	
relation	of	CR/IDC	with	molecular	tumor	progression.	On	the	other	hand,	we	did	not	find	a	
statistically	significant	difference	between	CR/IDC-negative	GS	3+4=7	and	GS	6	cases,	which	
further supports the question whether it is clinically relevant to distinguish CR/IDC-negative 
GS 3+4=7 from GS 6 prostate cancer.
Although prostate cancer with CR/IDC showed increased genomic instability, it is 
not yet clear to what extent these molecular alterations are exclusively present in CR/IDC 
tumor glands or whether these alterations can also be found in surrounding non-cribriform 
tumor glands. Using RNA in situ hybridization, we previously found that SChLAP1 was not 
only over-expressed in CR/IDC structures but also in adjacent non-cribriform cancer glands 
suggesting	 that	 it	 represents	 a	 field	 effect	 during	 tumor	 progression	 and	 not	 a	 specific	
characteristic of CR/IDC growth.73,76 In our study, CR/IDC was more frequently present in 
cases with higher GS. To exclude that genomic alterations were merely relating to higher GS 
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and not to CR/IDC per se, we performed PGA subgroup analysis and logistic regression for 
CNAs, which indeed revealed an independent associated with CR/IDC in the TCGA cohort. 
Further comparisons of microdissected growth patterns within individual patients are 
mandatory	to	determine	what	events	are	specific	for	CR/IDC	and	which	represent	general	
effects of progression.
Elucidation of the molecular alterations associated to CR/IDC is not only of interest 
for molecular-biology, but might also have future impact for prostate cancer diagnosis and 
management. Prostate biopsies only sample a limited volume of the entire tumor and might 
be false-negative for CR/IDC due to sampling artifact. Since IDC represents an extensive 
proliferation of neoplastic cells within pre-existent acini, which connect with the urethra, 
we	postulate	 that	 these	cells	 and/or	 their	DNA	can	be	 shed	 into	urine.	 Identification	of	
molecular alterations associated with CR/IDC in voided urine could form the base of non-
invasive tests for detection of aggressive CR/IDC.
The	current	study	has	several	limitations.	While	we	set	out	to	validate	our	findings	
in an independent cohort, we noticed that many events originally found in the TCGA cohort 
could	not	be	 confirmed	 in	 the	CPC-GENE	dataset.	This	may	be	explained	by	differences	
in cohort composition, since the TCGA was enriched for tumors with adverse pathologic 
features. In addition, the statistical power of the CPC-GENE cohort was lower than of 
the TCGA, as its study population was smaller, included samples with lower and more 
variable tumor percentage, and was strongly enriched for CR/IDC in GS 8-10. Nevertheless, 
both datasets independently revealed the association of CR/IDC with increased genomic 
instability	and	the	deletions	of	various	specific	genomic	regions	and	genes.	Furthermore,	
tumor	heterogeneity	and	sampling	artifacts	may	have	also	influenced	the	outcome	of	this	
study, as our current data was based on DNA derived from a freshly frozen section per 
patient. Hence, there may have been, for instance, CR/IDC growth in an adjacent region 
that	was	not	 sampled	 for	 genomic	analysis	 that	may	have	been	detected	due	 to	a	field	
effect. This might be the cause of the relatively small effect sizes in the current study. 
Lastly, we did not independently analyze CR/IDC growth in relation to adjacent tumor 
glands using, for instance, laser-capture microdissection or in situ hybridization.
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CONCLUSION
We found that pathologic CR/IDC growth pattern is associated genomic instability 
including deletions of 8p, 10q23, 13q22, 16q22-24, 17p13 and 21q22, as well as smaller 
8q24	amplification.	These	results	indicate	that	CR/IDC	is	a	histopathological	substrate	of	
molecular tumor progression and presents a rationale for its aggressive clinical behavior.
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DISCUSSION
The objective of this thesis was to study the role of cribriform growth in prostate 
cancer with respect to diagnosis, prognosis and molecular pathology. In this chapter, I will 
first	 summarize	 the	main	 findings	 and	 review	 their	 interpretation	 in	 the	 context	 of	 the	
current knowledge. I will then provide a discussion on methodological considerations and 
clinical applications. Lastly, I will discuss recommendations for future research.
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REVIEW AND INTERPRETATION OF MAIN FINDINGS
Is Gleason score 3+3=6 really malignant?
One of the main questions in this thesis is whether pure Gleason score 3+3=6 
tumors have the potential to metastasize. Previous studies on Gleason score 6 patients 
have reported negligible rates of biochemical recurrence after radical prostatectomy or 
salvation radiotherapy.1-3 Hernandez et al., for instance, showed that patients with organ-
confined	Gleason	score	≤6	prostate	cancer	do	not	develop	post-operative	metastases	nor	die	
from prostate cancer.3 In a more recent analysis containing >14 000 Ross et al.	did	not	find	
any	lymph	node	metastases	in	men	with	modified	Gleason	score	≤6	prostate	cancer	during	
follow-up.4	 Our	 study	 is	 in	 line	with	 these	 findings,	 and	 additionally	 shows	 that	 distant	
metastasis	 and	 disease-specific	 death	 do	 not	 occur	 in	 non-organ	 confined	Gleason	 score	
≤6	prostate	cancer	either.5 We therefore hypothesize that these tumors do not have the 
biologic	ability	to	metastasize	or	cause	disease-specific	mortality.
Previous autopsy studies have already provided considerable evidence that 
a substantial number of prostate cancers within the population exist that do not result 
in clinical symptoms or death. These, for instance, reported incidental prostate cancer 
prevalence	between	30	and	40%	in	men	older	than	50	years.6-8 Of these incidentally detected 
cancers,	at	least	70%	(cystoprostatectomy	series)	and	80%	(autopsy	series)	showed	presence	
of Gleason score 6 prostate cancer.6-10 These data support the argument of considering 
Gleason	score	6	as	a	benign	lesion.	Additionally,	the	Gleason	grading	modification	in	2005	
exceedingly	 limited	 the	 Gleason	 pattern	 3	 definition.	 As	 a	 result,	 men	 diagnosed	 with	
Gleason score 6 prostate cancer today are likely to have less aggressive tumors than those 
with a classical Gleason score 6 prostate cancer diagnosed before 2005.11 
The fact that Gleason score 6 prostate cancers have excellent outcome, raises the 
question by urologists whether these tumors are cancer at all. There are, however, several 
arguments against diagnosing Gleason score 6 as a benign lesion. Our study, for instance, 
showed that Gleason score 6 tumors are able to expand through the prostatic capsule 
and to invade the seminal vesicles, indicating local aggressive behavior similar to other 
malignancies. Prostate cancer glands also show loss of the basal cell layer microscopically, 
indicating invasion in the surrounding tissue. Gleason grade 3 glands additionally share 
molecular alterations associated with Gleason grade 4 glands, such as the TMPRSS2-ERG 
gene fusions.12,13 Furthermore, it is important to realize that studies showing excellent 
outcome of Gleason score 6 prostate cancer had been performed using radical prostatectomy 
specimens. This means that the entire tissue was available for histopathological analysis 
and does not include presence of high-grade components. Since considerable sampling 
147
error exists in diagnostic biopsies, these results cannot be directly translated to diagnostic 
biopsies. Like many solid tumors, prostate cancer is a heterogeneous disease and susceptible 
to biopsy sampling error. The biopsy Gleason score can underestimate the actual grade 
due	 to	missing	 significant	 tumor	 components.	 In	 a	 recent	 study	 containing	 7643	 radical	
prostatectomies with corresponding needle biopsies, Epstein et al.	 reported	 that	36%	of	
cases (1841/ 5071) were upgraded from a needle-biopsy Gleason score 6 to a higher grade 
at radical prostatectomy.14 Based on large active surveillance studies in men with Gleason 
score	6	on	biopsy,	up	to	33%	of	the	patients	still	need	therapeutic	intervention	primarily	due	
to Gleason score upgrading.15-20 At this moment, it is however impossible for the pathologist 
to determine which Gleason grade 3 glands in a biopsy specimen represent a pure Gleason 
score 6 tumor or a component of higher-grade tumor in which the high-grade component is 
not present in the respective tissue. Factors that have been associated with upgrading are 
serum PSA levels, clinical stage and tumor volume on biopsy.14 In addition, other ancillary 
tests that are still under investigation, such as mpMRI and molecular testing, show promising 
results.21-25 These tests could be, for instance, useful in identifying alterations associated 
with either low-risk or high-risk disease in Gleason score 6 patients.
Although	we	did	not	report	any	deaths	attributed	to	cancer	in	men	with	modified	
Gleason score 6 prostate cancer at radical prostatectomy, we and Ross et al. originally 
found several cases of metastatic disease in classic Gleason score 6 patients.4,5 Interestingly, 
microscopic review of their histology demonstrated presence of Gleason grade 4 pattern 
elements in all cases. These patients were treated and graded in the era before the 2005 
Gleason	grading	modification	when	these	patterns	were	still	considered	as	a	grade	3	pattern.11 
An important observation from these pathology reviews, which laid the foundation for this 
thesis was that the majority of the classic Gleason score 6 patients who had developed 
metastatic disease showed presence of cribriform tumor glands in their specimen.4
Cribriform prostate cancer
Our group has previously found that presence of cribriform growth in radical 
prostatectomy specimens is a major predictive factor for distant metastasis and disease-
specific	death	of	prostate	cancer	 in	Gleason	score	7	patients.	 In	 fact,	cribriform	growth	
was the strongest predictor of both adverse clinical events after surgical treatment in 
multivariable analysis, adjusted for other relevant clinico-pathologic variables, such as age, 
PSA, Gleason score and pT stage.26 In the past years several other groups using different 
patient cohorts and various clinical endpoints additionally validated the association of 
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cribriform growth with adverse outcome.27-33 We subsequently validated the independent 
prognostic value of cribriform growth in diagnostic needle biopsies using strong clinical 
endpoints. Importantly, we found that patients with Gleason score 3+4=7 without cribriform 
growth on diagnostic biopsy have similar patient outcomes as those with Gleason score 6, 
implying these patients may be potential candidates for active surveillance as well.34,35 
The cribriform pattern shows good interobserver reproducibility among pathologists, 
while patterns such as fused and ill-formed Gleason grade 4 are poorly reproducible.36 
Another study showed that the percentage of fused and ill-formed glands was inversely 
correlated with agreement among pathologists, whereas the cribriform pattern had no 
significant	 correlation	 with	 interobserver	 variability.37 This supports the hypothesis that 
cribriform growth might be a valuable additional parameter in selecting patients for 
active	 surveillance.	 In	 our	 final	 study,	we	 demonstrated	 that	 cribriform	prostate	 cancer	
is associated with increased genomic instability showing chromosomal deletions of 3p13, 
6q15,	8p21-23,	10q23,	13q14,	16q21-24,	18q21-23,	and	amplification	of	8q24.38 The genetic 
losses	and	amplifications	included	several	genes	related	to	aggressive	prostate	cancer	such	
as loss of PTEN, RB1, TP53	 and	amplification	of	MYC. Our study is in line with previous 
studies on genetic abnormalities related to cribriform and/or intraductal carcinoma 
using comparative genomic hybridization. Two studies observed more frequently loss of 
heterozygosity (LOH) in IDC than in the invasive prostate cancer component.39,40	Qian	et 
al.	showed	gain	of	chromosomes	7,	12,	and	Y,	loss	of	chromosome	8,	and	amplification	of	
c-MYC in cribriform cancer compared to other Gleason grade 3 and 4 patterns.41 The latter 
three studies, however, contained small sample sizes, while our current study included a 
large number of patients.38 In a meta-analysis on recurrent CNAs, Williams et al. compared 
568 primary prostate cancer tumor samples from 8 previous studies with 115 metastatic 
prostate cancer samples from 5 studies.42 Remarkably, the prevalence of recurrent CNAs 
in metastatic prostate cancers corresponded with the CNAs found enriched in cribriform 
prostate cancer, such as PTEN and NKX3-1. More recently, using break-points regions to infer 
phylogenetic relationships, Lindberg et al. showed that the clone closely related to the 
distant metastasis was found in intraductal carcinoma that had cribriform architecture.43 
Altogether,	 these	findings	 further	 support	 a	 strong	association	of	 cribriform	growth	with	
molecular	tumor	progression.	Vice	versa,	we	did	not	find	a	statistically	significant	difference	
in genetic abnormalities between Gleason score 3+4=7 without cribriform growth and 
Gleason score 6 cases, supporting the notion whether it is clinically relevant to distinguish 
cribriform-negative Gleason score 3+4=7 from Gleason score 3+3=6.
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What about the other grade 4 patterns?
After the ISUP consensus conference in 2005, ill-formed (or poorly formed) glands 
were considered a Gleason grade 4 pattern.11 The authors additionally recommended that 
high-grade tumor of any quantity on needle biopsy should be included within the Gleason 
score.	Thus,	a	needle	biopsy	that	is	involved	by	cancer	with	98%	Gleason	pattern	3	and	2%	
Gleason pattern 4 would be diagnosed as Gleason score 3+4=7. The Gleason score system 
modification	in	2005	led	to	a	significant	grade	inflation,	i.e.	a	decline	in	reported	incidence	
of	Gleason	score	6	tumors	and	relative	increase	of	Gleason	score	7	tumors.	The	modification	
resulted in better clinical outcomes in both patient populations, a statistical artifact also 
known as the Will-Rogers phenomenon.44,45 Patients with Gleason score 6 prostate cancer 
are considered candidates for active surveillance, whereas patients with Gleason score 
7 generally undergo therapeutic intervention.46 Others and we have shown that the ill-
formed pattern has a considerable intraobserver and interobserver variability among 
pathologists.36,47-52 This poorly reproducible pathologic variable is nonetheless an important 
clinical decision point for many patients. Patients with Gleason score 6 prostate cancer are 
candidates for active surveillance, whereas patients with Gleason score 7 generally undergo 
therapeutic intervention.46	As	a	matter	of	fact,	no	studies	to	date	have	specifically	validated	
the adverse prognostic value of the ill-formed pattern and its role in active surveillance 
enrolment of patients with prostate cancer. Zhou et al. recently suggested that adjacent 
tumor glands play an important role in decision-making in cases showing ambiguous ill-
formed patterns.52 The authors recommend that >10 poorly formed glands not immediately 
adjacent to other well-formed glands should be considered to represent ill-formed Gleason 
pattern 4. In contrast, poorly formed glands that are intermixed with well-formed glands, or 
≤5	poorly	formed	glands,	regardless	of	their	location,	should	be	diagnostic	features	arguing	
against Gleason pattern 4. Although such criteria seem reasonable, they are – like many 
previous studies on the distinction of well-formed pattern 3 glands versus ill-formed pattern 
4 glands – not based on clinical outcome data. Secondly, and perhaps more importantly, 
as	demonstrated	by	Labov’s	linguistic	work,	endeavors	to	set	a	classification	threshold	for	
categories	along	a	continuum	leads	to	significant	problems	with	category	reproducibility.53 
The ill-formed pattern is poorly reproducible and we agree with McKenney et al. that 
the	specific	histologic	assessment	of	“ill-formed	glands”	will	never	 reach	a	high	 level	of	
diagnostic	reproducibility	for	any	group	of	pathologists,	regardless	of	more	specific	criteria	
or increased education.32 We therefore believe that the ill-formed pattern itself should not 
be a criterion to exclude a patient from active surveillance, as the higher Gleason score 
most	likely	reflects	a	change	in	grading	practice	rather	than	tumor	biology.
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In 2009, Lotan et al. were	the	first	to	our	knowledge	to	publish	a	paper	on	grading	
prostate cancer with glomeruloid features.54 In this study the authors claimed that the 
glomeruloid pattern is strongly associated with high-grade prostate cancer on the same 
biopsy	core	(36/45,	80%).	Based	on	the	observation	that	in	several	cases	a	transition	could	
be seen among small glomerulations, large glomeruloid structures, and cribriform pattern 
4 cancer, the authors additionally suggest that glomerulations represent an early stage of 
invasive cribriform cancer and are best graded as Gleason pattern 4. These observations lay 
the foundation for the current ISUP recommendations, which recommend that glomeruloid 
glands should be assigned a Gleason pattern 4, regardless of morphology.54,55 No clinical 
outcome data was, however, available from the study by Lotan et al.54 Although their 
suggestion regarding grading seems plausible and pragmatic too, others and we could not 
find	 an	 association	 between	 glomeruloid	 and	 cribriform	 glands	 or	 high-grade	 cancer.26,33 
Moreover, both our studies found that presence of glomeruloid glands is independently 
associated with a better outcome of Gleason score 7 prostate cancer in multivariable 
analyses, which contradicts the idea that glomeruloid glands represent a precursor lesion 
of an aggressive cancer type. McKenney et al.	could	also	not	find	an	association	between	
glomeruloid glands and outcome.32 We believe that the smaller glomerulations surrounded 
by well-formed pattern 3 glands are more likely to show more indolent behavior than 
those transitioning to large glomerulations and/or cribriform glands. Interestingly, in our 
interobserver reproducibility study on Gleason grade 4 patterns we found that there is 
good interobserver reproducibility of small glomeruloid glands, but less in large glomeruloid 
glands as half of the observers considered these cribriform.36 Similar to the semantics in 
well-formed glands and ill-formed glands, there seems be a continuum in morphology of 
large glomeruloid and cribriform glands. The biology of glomeruloid glands, let alone their 
pathological meaning, remains unknown.
Intraductal carcinoma of the prostate
In	recent	years	the	clinical	significance	of	 intraductal	carcinoma	of	the	prostate	
– a morphological mimicker of invasive cribriform carcinoma – has been acknowledged. 
The current concept is that it represents divergent differentiation of a common precursor 
that either spreads invasively or via pre-existing ducts.56 Although not included in the 
Gleason grading system, intraductal carcinoma has been associated with Gleason grade 4 
and 5 patterns, advanced tumor stage, biochemical recurrence and distant metastasis.57-62 
Although invasive cribriform carcinoma and intraductal carcinoma are strictly speaking 
two different pathologic entities, they morphologically mimic each other closely and it is 
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possible they relate and exist on a pathological and biological continuum.63,64 In our studies 
we noticed in the majority of cases that both entities co-exist in the same tumor.26,34 The 
current concept is that intraductal carcinoma represents spread of high-grade prostate 
cancer into pre-existing ducts using these natural passages as low-resistance highways of 
rapid growth.39,63,65 We found that intraductal carcinoma and invasive cribriform glands 
are often present together in prostate cancer specimens, raising the question whether 
invasive cribriform glands could possibly represent invasion of intraductal carcinoma into 
surrounding tumor glands. Also, the lack of basal cells is not pathognomonic of invasive 
cribriform cancer as basal cells can be scattered and left unsampled in the slide. To date, 
little is known about how, for instance, intraductal carcinoma transitions to invasive 
cribriform	cancer	on	a	molecular	and	three-dimensional	 level.	Are	gland	sizes	or	specific	
stromal-epithelial interactions creating a complex anastomosing network of tumor glands of 
pathological	significance?	In	fact,	we	do	not	know	what	drives	the	formation	of	cribriform	
tumor	 glands.	Although	we	find	 several	 genetic	 abnormalities	 associated	with	 cribriform	
growth in prostate cancer, it remains unclear how the phenotype and genotype interact.
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METHODOLOGICAL CONSIDERATIONS
Study design
A limitation of our Gleason score 3+3=6 mortality study was that not all radical 
prostatectomy specimens were pathologically reviewed and scored according to the 
modified	Gleason	score.5 Recently, Dong et al. re-graded 806 radical prostatectomies with 
Gleason	score	3+3=6	and	3+4=7	prostate	cancer	according	to	the	modified	Gleason	grading	
system	and	report	an	upgrade	of	34%	from	classical	Gleason	score	3+3=6	prostate	cancer	
to	modified	Gleason	score	7	or	8	at	radical	prostatectomy,	but	not	a	single	case	of	Gleason	
score	≥7	was	downgraded	to	a	≤6	at	radical	prostatectomy.66 For this practical reason we 
only revised the classical Gleason score 3+3=6 cases with adverse patient outcome. Although 
we claim that Gleason score 3+3=6 patients do not die from their disease, all patients had 
received treatment. One could argue that these patients had been cured by their therapy 
and therefore had not developed metastatic disease. 
Another limitation from patient-outcome studies in this thesis is the retrospective 
design. For instance, the original ERSPC protocol included sextant biopsies, while current 
biopsy schemes are more extensive and increasingly MRI targeted aiming to reduce the 
chance of sampling artifact. In addition, there is a difference in treatment modalities 
compared with the 1990s. Low-risk patients studied in this thesis had mostly received active 
treatment, while today active surveillance would have been an acceptable strategy for 
them.	Nevertheless,	studying	a	variable’s	prognostic	impact	with	disease-specific	death	as	
an endpoint in prostate cancer demands for a long-term follow-up. Further research in a 
prospective setting is needed to validate the prognostic value of Gleason grade 4 patterns 
in contemporary protocol-based active surveillance protocols. 
Interobserver variability When pathologists look at a tumor under the microscope, they essentially look 
at a snapshot of a process that continuously grows and changes over time. This continuum 
makes	it	challenging	for	pathologists	to	set	reproducible	classification	thresholds	and	offers	
an explanation why the Gleason grading system in prostate cancer remains subjective 
despite	various	international	consensus	meetings	to	define	criteria.	Although	variability	in	
pathological grading does not always affect clinical-decision making, some thresholds have 
major clinical impact. In prostate cancer, for instance, the discrimination of Gleason score 
3+4=7 from 3+3=6 has clinical consequences. For our studies we scored many histological 
slides for various growth patterns, but cannot be certain that our judgment has been entirely 
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correct in all of the cases. If other pathologists, or even we, would repeat this job there will 
be	most	likely	variation	in	pattern	classification,	particularly	in	the	identification	ill-formed	
and	fused	glands.	The	fact	that	our	findings	indicate	that	Gleason	score	3+4=7	patients	with	
ill-formed glands have similar outcomes to those with Gleason score 3+3=6 further supports 
the poor reproducibility of these glands. We therefore believe that the ill-formed pattern 
itself should not be a criterion to exclude a patient from active surveillance, as the higher 
Gleason	score	most	likely	reflects	a	change	in	grading	practice	rather	than	tumor	biology.
Percentage Gleason grade 4
 Recent literature has suggested that quantifying the percentage of Gleason grade 
4 may be a more useful tool for risk prediction.67-69 Although most Gleason score 3+4=7 
disease are recommended to undergo active treatment, selected low-volume Gleason score 
3+4=7 patients could be considered for active surveillance. Recent guidelines recommend 
that patients with low-volume Gleason score 3+4=7 should only be considered for active 
surveillance	if	there	is	focal	presence	of	Gleason	grade	4,	i.e.	accounting	for	10%	of	the	total	
tumor volume.70 Based on our study, higher Gleason grade 4 percentages are often associated 
with presence of cribriform tumor glands.71 Since in our study percentage Gleason grade 4 
was inferior to presence of cribriform growth with regard to predicting patient outcome 
in a multivariable model, the quantifying approach does, to our opinion, not really offer 
a solution. Determining the Gleason grade 4 percentage greatly depends on core length 
and interobserver variability of high-grade patterns that are poorly reproducible. Although 
quantification	of	Gleason	grade	4	percentage	seems	an	objective	tool,	it	is	more	likely	a	
semblance of precision. We therefore endorse a more practical approach by establishing the 
presence of cribriform tumor glands, which is a reproducible qualitative feature instead of 
quantification	of	inherently	imprecise	quantification	of	growth	patterns.
Bioinformatics
While analyzing the two different patient cohorts, we noticed that a high number 
of copy number events detected in TCGA could also be validated in CPC-GENE when 
inspecting them individually, which was no longer the case after correcting for the multiple 
comparisons problem, implicating a lower statistical power for CPC-GENE due to the smaller 
sample size. Furthermore, both datasets differed in terms of the utilized array platform 
as well as Gleason score distribution, with TCGA featuring higher stage samples while 
CPC-GENE focused on lower to intermediate grade prostate carcinomas. The two cohorts 
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also	 showed	 significant	 differences	 in	 tumor	 percentage,	 which	might	 result	 in	 a	 lower	
signal-to-noise ratio in CPC-GENE compared to TCGA. Here, signal can be understood as 
the probability of being able to detect CNAs by measuring the amount of DNA. Since each 
measurement is taken from a mixture of cells, deviations from the baseline of two copies 
can	only	be	detected	if	sufficient	cellular	material	contains	the	altered	DNA	sequence	and	
therefore	causes	a	signal	increase	(amplification)	or	decrease	(deletion)	that	exceeds	the	
background noise. Therefore, with a higher number of non-cancerous cells present in each 
sample,	the	chance	to	observe	cribriform-specific	events	diminishes	as	the	global	average	
converges to the baseline of two copies. In combination, these differences might have 
influenced	our	ability	to	robustly	identify	CNA	events	in	the	CPC-GENE	cohort	in	a	similar	
manner as for TCGA.
Ideally, the discovery and validation cohort should feature identical characteristics 
and should be derived from the same background population, such as when randomly sub-
dividing a large dataset into training and testing set for cross-validation. Unfortunately, 
despite the enormous efforts undertaken in both studies, none of them features enough 
patient samples to support the required number of samples in each sub-group analyzed 
in our study (with one degree of freedom, ~32 samples are required per group to detect 
differences	with	an	intermediate-strength	effect	size	of	0.5	at	a	significance	level	of	0.05	
with	statistical	power	of	80%).	Since	in	practice	one	has	to	account	for	additional	differences	
due to heterogeneity of the disease, this number can easily increase to 50 and more samples 
for smaller effect sizes that result from CNAs being absent in subsets of patients.
Since both datasets separately suffer from a lack of samples, an alternative option 
would be to merge them into a larger dataset while accounting for batch effects, however, 
given the number of potential sources of variance (tissue sampling, DNA extraction, array 
platform, etc.), we chose to treat both cohorts independently and to focus on recurring 
events. To gain more statistical power and alleviate some of the negative effects mentioned, 
we	reduced	the	number	of	tests	by	binning	genes	with	matching	copy	number	profiles	and	
only performing one representative comparison for each group of genes. We also chose 
to use Boschloo’s exact test, a more powerful version of the classical Fisher’s exact test, 
for	 our	 analyses.	 In	 order	 to	 do	 so	 discrete	 calls	 for	 amplifications	 and	 deletions	 were	
required, prohibiting us from distinguishing heterozygous and homozygous deletions as 
well	as	differing	number	of	copies	for	amplified	genes.	Moreover,	the	chosen	thresholds	for	
calling	amplifications	and	deletions	can	influence	downstream	analyses	by	over-	or	under-
calling events. To avoid such issues as much as possible, our thresholds were chosen after 
close inspection of the distributions of log2 copy numbers of both datasets. Nevertheless, 
further improvements of the analytical pipeline might be achieved by comparing raw log2 
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copy number values instead of discrete calls, which could be implemented using ANOVA-like 
tests. This could allow an improved sub-grouping of samples, as a differentiation between 
hetero- and homozygous samples would be possible.
With	respect	to	the	validity	and	reproducibility	of	our	findings,	despite	the	large	
discrepancies between both cohorts, we showed that cribriform-positive status can 
be	 consistently	 correlated	 with	 increased	 genomic	 instability	 and	 specific	 CNA	 events.	
Moreover, our multivariable analysis in TCGA provided evidence that cribriform growth can 
be an independent predictor of outcome even when correcting for Gleason score, and an 
independent validation using an orthogonal technique will be needed to clarify whether 
cribriform growth indeed harbors distinct genomic aberrations compared to surrounding 
tissues.
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CLINICAL APPLICATIONS
Correlation with radiology
As multiparametric magnetic resonance imaging (mpMRI) of the prostate progresses, 
better	correlation	with	histology	could	possibly	lead	to	pre-biopsy	identification	of	cribriform	
tumor glands and at the same time used as a triage test to avoid unnecessary biopsies. 
To date, only two recently published studies have looked into the histologic correlation 
between	MRI	findings	and	cribriform	growth,	but	they	show	conflicting	results.72,73 However, 
as more research groups are becoming aware of the potential clinical relevance of cribriform 
prostate cancer, we expect that future MRI-correlation studies will give a better view on the 
pathologic-radiologic correlation.  
Risk prediction
Previous studies have shown that the risk calculator number 3 (RC3) of the European 
Randomized Study of Screening for Prostate Cancer (ERSPC; www.erspc.org) based on the 
Rotterdam cohort is an adequate risk-stratifying tool in men before prostate biopsy.74-76 
The RC3 uses pre-biopsy information such as PSA, digital rectal examination outcome and 
prostate volume to predict the probability of a biopsy-detectable prostate cancer and/
or	presence	of	Gleason	score	3+4=7	cancer	or	higher.	The	current	definition	of	clinically	
significant	prostate	cancer	 is,	however,	 largely	based	on	 the	presence	of	any	amount	of	
grade 4. We therefore suggest to include cribriform growth in a risk calculator as the 
parameter	for	clinically	significant	Gleason	score	3+4=7	prostate	cancer.	Presence	of	other	
grade 4 patterns would then be acceptable. In a recent study we aimed to improve the RC3 
by	inclusion	of	cribriform	pattern	in	the	definition	of	clinically	significant	prostate	cancer.	
Using	cribriform-specific	information	we	found	that	10%	of	the	patients	that	were	initially	
considered of having low-risk prostate cancer were upgraded to high-risk prostate cancer, 
and	vice	versa	33%	were	downgraded.77	Incorporating	cribriform-specific	information	could	
aid in the decision whether or not to do an MRI or biopsy. To date, Gleason score 7 has 
been	used	as	an	important	clinical	endpoint	in	many	studies,	and	sometimes	even	defined	
as ‘high-risk disease’, while it appears to be a rather subjective variable with doubtful 
clinical relevance. We therefore recommend including presence of cribriform growth in 
studies using Gleason score 7 cancer as an outcome measure, since this variable seems more 
reproducible and clinically relevant.
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Identifying therapeutic targets 
As described previously, cribriform prostate cancer is associated with an adverse 
outcome. Prognostic value does, however, not equal predictive value. In fact, we know 
little about the role of cribriform growth as a predictive marker for response to androgen-
deprivation therapy or chemotherapy. Also, little is known about how cribriform tumors 
respond to radiotherapy. Interestingly, one recent study using patient-derived xenografts 
of patients with advanced prostate cancer has demonstrated that intraductal carcinoma 
lesions are more likely to persist after androgen deprivation therapy.78 Further understanding 
of	the	biology	of	cribriform	growth	may	translate	into	preclinical	studies	to	find	effective	
therapeutic drugs for recurrent or metastatic cribriform prostate cancer. 
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SUGGESTIONS FOR FUTURE RESEARCH
The work described in this thesis has put cribriform growth forward as a relevant 
biomarker	 in	 prostate	 cancer.	 Our	 findings	 need,	 however,	 to	 be	 validated	 and	 further	
evaluated in longitudinal investigations. Our work has additionally generated many new 
questions that merit consideration in future research. 
Comprehensive genomic analysis of cribriform prostate cancer
 Our study on copy number variations and genomic instability in cribriform prostate 
cancer is just a mere start to what can be explored.38 Further and more comprehensive studies 
including, for instance, transcriptomic and epigenomic data are needed to acquire a better 
understanding of cribriform growth in prostate cancer. In situ hybridization experiments 
could	further	elucidate	whether	specific	copy	number	variations	or	differentially	expressed	
genes are limited to the cribriform tumor glands or also seen in the surrounding tumor 
glands. Molecular studies could also give more insight into the differences between invasive 
and intraductal cribriform prostate cancer.
Biology of cribriform morphology
Cribriform morphology is not only seen in prostate adenocarcinoma, but in many 
other adenocarcinomas of various organs. By studying adenocarcinomas with cribriform 
morphology	from	different	organs,	we	might	find	a	common	genetic	denominator.	Cribriform	
adenocarcinomas of the lung, stomach and colon are also associated with an adverse 
outcome, while cribriform adenocarcinomas of the breast and thyroid have an excellent 
outcome.79-84	According	to	the	molecular	classification	of	breast	cancer,	invasive	cribriform	
carcinoma is mainly of the luminal A-type, as estrogen and progesteron receptors are 
positively	immunoexpressed,	while	negative	for	increased	expression	and/or	amplification	
of Her2 receptor.80 In lung cancer, Mackinnon et al.	was	unable	to	find	a	specific	molecular	
signature for cribriform predominant carcinomas, whereas Warth et al. showed high rates 
of KRAS mutations, but none in EGFR.82,85 In micro-satellite unstable colon cancers, Kim et 
al. found an association between adverse outcome and cribriform morphology.83 In thyroid 
cancer, both the prognosis as well as the molecular alterations (i.e., presence of RET/
PTC translocation, and no BRAF mutations) are similar to those discovered in conventional 
papillary thyroid carcinoma.81	Based	on	these	findings,	none	of	these	cribriform	tumors	share	
a common genetic denominator, but they show aberrations seen in other adenocarcinoma 
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subtypes in the same organ. However, data containing comprehensive description 
of genomic, transcriptomic and epigenomic changes in numerous different tumor types 
and/or subtypes are now increasingly available online, some of which also containing digital 
histological slides. Similar to what we have done in our study, all adenocarcinomas with 
cribriform morphology could easily be scored by pathologists and compared to each other.
 
 
Urine-based molecular diagnostics
No matter how many prostate needle biopsies are taken, there is always a risk of 
sampling	error.	If	we	can	identify	specific	genetics	events	for	cribriform	prostate	cancer,	
we could intercept the biopsy sampling error by analyzing the patient’s urine. The prostate 
glands drain in the urethra prostatica. We therefore hypothesize that genetic material 
from cribriform prostate cancer that has been spread in preexisting ducts (intraductal 
carcinoma) can be more easily detected in voided urine than the genetic material from 
invasive tumor glands. From the latter we do not know if and how they are connected to the 
urethra prostatica. Voided urine is increasingly being used urological cancer diagnostics by 
measuring cancer-associated proteins, RNA transcripts, and methylation. Sample collection 
of urine is non-invasive and patient friendly. Although using copy number variation analysis 
may be suboptimal due to contamination with normal diploid cells from the urothelium 
and benign prostate epithelium, further studies on transcriptomics and epigenomics might 
reveal interesting candidate genes that can be more easily detected in urine.
Three-dimensional imaging
Histology is two-dimensional, while tumors grow three-dimensionally. Histology 
cannot provide a clear understanding on how glands in adenocarcinomas connect to each 
other. A three-dimensional approach might thus be interesting. In one study we, for instance, 
found that ill-formed glands are actually thinner versions of well-delineated glands, forming 
a similar kind of anastomosing network.86 Fused glands are also rather similar to grade 
3 glands, but contain more intertwining connections. Little is known about the three-
dimensional relation between various types of prostate cancer growth patterns. Since the 
disease is so heterogeneous and complex to understand, this might be a worthwhile avenue 
to explore.
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SUMMARY
The management of prostate cancer is clinically challenging, because of its 
variability in histomorphology, genetics and clinical outcome. Clinical-decision making 
currently	depends	upon	serum	prostate-specific	antigen	(PSA)	level,	clinical	tumor	stage,	
and a biopsy Gleason score given by the pathologist. The Gleason grading system is based 
on the architectural tumor growth patterns.  In needle biopsies, the score is based on 
the sum of the most frequent and highest growth pattern, for instance 3+4=7. In radical 
prostatectomy specimens the score is based on the two most common patterns. Patients 
with the lowest Gleason scores (5 and 6) have an excellent outcome, while those the highest 
Gleason scores (9 and 10) have the worst. In general, patients with Gleason score 6 (3+3) 
on needle biopsy do not need immediate treatment and are often candidates for active 
surveillance. Patients with Gleason score 7 or higher generally undergo active treatment, 
i.e. surgery or radiotherapy. Although the Gleason score remains one the most important 
prognostic factors in prostate cancer, patient outcomes of those with Gleason score 7 or 
higher still vary considerably. Improving risk assessment of Gleason score 7 patients is of 
particular interest, as this score on biopsy represents an important clinical threshold for 
active treatment. In the past decade the Gleason grading system has, however, been revised 
twice	leading	to	significant	grade	inflation.	From	a	pathological	perspective,	the	current	
Gleason score 7 (3+4 or 4+3) prostate cancer population represents a mixture of various 
histomorphological growth patterns that, as a whole, are regarded high grade. This thesis 
focuses	on	several	pathological	challenges	of	prostate	cancer	that	have	been	insufficiently	
addressed: the prognostic value of individual high-grade histomorphological growth patterns, 
their inter-observer reproducibility and their association with genetic abnormalities.
Chapter 1 begins with an introduction on prostate cancer and provides a background 
of previous studies. It additionally describes the aims and outlines of this thesis. Chapter 
2	 shows	 that	 patients	with	modified	Gleason	 score	 ≤6	 that	 had	been	 treated	by	 radical	
prostatectomy have an excellent clinical outcome and do not develop metastatic disease 
later	in	life	or	die	from	their	disease.	We	also	describe	that	a	significant	amount	of	patients	
with	 classic	 Gleason	 score	 ≤6	 that	 had	 an	 adverse	 clinical	 outcome	 after	 surgery	 had	
presence of cribriform tumor glands at pathological revision of the specimen. In chapter 3 
we	investigated	whether	presence	of	specific	histomorphological	tumor	growth	patterns	in	
Gleason score 7 patients are associated with an adverse outcome. We found that patients 
with	presence	of	cribriform	tumor	glands	had	a	significantly	worse	outcome,	while	those	with	
fused or ill-formed glands performed much better. Chapter 4 elaborates on the prognostic 
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value of cribriform growth, together with its mimicker intraductal carcinoma, in pre-
treatment diagnostic needle biopsies. Here, we show that presence of invasive cribriform 
growth and/or intraductal carcinoma (CR/IDC) is associated with a worse clinical outcome 
in various Gleason grading groups. This study also shows that survival rates of Gleason 
score 3+4=7 prostate cancer in the absence of CR/IDC growth (7-) are similar to that of 
Gleason score 6, suggesting that these patients could be candidates for active surveillance. 
Chapter 5	 explores	 the	 latter	 two	 patients	 populations	 more	 in	 depth	 by	 specifically	
studying their tumor characteristics and association with prognosis in different treatment 
groups using biochemical recurrence as outcome measure. This study shows that men with 
biopsy Gleason score 7- prostate cancer have similar survival rates to those with Gleason 
score 6 after radical prostatectomy or radiotherapy and additionally supports the suggestion 
that these patients may be candidates for active surveillance. In chapter 6 we discuss 
another potentially valuable pathological prognostic factor in diagnostic needle biopsies, 
i.e. percentage of Gleason grade 4 patterns, and analyze its prognostic value together 
with other contemporary clinically relevant variables and CR/IDC growth. Here, we show 
that CR/IDC growth outperforms percentage Gleason grade 4 in predicting clinical outcome 
of men with Gleason score 3+4=7 prostate cancer. To further underline the potential of 
cribriform growth as a clinically applicable prognostic marker, chapter 7 describes an inter-
observer reproducibility study on Gleason grade 4 growth patterns, showing that cribriform 
and glomeruloid patterns were mostly reproducible among pathologists, while fused and 
ill-formed were not. In recent years, presence of cribriform growth, genomic instability 
and several distinct copy number alterations have all been separately linked to aggressive 
prostate cancer and adverse patient outcome. In chapter 8 we close the circle and provide 
evidence that cribriform growth in prostate cancer is linked to genomic instability and copy 
number aberrations in distinct genomic regions that had been previously associated with an 
aggressive clinical course. Finally, in chapter 9	we	summarize	our	main	findings	and	review	
their interpretation in the context of the current knowledge. We also provide a discussion 
on methodological considerations, clinical applications and recommendations for future 
research.
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SAMENVATTING
De zorg omtrent prostaatkanker is een klinische uitdaging vanwege de variabiliteit 
in histomorfologie, genetica en patiëntenuitkomst. Tegenwoordig hangt de klinische 
beslisvorming	af	van	het	serum	prostaat-specifieke	antigen	(PSA),	klinische	tumorstadium	en	
de Gleason score op het biopt, gegeven door de patholoog. De Gleason gradering is een system 
gebaseerd op architecturale groeipatronen van de tumor. In diagnostische naaldbiopten 
is de score gebaseerd op de som van het meest voorkomende en hoogste groeipatroon, 
bijv. 3+4=7. In radicale prostatectomie preparaten is de score gebaseerd op de som van de 
twee meest voorkomende groeipatronen. Patiënten met de laagste Gleason scores (5 en 6) 
hebben een uitstekende uitkomst, terwijl degenen met de hoogste Gleason scores (9 en 10) 
de meest ongunstige hebben. Over het algemeen worden patiënten met een Gleason score 6 
(3+3) op het biopt niet direct actief behandeld, i.e. chirurgie of radiotherapie, maar zijn zij 
vaak kandidaten voor actieve surveillance. Patiënten met Gleason score  7 of hoger worden 
doorgaans wel actief behandeld. Hoewel de Gleason score een van de meest belangrijke 
prognostische factoren is in prostaatkanker, varieert de prognose van patiënten met Gleason 
score 7 of hoger nog sterk. Het verbeteren van de risicoschatting in Gleason score 7 patiënten 
is met name relevant, omdat deze score een klinisch afkappunt is voor actieve behandeling. 
In de laatste twee decennia is het Gleason graderingssysteem echter tweemaal gereviseerd 
wat	 uiteindelijk	 heeft	 geleid	 tot	 een	 significante	 graadinflatie.	 Vanuit	 een	 pathologisch	
perspectief  bestaat de huidige Gleason score 7 (3+4 of 4+3) prostaatkankerpopulatie uit een 
mix van verscheidene architecturale groeipatronen die, in hun geheel, worden beschouwd 
als hooggradig. Dit proefschrift benadrukt verschillende pathologische uitdagingen omtrent 
prostaatkanker die tot op heden onvoldoende zijn behandeld: de prognostische waarde 
van individuele hooggradige groeipatronen, hun interobserver variabiliteit en hun associatie 
met genetische afwijkingen.
Hoofdstuk 1 begint met een introductie over prostaatkanker en geeft 
achtergrondinformatie van voorgaande studies. De doelstellingen en opbouw van dit 
proefschrift worden hier eveneens beschreven. Hoofdstuk 2 beschrijft dat patiënten met 
een	gemodificeerde	Gleason	score	≤6	die	behandeld	zijn	middels	radicale	prostatectomie	een	
uitstekende prognose hebben en geen uitzaaiingen ontwikkelen of sterven aan de gevolgen 
van	prostaatkanker.	We	laten	ook	zien	dat	een	significante	hoeveelheid	van	de	patiënten	met	
een	klassieke	Gleason	score	≤6	met	een	ongunstige	prognose	na	de	operatie	aanwezigheid	
van het cribriforme groeipatroon had bij pathologische revisie van het preparaat. In 
hoofdstuk 3 onderzochten	wij	of	de	aanwezigheid	van	 specifieke	 tumorgroeipatronen	 in	
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Gleason score 7 patiënten zijn geassocieerd met een ongunstige prognose. Wij vonden dat 
patiënten	 met	 aanwezigheid	 van	 het	 cribriforme	 groeipatroon	 een	 significant	 slechtere	
prognose hadden, terwijl degenen met gefuseerde of grillige groeipatronen een zeer goede 
uitkomst hadden. Hoofdstuk 4 werkt de prognostische waarde van cribriforme groei samen 
met een patroon dat deze nabootst - intraductaal carcinoom - verder uit in diagnostische 
naaldbiopten. In deze studie laten we zien dat de aanwezigheid van cribriforme groei en/
of intraductaal carcinoom (CR/IDC) sterk is geassocieerd met een ongunstige prognose in 
verschillende Gleason score groepen. Wij laten eveneens ziens dat de overlevingskansen 
van Gleason score 3+4=7 patiënten zonder CR/IDC (7-) gelijk zijn aan die van Gleason score 
6. Wij suggereren vervolgens dat deze patiënten kandidaten voor active surveillance zouden 
kunnen zijn. Hoofdstuk 5 gaat dieper in op de twee laatstgenoemde patiëntenpopulaties 
door	 specifiek	 te	 kijken	 naar	 tumorkarakteristieken	 en	 associaties	 met	 prognose	 in	
verschillende behandelingsgroepen met biochemisch recidief als uitkomstmaat. Deze studie 
laat zien dat mannen met Gleason score 6 en 7- prostaatkanker gelijke overlevingskansen 
hebben na radicale prostatectomie en radiotherapie en aanvullend ondersteunt dat Gleason 
score 7- patiënten kandidaten zouden kunnen zijn voor actieve surveillance. In hoofdstuk 6 
bespreken wij een andere potentieel waardevolle pathologische variabele in diagnostische 
naaldbiopten, i.e. percentage Gleason graad 4 patronen, en analyseren diens prognostische 
waarde tezamen met andere hedendaagse klinisch-relevante variabelen en CR/IDC groei. In 
deze studie laten wij zien dat CR/IDC groei beter presteert dan percentage Gleason graad 4 
in het voorspellen van patiëntenuitkomst in Gleason score 7 patiënten.  Om de potentie van 
cribriforme groei als een klinisch-relevante prognostische marker verder te ondersteunen, 
geeft hoofdstuk 7 een studie weer naar de interobserver reproduceerbaarheid van Gleason 
graad 4 patronen, waarbij wordt aangetoond dat cribriforme en glomeruloïde patronen 
reproduceerbaar zijn tussen pathologen, terwijl grillige en gefuseerde patronen dat niet 
zijn. In recente jaren zijn de aanwezigheid van cribriforme groei, genomische instabiliteit en 
verschillende variaties in genkopieën los van elkaar geassocieerd met een agressief klinisch 
beloop. In hoofdstuk 8 maken we de cirkel rond en laten we zien dat cribriforme groei in 
prostaatkanker geassocieerd is met genomische instabiliteit en variaties in genkopieën in 
specifieke	genomische	regio’s	welke	in	voorgaande	studies	gelinkt	werden	aan	ongunstige	
prognose.  Tot slot worden in hoofdstuk 9 de algemene resultaten van dit proefschrift 
besproken en worden de bevindingen in een bredere context uitgelegd. Ook bespreken we 
methodologische overwegingen van onze studies, klinische toepassingen en ideeën voor 
toekomstig onderzoek.
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bedanken voor hun betrokkenheid, hulp en sympathie. Met een glimlach denk ik terug aan 
die wonderlijke momenten op kamertje 301. Als laatste wil ik mijn paranimfen bedanken. 
Lieve Kim, mijn maatje, we hebben elkaar leren kennen tijdens het onderzoek en in de 
afgelopen jaren een dierbare vriendschap opgebouwd. Ik heb bewondering voor je moed, 
daadkracht en gevoel voor humor. Het promotieonderzoek met jou was een spannende 
en dolkomische rit van begin (Schotland) tot eind (Spanje). Lieve Stéphanie, mijn oudste 
vriendin, bedankt dat je mijn paranimf wil zijn. Dit heeft voor ons beide een speciale 
betekenis. Bij het behalen van ons eerste diploma stonden wij in badpak naast elkaar. Meer 
dan twintig jaar later sta je opnieuw aan mijn zijde. Zullen we voor deze gelegenheid onze 
zwemspullen	maar	thuislaten?	

